

# Exhibit 203

**Supplemental Expert Report of John F. Flack, M.D., M.P.H.**

***In re: Valsartan Products Liability Litigation, MDL No. 2875 (D.N.J.)***

**I. Introduction**

This supplemental report is offered pursuant to Rule 26 of the Federal Rules of Civil Procedure, and I incorporate and adopt my prior report and opinions offered in this litigation in their entirety. My qualifications and publications have been updated on my current *curriculum vitae* attached as Exhibit A. During the previous four years I have not testified as an expert at trial or in deposition outside this litigation. A list of the materials considered in support of my opinions is attached as Exhibit B. My work reviewing materials and preparing this supplemental report has been billed at \$600 per hour. My hourly rate for deposition and trial testimony is \$850 per hour.

I have been asked on behalf of Defendants to provide an independent analysis of whether trace amounts of N-nitrosodimethylamine (“NDMA”) and N-nitrosodiethylamine (“NDEA”) found in valsartan products affect the value or benefit of the valsartan for the Plaintiffs who took the medication, and provide a rebuttal to the opinion of Plaintiffs’ expert Dr. Conti that the valsartan containing NDMA or NDEA – even that taken by patients prior to any recall and with full therapeutic effect - is somehow “worthless”. In my previous report I provided background and opinions on hypertension generally, including its diagnosis and treatment, risk factors, epidemiology, secondary causes, and comorbidities, all of which relate to the question here analyzing how to measure the benefit or value of valsartan. I have applied the same methodology as I utilize in my professional research and clinical practice outside of litigation as described in my prior report. Many of my opinions expressed in this report are based on my cumulative knowledge from many years of hypertension research and clinical practice and the literature I have reviewed over that time and on information I believe is generally known and accepted as true by those practicing in the hypertension community. Each of the opinions I have offered in this

supplemental report is given to a reasonable degree of scientific certainty and is based on scientific methods and procedures, the materials I have reviewed in connection with this litigation, as well as my education, training, knowledge, and experience. I reserve the right to supplement the list of materials reviewed, as well as to amend and supplement the opinions expressed in this report. I also reserve the right to respond to and rebut all information provided in discovery, which I understand is ongoing, and any opinions offered by Plaintiffs' experts at their depositions or at trial.

## **II. Supplemental Opinions**

### **a. The value of valsartan is derived from the intended use and clinical benefit for the individual patient(s) prescribed valsartan.**

The angiotensin receptor blocker, valsartan, is FDA approved for three cardiovascular conditions: 1) hypertension, 2) reduced ejection fraction heart failure<sup>1</sup>, and 3) post-myocardial infarction (heart attack) with heart failure or left ventricular dysfunction<sup>2</sup> (reduced ejection without clinically overt heart failure symptoms); and though not FDA approved for patients with chronic kidney disease, the proven benefit of angiotensin receptor blockers in these patients is thought to be a class effect (all ARBs protect the kidney).

The clinical benefit with use of valsartan in hypertension is almost exclusively related to its ability to lower blood pressure while in heart failure, post-myocardial infarction with heart failure of left ventricular dysfunction, and putatively in chronic kidney disease its clinical benefit

---

<sup>1</sup> Brauch L, Glazer RD, Aknay N, Vanhaecke J, et al. Morbidity, mortality, physiologic and functional parameters in elderly and non-elderly patients in the Valsartan Heart Failure Trial (Val-HeFT). *Am Heart J* 2004; 148(6):951-957

<sup>2</sup> White HD, Aylward PEG, Huang Z, Dalby AJ, et al. Mortality and morbidity remain high despite captopril and/or valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT). *Circulation* 2005;112(22):3391-3399.

is not closely related to its effect on blood pressure. These clinical benefits have been proven in randomized controlled clinical trials that were required prior to FDA approval of valsartan for clinical use; when considering blood pressure lowering drugs for approval, the FDA accepts effective blood pressure lowering as a surrogate for cardiovascular disease risk reduction (e.g, reduced stroke risk).

The value of valsartan to a patient varies depending upon their underlying risk factors and conditions which are reduced by valsartan. The absolute clinical benefit of a given patient using valsartan will vary based on how many of the above conditions they have as well as their overall risk for cardiovascular-renal disease. A meta-analysis involving over 50,000 hypertensive clinical trial participants definitively showed incrementally greater absolute cardiovascular disease risk reductions at progressively higher levels of pre-treatment cardiovascular risk<sup>3</sup>. I use cardiovascular disease and atherosclerotic cardiovascular disease interchangeably in this document. Thus, the higher the 10-year risk for atherosclerotic cardiovascular disease (ASCVD) as determined by a risk calculator (available online; [www.cvriskcalculator.com](http://www.cvriskcalculator.com)), the greater the absolute risk reduction for any magnitude of blood pressure lowering (in hypertensive patients) would be expected when treated with valsartan. Thus, these clinical benefits attributable to the use of the valsartan at issue and taken by patients in this case is not uniform across various patient types, as it will vary according to patient co-morbidity and ASCVD risk profiles.


---

<sup>3</sup> Blood Pressure Lowering Treatment Trialists' Collaboration. Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data. *Lancet* 2014;384(9943):591-598.

**b. The value of valsartan from a clinical perspective is unchanged by the presence of NDMA or NDEA.**

There is no available evidence to prove, or even to suggest, that NDMA has any detectable effect on blood pressure, the functioning of cardiovascular system or kidneys, or any diminution of the blood pressure lowering effect of valsartan. There is no evidence to suggest that the presence of NDMA in any prescription or over the counter drug has negatively impacted their known pharmacological effect(s). Accordingly, there is no biologically plausible basis to believe that the presence of NDMA in the valsartan at issue and taken by patients in this case lessened its clinical value to the patients who took it, i.e. the blood pressure lowering, or that it attenuated its favorable reduction of adverse clinical events in patients with reduced ejection fraction heart failure, post-myocardial infarction with heart failure or reduced left ventricular dysfunction, and/or chronic kidney disease. Also, in patients with hypertension, the affirmative clinical benefit of the valsartan at issue and taken by patients in this case can be shown by the blood-pressure-lowering effects, which will of course vary by patient.

Dated: January 12, 2022



---

John F. Flack, M.D., M.P.H.

# EXHIBIT A

Date of preparation: January 6, 2022

  
John M. Flack, MD, MPH, FAHA, MACP

Date: \_\_\_\_\_

CURRICULUM VITAE  
**JOHN M. FLACK, MD, MPH, FAHA, MACP, FASH**

**Clinic Address**      SIU School of Medicine  
Department of Internal Medicine  
751 N. Rutledge St.; Room 1100  
Springfield, IL 62794-9648

**Office:**            SIU School of Medicine  
Department of Internal Medicine  
701 N. First St., Ste. D442  
PO Box 19636  
Springfield, IL 62794-9636

**Home:**            4420 Foxhall Lane  
Springfield, IL 62711

**Telephone:**    (217) 545-2596 (O)  
(217) 545-8156 (F)

**E-mail:**          [jflack47@siumed.edu](mailto:jflack47@siumed.edu) (O)  
[jmarkguppy@aol.com](mailto:jmarkguppy@aol.com) (H)

**PERSONAL DATA:**

Date of Birth:        January 23, 1957, Hill AFB, Davis County, UT  
Marital Status:     Married, Jennifer Schoats Flack, J.D.  
Number of Children: Five daughters

**EDUCATION:**

8/88-6/90	M.P.H., (Epidemiology) University of Minnesota School of Public Health, Minneapolis, MN
8/88-6/90	Postdoctoral Research Fellow, (Cardiovascular Epidemiology) National Heart Lung and Blood Institute (NHLBI), Division of Epidemiology, University of Minnesota School of Public Health Minneapolis, MN
8/86-6/88	M.P.H., Program University of Oklahoma School of Public Health, Oklahoma City, OK
07-08,1987	Fellow, 13th U.S. Ten-day Seminar on the Epidemiology and Prevention of Cardiovascular Diseases, Sponsored by the American Heart Association, Lake Tahoe, CA
7/85-6/86	Chief Medical Resident, Department of Medicine, University of Oklahoma Health Sciences, Oklahoma City, OK



**John M. Flack, M.D., M.P.H.**

7/82-6/85 Internship/Residency, University of Oklahoma Health Sciences Center, Oklahoma Memorial Hospital, Oklahoma City, OK

7/78-6/82 M. D., University of Oklahoma School of Medicine, Oklahoma City, OK.

8/74-6/78 B.S., Chemistry (Math Minor), Langston University, Langston, OK

**RESEARCH INTERESTS:**

- 1) Clinical trial design, implementation, and monitoring
- 2) Utilization of ambulatory clinical databases to make minimally-biased estimates of the effect of hypertension treatment strategies not easily studied in RCTs
- 3) The vascular phenotype of resistant hypertension; characterization of salt-responsive biomarkers in resistant hypertension
- 4) Developing and validating clinical and vascular risk prediction markers/algorithms for prediction of new-onset resistant hypertension

**FACULTY APPOINTMENTS:**

2019	Sergio Rabinovich Endowed Chair of Internal Medicine
6/2016-present	Chief, Hypertension Section
5/2015-present	Professor of Medicine and Chair, Department of Internal Medicine Southern Illinois University School of Medicine, Springfield, Illinois
6/2014-5/2015	Professor of Medicine and Physiology Wayne State University School of Medicine, Detroit, Michigan
3/2008-5/2014	Chairman Department of Internal Medicine Wayne State University School of Medicine
3/2005-3/2008	Interim Chairman Department of Internal Medicine Wayne State University School of Medicine
4/2000-2/2005	Associate Chairman for Academic Affairs and Chief Quality Officer Department of Internal Medicine, Wayne State University School of Medicine
1/1999-3/2000	Associate Chairman for Clinical Research and Urban Health Outcomes Department of Internal Medicine, Wayne State University School of Medicine
1/1999-6/2003	Graduate Faculty Appointment, Professor, Department of Community Medicine Wayne State University School of Medicine
7/1997-12/1998	Associate Chairman, Department of Internal Medicine Wayne State University School of Medicine
7/1997-6/2003	Professor, Departments of Internal Medicine and Community Medicine

**John M. Flack, M.D., M.P.H.**

Wayne State University School of Medicine

7/1994-6/1997	Associate Professor of Surgery, Medicine and Public Health Sciences Bowman Gray School of Medicine, Winston Salem, North Carolina
6/1994-6/1996	Associate Professor, Division of General and Preventive Medicine, University of Minnesota School of Medicine, Minneapolis, Minnesota
9/1992-5/1994	Assistant Professor, Division of General and Preventive Medicine University of Minnesota School of Medicine
7/1990-8/1992	Assistant Professor, School of Public Health, Division of Epidemiology University of Minnesota
7/1986-7/1988	Instructor of Medicine University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma

**HOSPITAL OR OTHER PROFESSIONAL APPOINTMENTS:**

2021-present	Chair, SIU Physician Leadership Council (PLC), oversees scheduling and call center functions for the practice plan
2021-present	Member, American Heart Association (AHA) Health Equity Research Network Prevention of Hypertension Oversight Advisory Committee
2021-present	Member, American Heart Association (AHA) and American Medical Association (AMA) Target: BP Advisory Group
2019-present	Member, Continuous Quality Improvement Group (CQI), LCME Faculty Subcommittee
2019	Member, SIU Misconduct in Science Committee
2018	Mastership (MACP) American College of Physicians
2018	Member, American College of Physicians (ACP) Board of Regents
2018-present	President, American Hypertension Specialist Certification Program (AHSCP)
2014-2018	Vice President, American Hypertension Specialist Certification Program (AHSCP)
2017	Member, SIU Healthcare Board of Directors
2016	Chair, SIU School of Medicine Search Committee for Associate Dean of Research and Faculty Affairs
2013-2014	Chair, Nominating & Governance Committee, Wayne State University Physician Group
2012-2014	Board Member, Detroit Medical Center - PHO

**John M. Flack, M.D., M.P.H.**

2010-2015	Member, Advisory Board, Cardiovascular Research Institute (CVRI), Wayne State University
2009-2014	Secretary, Wayne State University Physician Group
2008-2015	Consultant, NIH R01 "Clinicians Concept of Genetics, Race and Ethnicity in Managing Chronic Illness", Principal Investigator, Linda Hunt, Ph.D., Michigan State University
2007-2009	Vice Chair, Wayne State University Physicians Group
2007-2015	Member, Executive Committee of Wayne State University Physicians Group
2007	Wayne State University President Search Committee, member
2006-2014	Chief, Division of Translational Research and Clinical Epidemiology
2006	Vice-President for Research, Wayne State University Search Committee
2005-2015	Detroit Medical Center Cardiovascular and Thrombosis Pharmacy & Therapeutics Subcommittee
2005-2009	Consultant, Center for Disease Control-funded Center for Excellence for Training and Research
2005-2014	Specialist in Chief for Internal Medicine, Detroit Medical Center, Detroit, MI
2005- 2014	Medical Executive Committee, Detroit Medical Center, Detroit, MI
2005- 2014	Executive Management Team, Detroit Medical Center, Detroit, MI
2005- 2014	Harper University Hospital Leadership Team, Detroit Medical Center, Detroit, MI
2005	Cardiac & Vascular Institute Steering Committee, Detroit Medical Center, Detroit, MI
2004- 2015	Consultant, John D. Dingell Veterans Affairs Medical Center, Detroit, MI
1998-1999	Chief of Medicine, Detroit Medical Center, Central Region Hospitals, Detroit, MI
1998-1999	Acting Director, Division of General Medicine, Wayne State University School of Medicine
1998-2000	Vice President, Vencor Hospital, Detroit/Metro-Medical Staff, Detroit, MI
1997-2006	Director, Cardiovascular Epidemiology and Clinical Applications (CECA) Program, Department of Internal Medicine, Wayne State University School of Medicine
1994-1997	Associate Director and Medical Director, Hypertension Center, Bowman Gray School of Medicine

**John M. Flack, M.D., M.P.H.**

1992-1994	Director, Division of General and Preventive Medicine, University of Minnesota, Minneapolis, MN
1992	Co-Director, Division of General Medicine, University of Minnesota, Minneapolis, MN
1990-1991	Deputy Director, Institute of Preventive Cardiology and Medicine, Metropolitan Mount Sinai Medical Center, Phillips Campus, Minneapolis, MN
1990-1991	Medical Staff, Abbott-Northwestern Hospital, Minneapolis, MN
1989-1991	Medical/Emergency Room Staff, Metropolitan Mount Sinai Medical Center, Minneapolis, MN
1989-1991	Consultant, Quality Quest Inc., Minneapolis, MN
1989-1991	Consultant, United Healthcare Corp., Minneapolis, MN
1986-1988	Associate Director, Hypertension Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK
1986-1988	Director, General Medicine Consult Service, University of Oklahoma Health Sciences Center
1977-1978	Research Chemist, Phillips Petroleum Company, Bartlesville, OK (summer)
1976	Analytical Chemist, AMOCO Production Company, Tulsa, OK (summer)

**MEMBERSHIP SOCIETIES:**

Sigma Pi Phi Fraternity  
Alpha Omega Alpha (AOA) Medical Honor Society  
American College of Physicians (fellow)  
Association of Professors of Medicine  
Association of Black Cardiologists (ABC)  
Detroit Medical Academy  
International Society on Hypertension in Blacks (ISHIB), Past President  
National Medical Association (NMA)  
Michigan Medical Society  
American Heart Association (AHA)  
    AHA Council for High Blood Pressure Research, member  
    Peer Review subcommittee, member  
    AHA Council on Hypertension  
    Professional and Public Education & Publications Committee, Chair  
    AHA Quality of Care and Outcomes Research, member  
    AHA Functional Genomics and Translational Biology, member  
    AHA Strategic Outcomes Subcommittee, member  
American College of Cardiology (fellow)  
American Medical Association  
Frontiers International, Springfield IL Chapter

John M. Flack, M.D., M.P.H.

# **LICENSURE AND BOARD CERTIFICATION:**

2015	Illinois
2012	Fellow, American Society of Hypertension (FASH)
1999-Present	Specialist in Clinical Hypertension, American Society of Hypertension (lifetime certification)
1997	Michigan (Active)
1994	North Carolina (Inactive)
1990	Basic Rescuer, American Heart Association
1990	Advanced Cardiac Life Support Provider, American Heart Association
1988	Minnesota (Inactive)
1985	Diplomate, American Board of Internal Medicine (lifetime certification)
1983	Diplomate, National Board of Medical Examiners
1982	Oklahoma (Inactive)

# **HONORS/AWARDS:**

2019	Awarded "Internal Medicine/Hypertension Top Doctor 2019"
2018	Illinois ACP Downstate Chapter Laurate Award
2017-2018	"Best Doctors in America" St. Louis Magazine
2016	"Medical Innovator" Award, from Sangamon County (IL) Medical Society
2014	Top Doctor
2014	Detroit Super Doctors 2014 from Super Doctors.com
2013	'Top Doctor' from Who's Who Global Directory
2012	"Academic Physician of the Year" from Oklahoma University School of Medicine
2010	Hour Magazine Top Doc
2009	Michiganian of the Year as presented by The Detroit News
2009	Hour Magazine's Top Health Professional for Hypertension
2009	QFORMA's Most Influential Doctor in Hypertension, USA Today
2008	Fellow of the American College of Physicians (ACP)
2008	MPRO Pillar Award of Excellence
2007-2008	Selected as one of Detroit's Top Docs
2007	American Heart Association's F. Dewey Dodrill Award for Excellence
2005	<i>Crain's Detroit Business</i> Health Care Hero Award for Outstanding Physician Achievement
2005	Awarded Pillar Award of Excellence for Reducing Health Disparities, Michigan Peer Review Organization
2005-2006	Selected as one of the "Best Doctors in America"
2004	Who's Who Among Executives and Professional in Healthcare
2004	Distinguished "Alumnus" Award, Langston University-outstanding accomplishment in the field of medicine and serving as speaker for honors convocation
2004	Distinguished "Alfred Deutsch" Award Wayne State University-Dept of OBGYN
2003-2004	Selected as one of the "Best Doctors in America"
2003	Distinguished Service Award of the National Kidney Foundation, Inc.
2003	Attending of the Month of March, Wayne State University -Dept of Med Harper University Hospital
2002-2003	Selected as one of the "Best Doctors in America"
2001	Fellow of the American Heart Association (F.A.H.A.)
2001	Department of Internal Medicine Wayne State University College Teaching Award
2001	Life-term Member of The National Registry of Who's Who. Published 2002 ed.
1998-1999	Selected as one of the "Best Doctors in America," Woodward/White, Inc.
1998	Dr. Daniel D. Savage Memorial Scientific Award, Association of Black Cardiologists

**John M. Flack, M.D., M.P.H.**

1995 Pee Dee Newspaper Group, Positive Image Award  
1995 Certificate of Appreciation for participation in the 11th Annual Martin Luther King Day Program, The University of Oklahoma Health Sciences Center  
1994 Selected as Faculty for Bush Faculty Development Program in Excellence and Diversity in Teaching, University of Minnesota-Twin Cities  
1993 Distinguished Research Award, International Society on Hypertension in Blacks  
1993 Distinguished Alumni Citation of the Year, National Association for Equal Opportunity in Higher Education  
1993 Gordon L. Starr Award Recipient, University of Minnesota  
1992 Personalities of America  
1992 Men of Achievement  
1991 Who's Who Among Rising Young Americans Award  
1988-1990 Higher Ability Minority Scholarship, University of Minnesota School of Public Health  
1988 Special Recognition Award, University of Oklahoma Health Sciences Center, Student National Medical Association  
1988 Black Student Services Special Recognition Award, University of Oklahoma Health Sciences Center  
1985 Award of Academic Excellence, VA Medical Center, Afro-American Program  
1982 Association of Black Personnel and Black People's Union, Outstanding Black Student Award, University of Oklahoma

**AD HOC:**

2021 Chair, AHA Health Equity Research Network Grant Review Committee  
2018 Member Writing Committee, American Heart Association Scientific Statement on Resistant Hypertension  
2017 NIH Invited Participant in the Training the Next Generation of Implementation Researcher for Health Equity, August 30-31  
2016 Reviewer, National Institutes of Health, Fellowships Review Meeting  
2015 American Heart Association Cardiorenal Clinical Peer Review Study Group  
2015 Reviewer, "Support for the National Institute of Environmental Health Sciences (NIEHS) Clinical Research Program" (8/20-21/2015)  
2015 Advisory Panelist, Emergency Medicine Perspective of Hypertension Management Advisory Panel, the Medicines Company (6/11/2015)  
2014 Invited Participant, NHLBI Health Inequities Think Tank Meeting (9/2014)  
2013 Invited Participant, Duke Resistant Hypertension Think Tank Meeting (8/2013)  
2012-present Director-at-Large, American Society of Hypertension Specialist Program  
2013-14 Member, Program Committee, Council on High Blood Pressure Research  
2011 Member, Fall Conference Committee, Council on High Blood Pressure Research (HBPR)  
2011 Editorial Board member, Journal of Cardiorenal Medicine  
2011 Chair, Ophthalmology Chair Search Committee, Wayne State University School of Medicine  
2008 Member, Data Safety and Monitoring Board of the "Mechanisms of Meditation in Hypertension in Blacks Trial" (NIH Funded), PI: Robert S. Schneider, MD.  
2006 Reviewer, NCMHD Special Emphasis Panel  
2005 Reviewer, NCMHD Centers of Excellence in Partnership for Community Outreach, Research on Health Disparities and Training (Project EXPORT – Establishing Exploratory Centers)  
2005 Member, NIH (NIEHS) High Profile Review Clinical Research Support Services  
2005 Chair, Hypertension Expert Working Group (NKF of Michigan)  
2005 Member, Research Review Committee Department of Internal Medicine



**John M. Flack, M.D., M.P.H.**

2005	Member, Wayne State University Research Advisory Committee
2005	Member, Wayne State University Population Sciences Panel
2005	Member, Wayne State University Hematology Oncology Academic Search Committee
2005	Member, Tarka Specialty Consultants Steering Committee
2005	Chair, CUAH Health Disparities Committee
2004	Member, DMC Medical Staff, Informal Investigation Committee
2004	Member, Council for the Advancement of Diabetes Research & Education (CADRE)
2004	Member, Preventive Cardiology Junior Faculty Awards Steering Committee (Pfizer, Inc.)
2004-2005	Member, Wayne County Delegate (Wayne County Med Society of Southeast MI)
2004	Reviewer, National Health and Medical Research Council (Australia)
2004	Member, National Kidney Disease Education Program Committee (NKDEP)
2004	Member, Wayne State University Hutzel Women's Hospital, Disciplinary Investigation Committee
2004	Member, NIH National Heart Lung and Blood Institute Sub-clinical Cardiovascular Disease Working Group
2003	Member, Metro Detroit Health Care Disparities Task Force (HFH)
2003	Reviewer, National Institute of Diabetes & Digestive & Kidney Disease
2003-2005	Member, Wayne State University INPHASE (Institutes for Population Studies Health Assessment, Administration, Services and Economics)
2002	Member, Steering Committee, National Kidney Disease Ed Program
2002-2004	Member, Epidemiology and Clinical Trials Center (EpiCenter), ABC
2002	Member, Program Committee Clinical Nephrology Meeting 2002 (NKF)
2002	Member, Worldwide Advisory Board, Norvasc (amlodipine besylate)
2001	Member, American Heart Association's Scientific Committee Session 2001
2001-present	Consultant, Center for Disease Control (WISEWOMAN) Well-Integrated Screening and Evaluation for Women Across the Nation
2001	Member, Affiliated Internist's Data Analysis Committee
2001	Member, Affiliated Internist's Ambulatory Steering Committee
2001	Member, Affiliated Internist's Informatics Committee
2001	Member, Affiliated Internist's Quality Improvement/Chronic Disease Management Committee
2001	Member, National Institute of Dental and Craniofacial Research-Special Emphasis Panel
2001	Member, American Heart Association, Metropolitan Detroit Board of Directors
2001	Co-Chair, Upcoming "Sixth Congress on the Treatment of Cardiovascular Disease in African-Americans (Speaker and Session Moderator)
2001	Chair, (NIH) National Institutes of Arthritis and Musculoskeletal and Skin Diseases Special Emphasis, Panel Review Group
2001	Member, Medical and Scientific Advisory Board (MSAB), National Kidney Foundation
2000	Member, Michigan Peer Review Organization (MPRO), Board of Directors
2000-2002	Member, Association of Professors of Medicine, Departmental Finance and Management Committee, Washington, DC
2000	Member, Mott Center, Advisory Committee, Wayne State University and DMC Detroit, Michigan
2000	Chairman, Cardiovascular Risk Factor: New Challenges, New Opportunities Part I: Angiotensin-II & Cardiovascular Risk, American College of Cardiology, (ACC) Anaheim, CA
1998	Member, PSO Contracting & Reimbursement Work Group and Managed Care Contract Review Committee, DMC, Detroit, Michigan
1998	Scientific Program Chairman, Third Annual Congress on the Treatment of Cardiovascular Diseases in African-Americans, Dallas, TX

**John M. Flack, M.D., M.P.H.**

1998 Reviewer, Abstracts for ACC 48<sup>th</sup> Annual Scientific Session, Dallas, TX  
1998 Reviewer, K23 and K24 Grant Awards, NHLBI  
1997 Reviewer in Reserve, Agency for Health Care Policy  
1997 Reviewer, Abstracts for American College of Cardiology (ACC) 47<sup>th</sup> Annual Scientific Session, Bethesda, MD  
1997 Chairman, Expert Panel on Optimal Target-Organ Protection and Survival in African-Americans, Orlando, FL  
1997 Scientific Program Chairman, Second Annual Congress on the Treatment of Cardiovascular Diseases in African-Americans, Orlando, FL  
1997 Reviewer, "Clinical Trials Unit", NIDDK, U01 DK54047-01  
1996 Grant Reviewer, Agency for Health Care Policy Research, Office of Scientific Affairs, Rockville, MD  
1994 Member of Writing Group, National High Blood Pressure Education Program Working Group on Hypertension and Renal Disease  
1992 Reviewer, "The Biology of Kidney Disease and Hypertension in Blacks", RFA DK/92-11  
1991 Member, Writing Group to Revise American Heart Association Recommendations for Human Blood Pressure Determination by Sphygmomanometers  
1991 Reviewer, NIH Small Grants Program (R03)  
1991 Behavioral Science, Epidemiology and Prevention Study, American Heart Association  
1990 Reviewer, NHLBI Bogalusa Heart Study, New Orleans

#### **STUDY SECTIONS:**

2014-2018 Member, National Institute of Health NHLBI Institutional Training Mechanism Review Committee  
2007-2010 Member, Environmental Health Sciences Review Committee of the National Institute of Environmental Health Sciences  
2007-2011 Member, Psychosocial Risk and Disease Prevention Study Section, Office of Behavioral and Social Sciences Research/NIH  
1999-2001 Steering Committee, OPERA Study (International), Bristol Meyers Squibb  
1998-2002 Member, Agency for Health Care Policy Research (AHCPR), Health Care Quality and Effectiveness Research (HCQER) Study Section  
1992-1996 Member, Research Centers in Minority Institutions (RCMI) Review Committee, National Institutes of Health

#### **PROFESSIONAL SERVICE:**

2021-present Member, AHA Manuscript Oversight Committee  
2020-present Chair, AHA Hypertension Professional Education and Publication Committee  
2019-2020 Vice Chair, AHA HTN Professional & Public Education & Publications Committee  
2019-present ACP Education and Development Committee  
2019-present ACP Diversity and Inclusion Subcommittee  
2019-present AHA Council on Hypertension Leadership Committee  
2019-present AHA HTN Trainee Advocacy Committee of the Council on Hypertension  
2018-present American College of Physicians Board of Regents  
2017-2019 AHA Research Strategic Outcomes Subcommittee  
2018 Member, Association of Black Cardiologist (ABC) Advisory Group  
2018 Vice Chair, American Heart Association (AHA) Hypertension Professional Education Committee  
2016 Chair, Search Committee for the Associate Dean, Research (SIU)  
2016-present Associate Editor, American Journal of Hypertension



**John M. Flack, M.D., M.P.H.**

2015-2017	Vice President, American Society of Hypertension (ASH) Specialist Board
2015	Member, American Heart Association (National) Research Committee
	Member, Peer Review Subcommittee
2014 – 2016	Member, Professional and Public Education and Publications Committee of the Hypertension (HYPE) Council
2009	Member, Karmanos Cancer Center Director Search Committee
2009	Inaugural Member, Cardiovascular Research Institute Advisory Board, Wayne State University
2008-2015	Member, Affiliation Partnership VA/DMC/Wayne State University
2008	Member, Longitude Health: Guided Health and Wellness, Professional Advisory Board Translation, University of North Carolina at Chapel Hill
2005	Chair, Morehouse School of Medicine, Clinical Research External Advisory Committee
2005	Member, National Kidney Foundation, Hypertension Expert Group
2005	Member, Association of Professors of Medicine (APM)
2005	Member, Association of Professors of Medicine (APM) Diversity Subcommittee
2005	Member, Michigan Peer Review Organization (MPRO)
2005	Member, Metro Detroit American Heart Association
2005	Member, High Blood Pressure Council of the American Heart Association
2004	Member, Wayne County Medical Society Southeastern Michigan, Nomination and Election Committee
2004	Member, American Society of Hypertension, Inc, Board of Directors, Midwest Regional Chapter
2004	Immediate Past President, International Society on Hypertension in Blacks (ISHIB)
2003	Member, Medical and Scientific Advisory Board, National Kidney Foundation of Michigan
2002	Member, University Physician Services, Board of Directors
2001-2003	President, International Society of Hypertension in Blacks (ISHIB)
2002	Member, Henderson Scholars Program-University of Oklahoma-Leadership Advisory Committee
2001	Member, Wayne County Medical Society, Membership Committee
2001-2003	Member, Medical and Scientific Advisory Board, National Kidney Foundation
2001	Honorary Member, Pathfinders, in Medicine Awards Committee
2001	Member, Wayne State University Advisory Committee, Liborio Tranchida, MD, Endowed Chair Campaign, Detroit, MI
2001-2002	Member, DMC Managed Care Contract Review Committee, Detroit, MI
2001	Member, DMC Hutzel Women's Hospital Stages of Life Program Team", Detroit.
2001-2003	Ex-Officio, Member of National Kidney Foundation, Medical and Scientific Advisory Committee
2000-present	Chair, Affiliated Internist Investment Committee, Detroit, MI
2000-2001	Board of Directors, Member, United Medical Management Co., Inc., Detroit, MI
1999-present	Chair, DMC Central Region Credentialing Committee
1998-2000	Reviewer, Harper Hospital Medical Staff, Department of Medicine, Seed Grants
2000	Abstracter Grader, Annual Scientific Session American College of Cardiology
1999	Abstract Grader, American College of Cardiology 49 <sup>th</sup> Annual Scientific Session
1999	Member, Internal Review Committee for the Department of Emergency Medicine, Wayne State University School of Medicine (Chair of Administrative Review)
1998	Member, Senior Servicer Planning and Advisory Committee, Detroit Medical Center
1998	Member, PSO Contracting and Reimbursement Group, Detroit Medical Center
1998	Member, Pediatric Internal Review Committee, Wayne State University School of Medicine
1998-2003	Board Member, Consortium for Southeastern Hypertension Control (COSEHC), Wake Forest University Baptist Medical Center, Winston-Salem, NC

**John M. Flack, M.D., M.P.H.**

1996-present	Member, External Advisory Committee to the Interdisciplinary Cardiovascular Group of Morehouse School of Medicine
1996	(Special Government Employee), FDA, Center for Drug Evaluation and Research, Division of Metabolic and Endocrine Drug Products
1995-1998	Steering Committee, Breast Cancer Prevention Trial (BCPT)
1995-1997	Protocol Committee General Clinical Research Center (GCRC), Bowman Gray School of Medicine
1995-1997	Advisory Committee, General Clinical Research Center (GCRC), Bowman Gray School of Medicine
1995	National Kidney Foundation, Early Intervention & Prevention Task Force
1995-present	Board of Trustees, International Society on Hypertension in Blacks, Inc. (ISHIB)
1995-1997	Clinical Research Practices Committee (GCRC), Bowman Gray Medical School
1995	Chairman, Personnel Committee, International Society on Hypertension in Blacks, Inc. (ISHIB)
1995	Finance and Audit Committee, International Society on Hypertension in Blacks, Inc. (ISHIB)
1995-1996	Membership Committee, American Society of Hypertension
1995-1996	Chairman, Parke-Davis, Southeastern United States African American Initiative
1995-1997	Steering Committee, Breast Cancer Prevention Trial (BCPT)
1995-1997	Cardiovascular Committee, Breast Cancer Prevention Trial
1995	Bristol-Myers Squibb Diabetes Education Faculty
1993-1994	Long-Range Strategy Planning Committee, Department of Medicine, University of Minnesota
1993-1994	Chair, Primary Care Subcommittee of the Long-Range Strategy Planning Committee, Department of Medicine, University of Minnesota
1993-1994	Professional Services Committee, University of Minnesota
1993-1994	Advisory Council, HealthSpan Research
1993-1994	Managed Care Task Group, University of Minnesota Clinical Associates
1993-1994	Academic Affairs Faculty Working Group, University of Minnesota
1992-present	African-American Lipid and Cardiovascular Council (AALCC)
1992-1993	Agenda Planning Committee, American Heart Association
1991-1992	Who's Who Among Rising Young Americans
1991-1994	Board Member, American Heart Association, Minnesota Affiliate
1991-present	The American Society of Hypertension
1990-1991	Subcommittee, Epidemiology MPH Admissions, University of Minnesota School of Public Health
1990-present	Research Awards Committee, Division of Epidemiology, University of Minnesota School of Public Health
1988-2015	Faculty Advisor, Student National Medical Association, University of Oklahoma College of Medicine Chapter
1987-1988	Residency Advisory Committee, Department of Medicine, University of Oklahoma
1987-1988	Seed Grant Review Committee, University of Oklahoma College of Medicine
1986-1988	Quality Assurance Committee, Oklahoma Foundation for Peer Review
1986-1988	Medical Records Committee, Oklahoma Memorial Hospital
1986-1988	Medical College Admissions Board, University of Oklahoma College of Medicine
1986-1987	Advisory Committee, Industrial Cooperative Education, Douglas High School, Oklahoma City, OK
1982-1983	Long-Range Planning Committee, Oklahoma University Health Sciences Center
1981-1982	Medical College Admissions Board, Oklahoma University Health Sciences Center

**EDITORIAL BOARDS:**

**John M. Flack, M.D., M.P.H.**

2014-	Metabolic Syndrome and Drug Therapy
2014-	Journal of Endocrine Disorders
2014-	Journal of Clinical Nephrology and Research
2013-Present	Annals of Clinical & Experimental Hypertension
2013-Present	Journal of Endocrinology, Diabetes & Obesity
2013-Present	British Biotechnology Journal
2012-Present	Advances in Combination Treatments for Hypertension
2012-Present	Journal of Diabetes Research and Clinical Metabolism (JDRCM)
2011-Present	Clinical and Experimental Pharmacology and Physiology
2011-Present	Kidney and Blood Pressure Research
2011-Present	CardioRenal Medicine
2009-Present	International Journal of Hypertension
2009-Present	Hypertension
2008-Present	Integrated Blood Pressure Control
2007-Present	Therapeutic Advances in Cardiovascular Disease
2006-Present	Journal of Clinical Hypertension
2006-Present	Current Cardiovascular Risk Reports
2005-Present	Current Hypertension Reviews
2003-Present	Hypertension
2003-Present	Internal Medicine/Cardiology News
1993-1998	ABC Digest of Urban Cardiology
1992-1994	Issues in Hypertension and Atherosclerosis
1992-1995	Urban Health
1991-1998	Obesity and Health
1990-Present	Journal of Ethnicity and Disease

**MANUSCRIPT REVIEWER:**

Advanced Studies in Medicine (ASiM)  
American Journal of Cardiovascular Drugs  
American Journal of Alzheimer's Disease and other Dementias  
American College of Cardiology (Abstract Grader)  
American Journal of Epidemiology  
American Journal of Hypertension  
American Journal of Medicine  
American Journal of Nephrology  
American Journal of Physiology – Heart and Circulatory Physiology  
Annals, Academy of Medicine, Singapore  
Annals of Clinical and Experimental Hypertension  
Archives of Internal Medicine  
BMC Cardiovascular Disorders  
British Biotechnology Journal  
Cardiology & Therapy  
CardioRenal Medicine  
Circulation (Journal of the American Heart Association)  
Clinical and Experimental Pharmacology and Physiology  
Diabetes Care  
Diabetes Metabolism Research and Reviews  
Expert Opinion on Pharmacotherapy  
Expert Review of Endocrinology & Metabolism  
Future-Drugs Ltd  
Heart Failure Reviews

**John M. Flack, M.D., M.P.H.**

Hypertension  
Hypertension Research  
Integrated Blood Pressure Control  
International Journal of Clinical Practice  
Journal of the American College of Cardiology (JACC)  
Journal of the American Medical Association  
Journal of the American Society of Hypertension (JASH)  
Journal of the Cardiometabolic Syndrome  
Journal of Clinical Hypertension  
Journal of Ethnicity and Disease  
Journal of Ethnicity and Health  
Journal of Laboratory and Clinical Medicine  
Journal of Neurological Sciences  
Journal of General Internal Medicine  
Journal of Behavioral Medicine  
Journal of Human Hypertension  
Journal of Experimental Medicine  
Journal of American Geriatric Society  
Journal of Vascular Medicine  
Journal of the Renin Angiotensin Aldosterone System  
Lipids in Health and Disease  
Mayo Clinic Proceedings  
Medical Care  
Medicine  
Nature Clinical Practice Cardiovascular Medicine  
Nutrients Reviews Cardiology  
Post Graduate Medicine  
Preventive Medicine  
Public Health Association  
Redox Report  
Therapeutic Advances in Cardiovascular Disease  
West Indian Medical Journal  
Women's Health in Primary Care

#### **ASSOCIATE EDITOR**

American Journal of Hypertension  
CardioRenal Medicine (ended 2018)  
International Journal of Hypertension (2014 - 2017)

#### **COMMUNITY SERVICE:**

2018	Member, Springfield Urban League Board of Directors
2018	Member, Frontiers International, Springfield Chapter
2016	Central Management Services Home Health webinar "One Giant Leap for Preventive Cardiovascular Care"
2015	Springfield (IL) Branch NAACP general meeting "Health Concerns for People of Color"
2013	New Detroit "Impacting Institutional Practices Health Disparities Work Group".
2008	Detroit Public Library - Black History Month "Changes That Will Make a Difference Today and Tomorrow: What the Current Research Demonstrates"
2005	Owen Elementary Head Start Program-March Parent Meeting

John M. Flack, M.D., M.P.H.

“Preventing Hypertension, Heart Disease & Diabetes in our Children with Proper Nutrition”  
2005 Center for Urban and African American Health (CUAAH)  
-Past Present & Future of African American Research  
2004 Center for Urban and African American Health (CUAAH)  
-Annual Martha G. Scott Health Screening Fair  
2004 Helping Educate African American and Latinos on research being conducted on health disparities “Cutting Edge Newsletter” (*article written on CUAAH*)  
2003-2015 Mentoring Program Wayne State University-School of Medicine  
2003 Wayne County Community College “Combating Health Disparities” (lecture/panel)  
2003 Wayne County Department of Health “Cardiovascular Drug Therapy Which Drug for Which Patient” (lecture/discussion)  
2002 Wayne State University-CECA Program, “Health Screening Fair”  
2001 Senator Raymond M. Murphy’s African American Health Conference  
2001 NIH National High School Students Summer Mentoring Research Program  
2001 100 Black Men of Greater Detroit  
1994 Hennepin County Medical Society, “Success By 6” Program  
1994 Mentor Program at Willard Math, Science and Technology Elementary School

#### TEACHING:

2016 Southern IL University School of Medicine  
Grand Rounds, “Is Vitamin D Deficiency an Important Therapeutic Target?”  
2015 Southern IL University School of Medicine  
Grand Rounds, “Demystifying the Enigma of Resistant Hypertension”  
2007 Wayne State University  
Presidential Health Disparities Conference  
“Is Vitamin D an Important Cause of Obesity as Well as a Mediator of Obesity-Related Disease?”  
Wayne State University  
Summer Lecture Series  
“Hypertension: Interns Part I”  
Wayne State University  
Neurology Grand Rounds  
“Ruminations Regarding the Excess Cardiovascular-Renal Disease Burden in U.S. Blacks: Clues from Interlinked Deranged Physiological Pathways”  
Wayne State University  
Year II Clinical Medicine Course  
“An Approach to Understanding Health Disparities”  
Wayne State University  
Year I Clinical Medicine Course  
“Ethnic and Racial Disparities”  
2005 Wayne State University  
Department of Family Medicine/Clinical Medicine Lecture  
“What is Race? What is Ethnicity?”

John M. Flack, M.D., M.P.H.

Wayne State University  
Department of Family Medicine/Clinical Medicine Lecture  
“An Approach to Understand Health Disparities”

Wayne State University  
Resident Summer Lecture Series  
“Hypertensive Urgencies, Emergencies, and BP Management During Acute Stroke”

Wayne State University Guest Lecturer, Community Medicine Students  
“Cardiovascular Epidemiology: An Overview”

In-patient ward rounding, February (Detroit Receiving Hospital)

2004

Wayne State University  
Dept of Medicine 2<sup>nd</sup> Asian American Conference  
“What’s New in Hypertension?”

DMC-Dept of Obstetrics & Gynecology (Sinai-Grace)  
“Hypertension Therapeutics in Women: Special Issues”

Wayne State University-African American Student Society  
“Unraveling Selected African American Health Disparities with a  
Multi-disciplinary Team”

Wayne State University Department of Medicine  
Endocrinology Grand Rounds  
“Why Does Sodium Raise BP in Obese Persons”  
Synergy Medical Covenant Healthcare

Internal Medicine Grand Rounds  
“Hypertension in Blacks”

Wayne State University  
Medical Alumni Association Conference  
“Obesity/Hypertension”

Wayne State University-Neurology Grand Rounds  
“Management of BP in Acute Stroke, Hypertensive Emergencies and Urgencies”

Wayne State University  
Emergency Medicine Grand Rounds  
“Management/Disposition of New Onset & Uncontrolled Hypertension in the  
Emergency Department”

Wayne State University  
Family Medicine Conference  
“An Approach to Understand Health Disparities”

Grady Memorial Hospital-Grand Rounds  
“The Pervasive Metabolic & Hemodynamic Consequences of Obesity: No Good  
News”

Wayne State University



**John M. Flack, M.D., M.P.H.**

Resident Summer Lecture Series  
“Hypertension Update”

Wayne State University  
Center for Urban and African American Health Lecture Series  
“Obesity: The Pervasive Weapon of Mass Public Health Destruction”

Wayne State University Symposium  
Michigan Consortium for Minority Health & Academic Development  
“Racial & Ethnic Disparities: The looking glass into broader societal and health systems problems”

Wayne State University  
American Medical Student Association Conference  
“What are Healthcare Disparities”

Wayne State University-University Internal Medicine Specialists  
Employee In-service lecture and discussion  
“Hypertension: The Silent Killer”

Wayne State University  
Department of Family Medicine/Clinical Medicine  
“Ethnic & Racial Disparities in Health Status”

2003

Wayne State University  
Grand Rounds “Clinical Patient Care”  
Grand Rounds “Hypertension Update”

General Motors Occupational Health symposium “What’s New in Hypertension?”  
In-patient ward rounding, March (Harper Hospital)  
Wayne State University-School of Medicine  
Preventive Medicine in Public Health  
“Ethnic Race Disparities in Health Status”

DMC-Sinai-Grace Hospital  
“Hypertension Emergencies and Urgencies”

Wayne State University-School of Medicine  
“Advanced Hypertension Management Course”

2002

Wayne State University-School of Medicine  
Pathophysiology  
Year II Medical Students  
Clinical Research Center Lectures Series

Wayne State University-School of Medicine  
2<sup>nd</sup> Annual Update in Internal Medicine - Bay Harbor  
“Controversies and New Developments in High-Risk Hypertension: Focus on Diabetes Mellitus, Kidney Disease in AA”

In-patient ward rounding, March (Harper Hospital)

National Kidney Foundation (NKF) Clinical Nephrology Lectures

**John M. Flack, M.D., M.P.H.**

- 2001            In-patient ward rounding, January (Harper Hospital)
- Wayne State University-Mini Medical School  
“Living with Hypertension”
- Wayne State University-School of Medicine  
Pathophysiology  
Year II Medical Students
- Wayne State University-School of Medicine  
Clinical Perspectives on Vascular Health  
Year III Medical Students
- Wayne State University-School of Medicine  
1<sup>st</sup> Annual Update in Internal Medicine - Bay Harbor, MI  
“An Ounce of Prevention and a Pound of Cure”
- American Society of Hypertension (ASH)  
Certified Specialist Exam-“Specialist in Clinical Hypertension”
- Wayne State University-School of Medicine  
Preventive Medicine in Public Health  
“Ethnic and Racial Disparities in Health Status
- 2000            In-patient ward rounding, April (Detroit Receiving Hospital) and June, (Harper Hospital)
- OSCE Exam  
Third year students  
Wayne State University- School of Medicine
- “Hypertensive, Urgencies, Emergencies, & Common Secondary Causes”  
Cardiology Board Review Course  
Wayne State University – School of Medicine
- “Diagnosis and Treatment of Hyperaldosteronism”  
Endocrinology Review Course  
Wayne State University- School of Medicine
- Supervise an Endocrinology fellow in clinic one-half day per week.
- 1982            “Peripheral Vascular Disease/HTN”  
Board Review Course for Residents  
Wayne State University- School of Medicine
- 1997            Seventh Annual Physician Assistant Satellite Comprehensive Review Course “Hypertension Update.”  
Wake Forest University School of Medicine
- 1996            Physician Assistant Program  
Course on “Hypertension.”  
Wake Forest University School of Medicine



John M. Flack, M.D., M.P.H.

**RADIO/TELEVISION APPEARANCE(S):**

2019, WTAX “Ask the Expert” Radio show guest appearance

2016, WILL-AM, NPR, The 21<sup>st</sup> Show, “Precision Medicine Initiative”, August 3 (*live taping*)

2015, WICS TV (Springfield, IL), “African Americans Twice as Likely for Sudden Cardiac Arrest”, July 21

2010, WJBK, “ASPREE Study: Aspirin and Aging in the Elderly”, July 21

2010, WWJ 950 am, “ASPREE Study: Aspirin and Aging in the Elderly”, July 20

2005, WXYZ, “CVRx Surgical Procedure for Treatment of Hypertension”, July 13 (*live taping*)

2005, CBS, Street Beat with Edward Foxworth, “The American Heart Association and its effect on African-Americans”, January 31 (*live taping*)

2004, UPN/CBS “Hypertension in African Americans”, October 11 (*live taping*)

2004, WLQV 1500 AM “Ask the Doctor” Live radio talk show, October 13

2004, The Dr. Jimmy Womack Show-WGPR 107.5 FM, “Hypertension”

2002, HealthQuest Live, hosted by the publisher of HealthQuest Magazine, Sara Lomax Reese, WURD 800 AM Philadelphia.

2001, The Dr. Jimmy Womack Show-WGPR 107.5 FM, “Hypertension”, December 16

2001, Diane Watkins Show-WHPR 88.1 FM and TV 68, “Hypertension Unchecked Silences Hearts”, [H.U.S.H.], May 25

1999, Newspaper USA Today coverage of discovery that the Angiotensin converting Enzyme gene (II) polymorphism predicts salt-sensitivity in normotensive African-Americans, March 25.

1998, Network Television, Program on the weight loss drug Sibutramine, 48 Hours

**FACULTY, PRE-POSTDOCTORAL FELLOWSHIP MENTORING:**

Tarek El-Achkar, MD (Assistant Professor, Department of Medicine/Nephrology, Indiana University); mentored him and co-authored a manuscript with him while a Resident at Wayne State.

Philip Levy, MD (Associate Professor of Emergency Medicine, Wayne State University); served as his Robert Woods-Johnson Clinical Scholars Mentor.

Rosalind Peters, RN, MSN, PhD; mentored her and also served on her dissertation committee at Wayne State University College of Nursing (currently an Associate Professor at Wayne State).

John M. Flack, M.D., M.P.H.

Samar Nasser, PAC, PhD; served as chair of her PhD dissertation committee (Physiology) between 9/1/2005 – 1/18/2011, degree conferred 5/31/2011. Dissertation title: “*Effect of Dimethylarginine Dimethylaminohydrolase in the Development of Salt Sensitivity*”

Anna Valina-Toth, MD, PhD; served as chair of her PhD dissertation committee (Physiology) between 6/1/2006 – 6/26/2009, degree conferred 5/3/2011. Dissertation title: “*Vitamin D and Parathyroid Hormone: Relationships with Obesity, Nitric Oxide Metabolites, Oxidative Stress, Blood Pressure, Vascular Function and Salt Sensitivity in African Americans*”

Beth Staffileno, PhD (Associate Professor, Rush University Medical Center, College of Nursing); recruited and mentored her at Wayne State University as a junior faculty prior to her departure for Rush University.

#### STUDENT AND RESIDENT MENTORING:

- 2018 Ashley Hill (Certified Nurse Practitioner) mentor for her DNP research project
- 2016 Sona Fokum, (10<sup>th</sup> grade student at Illinois Math and Science Academy), mentored her on a project focused on developing a risk prediction score for resistant hypertension.
- 2016 Bashar Amr, PGY IV (Chief Medicine Resident), mentored him on the project “Higher Systemic Vascular Resistance Impairs Hypertension Control (project took 2<sup>nd</sup> place at the 26<sup>th</sup> Annual Southern Illinois University Trainee Research Symposium)
- 2006 Crystal Simpson, MD, PGY II (St. John’s Internal Medicine Program) is doing research rotation focused on identifying the correlate of hypokalemia on subsequent BP responses.
- 2006 Julie Wright, MD, PGY III Resident research rotation focused on understanding the linkage of albuminuria and hemoglobin/RBC mass in persons with chronic kidney disease independent of estimated glomerular filtration rate.
- 2006 Krithi Ramesh, MD, PGY II Resident research rotation focused on understanding the impact of glycemic control on longitudinal blood pressure responses in persons with diabetes and hypertension who are pharmacologically treated; also examined the interactive effect of glycemic control with statin therapy on BP responses.
- 2006 Ratnavalli Pasupulati, MD, PGY II is doing a research project using MedTrace electronic medical record to determine if the BP lowering effect of statins is consistent across a broad range of kidney function.
- 2006 Hypertension Clinic Resident Physicians Second Clinic Rotation  
½ day/week for 6 months  
John Tsay, MD, PGY II  
Kristen Kingzett, MD, PGY II  
Julie Wright, MD, PGY III

**John M. Flack, M.D., M.P.H.**

- 2005 Surabel Gebrreselassie, MD, PGY III Resident research rotation in the Cardiovascular Epidemiology and Clinical Applications Program (CECA). Project: Determine the impact of important factors - particularly statin drug therapy and diuretics on the diurnal variation in ambulatory BP in persons referred for measurement of ABPM. Also determine the longitudinal impact of statins and diuretics on the cuff systolic and diastolic BP. (July, 2005)
- 2005 Kavitha Potluri, MD, PGY II Resident research rotation in the Cardiovascular Epidemiology and Clinical Applications Program (CECA). Project: Develop an algorithm for identification of patients who have undergone screening for critical renal artery stenosis with renal artery duplex scanning, and develop an algorithm for identifying patients in MedTrace with critical renal artery stenosis/renovascular hypertension. (September and October, 2005)
- 2005 Rekha Galla, MD, PGY II Resident research rotation in the Cardiovascular Epidemiology and Clinical Applications Program (CECA). Project: Develop an algorithm for identification of patients who have undergone screening for critical renal artery stenosis with renal artery duplex scanning, and develop an algorithm for identifying patients in MedTrace with critical renal artery stenosis/renovascular hypertension. (September, 2005)
- 2005 Neelima Penugonda, MD, PGY II Resident research rotation in the Cardiovascular Epidemiology and Clinical Applications Program (CECA). Project: Work on the development of a multi-component quality measure for BP care and describe the various properties of the antihypertensive therapeutic index.
- 2005 Pravati Das, MD, PGY III Resident research rotation in the Cardiovascular Epidemiology and Clinical Applications Program (CECA). (Sept. & Oct., 2005)
- 2005 Jaravaza Tinevimbo, MD, PGY II Resident research rotation in the Cardiovascular Epidemiology and Clinical Applications Program (CECA). Project: Examine the role of thiazolidinedione (TZD's) on longitudinal BP change in persons with diabetes. (Sept., 2005)
- 2005 Jason Ramos, MD, MS IV, 1 month research rotation (March 2005)
- 2005 Chalini Chandra, MD PGY-III, 1 month clinical and research rotation (March 2005)
- 2004-2008 Mentoring-Wayne State University School of Medicine student(s) classes of:  
2005- Andrew Weise & Andrew Muskovitz  
2007- Mark Zakaria, Ryan Agema, Salman Baig, Michelle Bizon, William Cutriss, & Henrikas Vaitkevicius  
2008- Ralph Dilisio, Antonia Jerkins, Manish Kapadia, Dayna Le Platte Patricia Pentiak & Rachel Weisenfeld
- 2004 Howard Blank, MD, PGY II Resident research rotation in the Cardiovascular Epidemiology and Clinical Applications Program (CECA). Research project on the rates as well as determinants of blood pressure control in ~500 patients with diabetes mellitus seen in two internal medicine teaching clinics over the course of 1 year.
- 2004 Lenor Corsino-Nunez, MD, PGY III Resident research rotation in the Cardiovascular Epidemiology and Clinical Applications Program (CECA) project related to the process of care measures and cardiovascular risk factor control in

John M. Flack, M.D., M.P.H.

persons with diabetes receiving care. Dr. Corsino-Nunez will also work in the Hypertension clinic for 6 months from July-Jan, 2005.

- 2004 Crystal Simpson, Medical student Year IV, Wayne State University School of Medicine. Crystal worked on conceptualization and development of clinical research projects involving secondary data analyses of already completed research projects. Worked in the Hypertension clinic three half days a week.
- 2004 Ivan Hanson, Medical student Year IV. Wayne State University School of Medicine research rotation in the Cardiovascular Epidemiology and Clinical Applications Program (CECA). Project - Describe the overall BP control rates along with the overall characteristics of the hypertensive patients
- 2003-2007 Mentoring-Wayne State University School of Medicine student(s) classes of:  
2004- Fadi Eliya  
2005- Andrew Weise, Andrew Muskovitz & Jeffery Tang  
2006- John Briles & Jamie Johnson  
2007- Mark Zakaria, Ryan Agema, Salman Baig, Michelle Bizon, William Cutriss & Henrikas Vaitkevicius
- 2003 Ali Khan, MD, PGY II Resident research rotation in the Cardiovascular Epidemiology and Clinical Applications Program (CECA).
- 2003 Deepak Koul, MD, PGY II Resident research rotation in the Cardiovascular Epidemiology and Clinical Applications Program (CECA). Project related to the benefits of revascularization in African Americans with critical renal artery stenosis and predictors of a good outcome after angioplasty and stenting in patient with critical renal artery stenosis.
- 2003 Leonor Corsino, MD, PGY II Resident research rotation in the Cardiovascular Epidemiology and Clinical Applications Program (CECA). Project related to the comprehensive training support intervention for diabetes [CTSI-D].
- 2003 Farrukh Koraishy, MD, PGY II Resident research rotation in the Cardiovascular Epidemiology and Clinical Applications Program (CECA). Project related to the study of sodium sensitivity in blacks [SNaP].
- 2003 Lalitha Rudraiah, MD, PGY III Resident research rotation in the Cardiovascular Epidemiology and Clinical Applications Program (CECA). Project entitled "Alterations in Circulation Blood Pressure Rhythms in Persons with Reduced Kidney Function and/or Proteinuria".
- 2002 Abhijeet Goyal, MD, PGY I, Wayne State University-Medical School. Mentor to an internal medicine resident house officer.
- 2002 Sandhi Nimmagadda, MD, PGY III, Resident research rotation in the Cardiovascular Epidemiology and Clinical Applications Program (CECA). Project was to determine the overall prevalence of CVD kidney risk factors and their control amongst persons referred to our clinic with diabetes mellitus.
- 2002 Anita Khanna, MD PGY II, Resident research rotation in the Cardiovascular Epidemiology and Clinical Applications Program (CECA). Project was to determine the overall impact of the MedTrace system on the effectiveness of management of hypertension amongst persons with reduced kidney function.

John M. Flack, M.D., M.P.H.

- 2002 Crystal Jones, MD, PGY II, Resident research rotation in the Cardiovascular Epidemiology and Clinical Applications Program (CECA) Secondary data analysis of clinical database. Project was focused on identifying predictors of blood pressure response in hypertensive patients with reduced kidney function.
- 2002 Sidhu Mandeep, MD, PGY III, Resident research rotation in the Cardiovascular Epidemiology and Clinical Applications Program (CECA). Project NSAID's influence BP responses in persons with hypertension, does this effect differ by level of GFR as well as albuminuria status?
- 2002 Evans Mokwe, MD, PGY I, Resident research rotation in the Cardiovascular Epidemiology and Clinical Applications Program, (CECA). Project focused on the role of race, per se, in predicting BP response that is independent of indifiabile potential confounders? Abstract entitled "*Determinants of Blood Pressure Response to Ace Inhibitor Monotherapy in Hypertensive African Americans and Caucasians*" accepted at the Annual American Society of Hypertension Scientific Meeting, New York, May 13, 2003.
- 2001 Damanjeet Chugh, MD, PGY II, Resident research rotation in the Cardiovascular Epidemiology and Clinical Applications Program (CECA). Worked on the development of MDRD estimator of Glomerular filtration rate (EGFR) pocket-sized reference card for men and women base on age, gender, race and serum cretinine level.
- 2001 Karandeep Singh, MD, PGY III, Resident research rotation in the Cardiovascular Epidemiology and Clinical Applications Program (CECA), Secondary analysis of clinical database. Abstract entitled-Role of race in predicting blood pressure response independent of identified potential confounders-presented at the ASH meeting, San Francisco, June 8-12, 2002.
- 2001 Jawaint Rangi, MD, PGY II, Resident research rotation in the Cardiovascular Epidemiology and Clinical Applications Program (CECA) Analyses from existing Clinical trial data sets. [ATIME] Accupril Titration Interval Management Study and the Sodium Sensitivity in Blacks Study.
- 2001 Bede Nnolim, MD, PGY II, Resident research rotation in the Cardiovascular Epidemiology and Clinical Applications Program (CECA). Development of MDRD Estimate of Glomerular Filtration rate (EGFR) reference card for men and women based on age, race, gender and serum creatinine measurement.
- 2001 Tarek El-Achkar, MD, PGY II, Resident, research rotation in the Cardiovascular Epidemiology and Clinical Applications Program (CECA). Performed a secondary data analysis on the National Kidney Foundation Kidney Early Evaluation and Prevention Program database [N=7000] that resulted in a manuscript entitled "Higher Prevalence of Anemia with Diabetes Mellitus in Moderate Kidney Insufficiency" and an abstract accepted for presentation at the American Diabetes Association (ADA), 2002, entitled "Higher Prevalence of Anemia with Diabetes Mellitus in Moderate Kidney Insufficiency."
- 2001-2002 Hisham Alrefai, MD, Endo Fellow, has worked on two major research projects this year. First, Dr. Alrefai academically performed an analysis on our clinic database that should statin therapy lowers blood pressure significantly in drug – treated hypertensive patients. A second major project was an analysis of this same clinical

John M. Flack, M.D., M.P.H.

database to delineate the impact of non-selective non-steroidal anti-inflammatory drugs and selective COX-2 inhibitors on blood pressure response to anti hypertensive therapy by level of kidney function in drug-treated hypertensive.

- 2001                    NIH-Charles R. Drew University of Medicine & Science National Summer Mentoring Program- Michael McIver 12<sup>th</sup> grade, University Liggett High School and Natalie Taliaferro 12<sup>th</sup> grade Mercy High School, Project title: The Relationship of Kidney Function and Cardiovascular Risk Factors in Men and Women at Risk for Kidney Disease.
  
- 2000                    Rob Thornburg, 4<sup>th</sup> year student, Wayne State University. Secondary analysis of Hypertension Clinical database. Abstract entitled "*Factors Correlated to Blood Pressure Response in Hypertensive Patients with Type 2 Diabetes Mellitus*", accepted for presentation at the American Society of Hypertension, Scientific meeting, San Francisco, CA 2001.
  
- 2000                    Karl Duncan, MD, PGY II, Resident, research rotation in the Cardiovascular Epidemiology and Clinical Applications Program (CECA). Secondary analysis of Hypertension Clinical database. Abstract entitled, "*The Influence of Urinary Albumin Excretion and Estimated Glomerular Filtration Rate on Blood Pressure Response in Drug-Treated Hypertensive Patients in an Academic Hypertension Clinic*", accepted for presentation at the 2001 American Society of Hypertension Scientific meeting, San Francisco, CA. A manuscript from this abstract is nearly complete.
  
- 2000                    Edouard Daher, MD, faculty mentee was successful in securing internal "Seed Grant" funding during calendar year 2000.
  
- 2000                    Karandeep Singh, MD, PGY II, Resident, research rotation in the Cardiovascular Epidemiology and Clinical Applications program (CECA). He performed a secondary analysis of our clinical database.
  
- 1998-2000           Navdeep Mann, MD, PGY III, Resident, completed a five week research rotation under my tutelage. Co-authorship of a book chapter on renal artery stenosis and general research mentoring
  
- 2000                    Rosalind Peters, RN, MSN, Doctoral Student: Member of Ph.D., Dissertation Committee Wayne State University College of Nursing Center for Health Research. Co-authored peer-reviewed manuscript together.
  
- 1999-2002           Joanne Studley, Wayne State University, Undergraduate Student, Project: Secondary data analysis of the "Treatment of Low HDL Cholesterol (TOLC) dataset."
  
- 1997                    Charles Holmes, fourth-year Wayne State University Medical Student, Project: Secondary data analysis of the NHLBI-funded [SNaP] Sodium and Blood Pressure dataset; "Interaction of Obesity and the Renin-Angiotensin Aldosterone-Kinin System in Mediating Salt-Sensitivity in Normotensive African-Americans."
  
- 1997                    Jyothy John Puthumana, third-year Wayne State University Internal Medicine Resident Project: Secondary data analysis of the SNaP dataset; "Relationship of Obesity to Blood Pressure Response to Dietary Sodium Manipulations in Normotensive African-Americans"



John M. Flack, M.D., M.P.H.

**GRANTS AND CONTRACTS SUPPORT (ACTIVE):**

1. Title: Chronic Renal Insufficiency Cohort Study (CRIC)  
Funding: University of Michigan NIDDK 5K24DK062234 UM Subcontract (\$613,942)  
Purpose: NIH-Sponsored, multicenter, prospective cohort study designed to determine the risk factors for accelerated decline in renal function and to evaluate the incidence and risk factors for cardiovascular disease (CVD) in patients with chronic renal insufficiency (CRI).  
Period: 05/04-ongoing  
Role: Co-Investigator-Wayne State University site  
FTE: 0%
2. Title: Bayer Protocol 16244: A Randomized, double-blind, placebo-controlled, parallel-group, multi-center, event-driven Phase III study to investigate the efficacy and safety of finerenone, in addition to standard of care, on the progression of kidney disease in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease.  
Funding: Bayer  
Period: 12/18/2015—ongoing  
Role: Principal Investigator – Southern Illinois University  
FTE: 5%
3. Title: A Phase 3 randomized, open-label, active-controlled, parallel-group, multi-center, event driven study in non-dialysis subjects with anemia associated with chronic kidney disease to evaluate the safety and efficacy of GSK1278863 compared to darbepoetin alfa  
Funding: Glaxo Smith Kline (approx. \$210,000)  
Purpose: To demonstrate whether GSK1278863 is non-inferior or superior to darbepoetin alfa for cardiovascular safety  
Period: 04/2016-Ongoing  
Role: Principal Investigator  
FTE: 5%
4. Title: Southern Illinois University – Illinois Hospital Association Hypertension TeleECHO Clinic Grant  
Funding: Center for Medicaid Services (CMS)/Illinois Hospital Association (AHA)  
Purpose: To develop and deliver a hypertension management curriculum to primary care providers in southern and central Illinois using interactive case-based approaches via teleconferences  
Period: 2017 – 2019  
Role: Principal Investigator  
FTE: 7.5%
5. Title: Bayer Protocol 17530: A Randomized, double-blind, placebo-controlled, parallel-group, multi-center, event-driven Phase III study to investigate the efficacy and safety of finerenone on the reduction of cardiovascular morbidity and mortality in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease in addition to standard of care.  
Funding: Bayer  
Period: 12/18/2015—ongoing  
Role: Principal Investigator – Southern Illinois University  
FTE: 5%

John M. Flack, M.D., M.P.H.

6. Title: CALM-2: Controlling and Lowering Blood Pressure with the MobiusHD  
Funding: Vascular Dynamics  
Period: 3/16/2018 – ongoing  
Role: Principal Investigator – Southern Illinois University  
FTE: 3%
7. Title: NEW-HOPE: A Phase 2, Open-Label, dose-Titrating Safety and Efficacy Study of QGC001 Administered Orally, Twice Daily, Over 8 Weeks in Hypertensive Overweight Subjects of Multiple Ethnic and Racial Groups in the United States.  
Funding: Quantum Genomics  
Period: 1/22/2018 – ongoing  
Role: Principal Investigator – Southern Illinois University  
FTE: 3%
8. Title: RADIANCE-HTN: A study of the ReCor Medical Paradise System in Clinical Hypertension  
Funding: ReCor Medical  
Period: 5/15/2018 – ongoing  
Role: Principal Investigator – Southern Illinois University  
FTE: 3%
9. Title: PRECISION: Multi-center, blinded, randomized, PaRallEl-group, Phase 3 study with aprocltentan in Subjects with ResIstant Hypertension (RHT).  
Funding: Idorsia  
Period: Anticipated 7/2018 – ongoing  
Role: Principal Investigator – Southern Illinois University  
FTE: 3%
10. Title: SIU Hypertension Registry  
Funding: SIU Internal Funding  
Period: 3/20/2020 –  
Purpose: To do extensive non-invasive vascular and body composition phenotyping in several high-risk hypertension subgroups (resistant & refractory hypertension, women with history of any hypertensive disorder of pregnancy, and patients with primary aldosteronism); these cohorts will be followed longitudinally and compared to their natural comparator groups to better understand how these conditions mediate high vascular risk.

**GRANTS AND CONTRACTS (Pending Review):**

1. Title: Biological Screening for Medication Adherence in SPRINT (R21HL153658)  
Funding: NIH  
Purpose: To directly measure antihypertensive drug metabolites in stored SPRINT study samples to understand their relationship to blood pressure responses, serious adverse events (SAEs) and CVD-renal study outcomes.  
Period: 7/1/2020 – 6/30/2022  
Role: Principal Investigator  
FTE: 7.5%
2. Title: Impact of Objectively Measuring Antihypertensive Medication



John M. Flack, M.D., M.P.H.

Adherence on CVD-Renal/Mortality Attributable to Hypertension Phenotypes in CKD Patients  
Funding: NIH/CRIC Opportunity Pool  
Purpose: To directly measure antihypertensive drug metabolites in stored CRIC study samples to understand the extent of adherence to antihypertensive medications in CKD patients and also to determine the impact of medication on CVD-renal and mortality risk estimates to various hypertensive phenotypes.  
Period: 12/31/2020 – 1/01/2021  
Role: Principal Investigator  
FTE: 0.24 calendar months

**GRANTS AND CONTRACTS (Submitted but Unfunded):**

1. Title: Effect of Vitamin D in Pre-diabetes and Obesity  
Funding: NIDDK  
Purpose: To determine the relative impact of high-dose Vit D (3600IU/D) relative to low-dose (500IU/D) on visceral adiposity, glycemic control, inflammation and traditional CVD risk factors in obese normotensive African Americans with pre-diabetes.  
Period: 9/1/2013 – 8/31/2017 (Not funded)  
Role: Principal Investigator  
FTE: 30%
2. Title: Maximizing Hypertension Treatment Effectiveness (MHyTE) study (R01NR019474)  
Funding: NINR  
Purpose: A cluster randomized trial testing whether a distance learning intervention aimed at rural physicians and nurses improved BP lowering; hypertension related process of care measures, professional competence the intervention uses the flipped classroom approach. (Grant was administratively triaged because professional education was outside the scope of their funding priorities)  
Period: 7/1/2020 – 6/30/2025  
Role: Principal Investigator  
FTE: 7.5%

**GRANTS AND CONTRACTS (COMPLETED):**

1. Title: Adjunct Vitamin D Therapy with Vitamin D as a Means to Reduce Disparities Subclinical Target-Organ Cardiac Damage Among Vulnerable Hypertensive Patients.  
Funding: NIH/NIMHD (1R01 MD005849-01A1) (\$1,250,000)  
Purpose: Vitamin D deficiency may be an important contributor to racial differences in hypertensive heart disease but whether adjunct vitamin D therapy provides benefit is unknown. We seek to ascertain the effect of adjunct vitamin D therapy on left ventricular hypertrophy (primary aim), myocardial fibrosis and central vascular function (secondary aims) at one-year using a placebo controlled, randomized design.  
Period: 03/01/11-02/28/16  
Role: Co-investigator

John M. Flack, M.D., M.P.H.

- FTE: 5%
2. Title: Aspirin in Reducing Events in the Elderly (ASPREE)  
Funding: National Institute on Aging/Berman Center for Outcomes and Clinical Research Subcontract (\$2,088,000)  
Purpose: The purpose of this project aims to assess whether aspirin can not only prolong life but help provide a life free of physical disability and/or dementia for healthy older people.  
Period: 04/01/2010 through 03/31/2017  
Role: Principal Investigator-Wayne State University site  
FTE: 5%
  3. Title: Vitamin D Augmentation of Tekturna® (Aliskiren) in Hypertension (VDATH)  
Funding: Novartis Pharmaceutical Corporation (\$512,733)  
Purpose: The overarching hypothesis is that African Americans with hypertension have an overactive renin angiotensin system at the tissue level and a metabolic milieu (high oxidative stress and depressed nitric oxide metabolism), both conceivably as a consequence of or at least significantly influenced by, vitamin D deficiency. We posit that this results in the lesser average BP response to monotherapy with renin angiotensin system blockers. (Investigator initiated; sponsor terminated study after enrolling 10 patients because of safety concerns with aliskiren emanating from another trial)  
Period: 01/01/2011 through 07/31/2012  
Role: Principal Investigator  
FTE: 5%
  4. Title: Community Network Program for Older Underserved African American Adults  
Funding: NIH (NCI) \$2,580,746  
Purpose: To propose an active and comprehensive community-based program to reduce disparities of breast, prostate, colorectal, and lung cancer in older African American Adults in metropolitan Detroit.  
Period: 04/01/05 through 03/31/10  
Role: Co-Investigator  
FTE: 10%
  5. Title: A Prospective, Randomized, Open-Label Clinical Trial to Evaluate the Effect of Tekturna® (Aliskiren), Angiotensin Inhibitors, Diuretics, and Calcium Channel Blockers on Coronary Flow Reserve in Patients with Type II Diabetes and Hypertension  
Funding: Novartis Pharmaceutical Corporation/William Beaumont Hospitals Subcontract \$53,448  
Purpose: To evaluate the effects of a Tekturna (aliskiren) on coronary flow reserve in diabetic, hypertensive patients being treated with an ACE inhibitor and amlodipine.  
Period: 04/01/2010 through 03/31/2011  
Role: Principal Investigator
  6. Title: Mechanisms of Meditation in Hypertension in Blacks  
Funding: NIH-NHLBI  
Institution: Maharishi University of Management Research Institute/Center for Natural Medicine and Prevention

John M. Flack, M.D., M.P.H.

- Purpose: To develop research infrastructure to enhance the conduct of multi-disciplinary, disparities related research.  
Period: 2/2008-2012  
Role: Data Safety and Monitoring Board Member  
FTE: 0%
7. Title: Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL)  
Funding: National Institute of Health/University of Toledo Subcontract \$26,925  
Purpose: A prospective, multi-center, unblinded, two-arm, randomized trial to test the hypothesis that medical therapy with stenting of significant renal artery stenoses in patients with systolic hypertension reduces the incidence of adverse cardiovascular and renal events compared with medical therapy alone.  
Period: 9/06 through 12/12  
Role: Principal Investigator-Wayne State University site  
FTE: 1%
8. Title: Center for Urban and African American Urban Health.  
Funding: National Institute of Environmental Health Science [ES-012395] \$5,946,924  
Purpose: Understanding the mechanisms operating at multiple levels (environment, lifestyle, physiology, genetics) mediating known disparate chronic conditions and their precursors and to identify preventive strategies and therapeutic approaches that might alleviate the disproportionate burden of disease  
Period: 09/01/2003 through 05/31/2008  
Role: Principal Investigator  
FTE: 25 %  
  - Principal Investigator Administrative Core (\$543,876)  
10% Effort
  - Principal Investigator Individual R01 Project:  
Obesity, Nitric Oxide, Oxidative Stress and Salt Sensitivity  
(\$483,796) 15% Effort
9. Title: Research Enhancement Grant  
Funding: Wayne State University Office of the President & Provost \$1,800,000  
Purpose: To develop research infrastructure to enhance the conduct of multi-disciplinary, disparities related research.  
Period: 11/2004-10/2007  
Role: Principal Investigator  
FTE: 0%
10. Title: Comprehensive Treatment and Support Intervention [CTSI-D] for Diabetes  
Funding: International Society of Hypertension in Blacks/Association of Teachers in Preventive Medicine/Center for Disease Control \$402,756.00  
Purpose: Intervention to provide a comprehensive, evidence-based decision support to internal medicine house-officers and attendings using the MedTrace electronic medical clinical decision support system at two internal medicine resident clinics at major academic centers.  
Period: 1/2002 through 12/2005  
Role: Principal Investigator  
FTE: 13%

John M. Flack, M.D., M.P.H.

11. Title: Nurse-Managed Blood Pressure Telemonitoring with African Americans  
Funding: National Institute of Health \$1,490,000.00  
Purpose: To compare usual care only with home telemonitoring/telecounseling plus usual care to determine which has the greatest effect on change in blood pressure from baseline; and to examine why the intervention works to control blood pressure by examining selected mediators, ie, dietary habits, physical activity level, weight loss, reduced alcohol intake habits, physical activity level, weight loss, reduced alcohol intake, compliance with an antihypertensive medication regimen, and contact with primary care provider.  
Period: 09/2000 through 09/2005  
Role: Co-Investigator  
FTE: 6%
12. Title: Secondary Prevention of Small Subcortical Strokes (SPS3)  
Funding: University of Texas Health Science Center NIH-NINDS  
Purpose: To define efficacious therapies for cerebral small artery disease and its two most common clinical manifestations: small subcortical strokes (S3) (a.k.a. lacunar strokes) and cognitive decline (vascular dementia)  
Period: 03/2003-02/2004  
Role: Investigator  
FTE: 10%
13. Title: Multi-center, Double-blind, Randomized Placebo-controlled Parallel Group  
Funding: MSP Singapore Co., LLC c/o Merck & Co., Inc.  
Purpose: 6-week study to evaluate the efficacy and safety of ezetimibe 10/day when added to ongoing therapy with a statin versus statin therapy alone, in patients with hypercholesterolemia who have not reached National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III target LDL-cholesterol level.  
Period: 05/20/2002 through 02/01/ 2003  
Role: Principal Investigator  
FTE: 5%
14. Title: A 6-week Randomized, Open-label, Comparative Study to Evaluate the Efficacy and Safety of Rosuvastatin and Atorvastatin in the Treatment of hypercholesterolemia in African-American subjects (ARIES).  
Funding: Astra Zeneca Pharmaceutical  
Purpose: Compare the efficacy of 2 doses of rosuvastatin (10 & 20 mg) with 2 doses of atorvastatin (10 & 20 mg) in African-American Subjects with high cholesterol by measuring the percent change in LDL-C from base line after 6 weeks of treatment.  
Period: 01/02/2002 through 05/15/2003  
Role: Principal Investigator  
FTE: 5%
15. Title: A Randomized, Multicenter, Double-Blind, Parallel group Study to Determine the Safety and Efficacy of Lotrel versus Enalapril in the Treatment of Hypertension in an African-American Population with Type 2 Diabetes  
Funding: Novartis Pharmaceuticals \$42,460.00  
Purpose: Determine the safety and effectiveness of lotrel (a combination of enalapril in the treatment of high blood pressure (hypertension) in African American men and women who have Type II Diabetes.  
Period: 12/2/2002 through 10/30/2003

John M. Flack, M.D., M.P.H.

- |  |       |                        |  |
|--|-------|------------------------|--|
|  | Role: | Principal Investigator |  |
|  | FTE:  | 5%                     |  |
- 
- |     |          |  |             |
|-----|----------|--|-------------|
| 16. | Title:   | A Multicenter, Open-label, Flexible Dose Escalation Study to Evaluate the Correlation between event Log Parameters, Self Esteem/Overall Relationships Efficacy of Viagra ®) (Sildenafil Citrate) in Men with Erectile Dysfunction  |             |
|     | Funding: | Pfizer Pharmaceuticals   | \$11,437.50 |
|     | Purpose: | To determine the correlation between changes in the self-esteem domain score of the Self-Esteem/Overall Relationship Questionnaire (SEAR) and measures of intercourse success (obtained from patient event logs), and improved erectile function (obtained from the Erectile Function (EF) domain of the (IIEF) in male outpatients with erectile dysfunction. |             |
|     | Period:  | 5/2002-12/2002   |             |
|     | Role:    | Principal Investigator   |             |
|     | FTE:     | 4%   |             |
- 
- |     |          |   |             |
|-----|----------|---|-------------|
| 17. | Title:   | The DREAM (Diabetes Reduction Assessment with Raimpril and Rosiglitazone Medication) Trial  |             |
|     | Funding: | Hamilton Health Sciences Corp.  | \$68,250.00 |
|     | Purpose: | The DREAM trial is designed to determine if treatment with either ramipril and/or rosiglitazone will prevent or reduce the incidence of diabetes in people with impaired glucose tolerance (IGT) or impaired fasting glucose (IFG). |             |
|     | Period:  | 6/4/2002-12/31/2007   |             |
|     | Role:    | Principal Investigator  |             |
|     | FTE:     | 5%  |             |
- 
- |     |          |  |          |
|-----|----------|--|----------|
| 18. | Title:   | A 12-Week, Multicenter, Double Blind, Parallel, Forced-Titration Study of Teveten Eprosartan Mesylate; SK&F 108566-J) at Doses of 600 mg and 1200mg Given Once Daily and Enalapril (20mg and 40mg) Given Once Daily Compared to Placebo in African-American Patients with Essential Hypertension SitDBP>95 and <109 mmHG and SitSBP >145 and <179 mmHg) During Periods With and Without Supplemental Salt Intake (100mmol/day) Protocol 155. |          |
|     | Funding: | SmithKline Beecham Pharmaceuticals   | \$42,480 |
|     | Purpose: | To determine the blood pressure lowering efficacy of a novel angiotensin receptor antagonist in African-Americans, to determine the influence of dietary sodium administration on the antihypertensive efficacy of this agent in stage 1-2 hypertensives.  |          |
|     | Period:  | 1998-ongoing   |          |
|     | Role:    | National Principal Investigator of this Multicenter Clinical Trial   |          |
- 
- |     |          |   |  |
|-----|----------|---|--|
| 19. | Title:   | Sodium and Angiotensin Peptide Protocol [SAAP] A Pilot Study  |  |
|     | Funding: | Internal Funding  |  |
|     | Purpose: | Evaluating the impact of dietary sodium consumption on both ambulatory and cuff blood pressure, arterial compliance and to correlate sodium consumption with markers of target-organ-damage in African American women with normal to high blood pressure. |  |
|     | Period:  | 1998  |  |
|     | Role:    | Principal Investigator  |  |
- 
- |     |          |  |          |
|-----|----------|--|----------|
| 20. | Title:   | Hemodynamic Determinants of the Blood Pressure Response to Accumulated Physical Activity in African American Women |          |
|     | Funding: | Harper Hospital Foundation   | \$24,981 |

**John M. Flack, M.D., M.P.H.**

- Purpose: To investigate the hemodynamic and hormonal effects of moderate intensity physical activity on sedentary African-American women with high-normal to stage 1 blood pressure evaluation.  
Period: 1998-99  
Role: Principal Investigator
21. Title: Evaluation of the Antihypertensive Efficacy, Safety, and Tolerability of Candesartan Cilexetil in Comparison to Amlodipine: A Multicenter, Double Blind, Randomized, Parallel Group, Forced Titration Study (CASTLE Study) Protocol # 176  
Funding: Astra Merck \$30,000  
Purpose: Evaluate the efficacy, safety and tolerability of Candesartan cilexetil in hypertensive  
Period: 1998  
Role: Principal Investigator
22. Title: A Multicenter, Double-blind, randomized, parallel group, placebo-controlled study to investigate the antihypertensive efficacy and safety of Losartan in African Americans with mild-to-moderate hypertension (protocol 172)  
Funding: Merck & Company  
Purpose: To investigate the antihypertensive efficacy of losartan in African Americans with mild-to-moderate hypertension  
Period: 1998  
Role: National Principal Investigator of this Multicenter Clinical Trial
23. Title: A Multicenter, Single-Blind Trial Evaluating the Efficacy of Amlodipine in Patients with Severe Hypertension R0515  
Funding: Pfizer, Incorporated \$39,760  
Purpose: Evaluate efficacy of amlodipine in patients with severe hypertension  
Period: 1997  
Role: Principal Investigator (#H09 16 97 (MO1)-FB)
24. Title: Efficacy of Candesartan Cilexetil in Hypertensive Black Patients: A Double Blind, Randomized, Placebo Controlled, Parallel Group Design Study with an Open Label, Long Term Extension (ABC, Protocol 140)  
Funding: Astra Merck \$60,000  
Purpose: To evaluate the efficacy of Candesartan in African Americans with mild-to-moderate hypertension.  
Period: 1998  
Role: Principal Investigator
25. Title: Accupril Titration Interval Management Evaluation Trial (ATIME Study, Protocol 906-394)  
Funding: Parke-Davis \$555,445  
Purpose: To provide data coordination services for Antihypertensive drug trial involving 3000 participants at 400 clinical sites in the United States  
Period: 1996-1998 (completed)  
Role: Principal Investigator (Investigator Initiated)
26. Title: "RFA, Vascular Disease Academic Award  
Funding: NHLBI HL-94-015/k07 \$561,660  
Purpose: To promote the discipline of vascular medicine through teaching, clinical, and research activities.



John M. Flack, M.D., M.P.H.

- Period: 1995-00  
Role: Co-Principal Investigator/Medical Director
27. Title: "A Randomized Double-Blind, Outpatient, Dose-Titration Trial of ANA-756 vs. Atenolol (Beta-Blocker) In Patients with Essential Hypertension  
Funding: Wyeth-Ayerst Research  
Purpose: To compare the safety and effectiveness of increasing doses of ANA-756 and atenolol (beta-blocker already on the market) on the change in blood pressure in patients with essential hypertension.  
Period: 1995-95  
Role: Co-Principal Investigator
28. Title: "Study of Coronary Heart Disease Risk Factors in Young Adults (CARDIA)"  
Funding: NHLBI/NIH NO1 HV487048 \$2,471,875  
Purpose: To monitor the evolution of cardiovascular risk factors and their determinants in a biracial cohort of young adults.  
Period: 1993-94  
Role: Principal Investigator
29. Title: "Women's Health Trial"  
Funding: NIH - N01 WH3 2101 \$10,863,212  
Purpose: A randomized, controlled, multicenter trial designed to evaluate the feasibility of recruiting women of different socio-economic status and minority groups and to determine whether these women can achieve and maintain low-fat eating habits.  
Period: 1993-95  
Role: Co-Principal Investigator (Dr. Grimm, Principal Investigator)
30. Title: "Multicenter Efficacy and Tolerability Study Comparing Proscar (Finasteride) and Placebo in the Treatment of Symptomatic Benign Prostatic Hyperplasia in a Primary Care Setting (PROSCAR Study)"  
Funding: Merck Human Health \$37,500  
Purpose: To examine the efficacy and tolerability of therapy with Proscar (finasteride) in patients with moderate to severe symptomatic benign prostatic hypertrophy.  
Period: 1993-95  
Role: Principal Investigator
31. Title: "Healthy Eating and Lifestyle Program (HELP)"  
Funding: \$3,000  
Purpose: Attempt to decrease the prevalence of cardiovascular risk factors in two predominantly African-American church congregations through peer counseling.  
Period: 1993-94  
Role: Principal Investigator
32. Title: "Sodium Sensitivity in Blacks" (SNaP)  
Funding: NIH/NHLBI R01 - HL - 46630 - 01A1 \$1,394,250  
Purpose: To identify factors which predict a pressor effect with sodium chloride administration in African Americans.  
Period: 1992-94  
Role: Co-Principal Investigator (Dr. Grimm, Principal Investigator)
33. Title: "Craniomandibular Disorders: Long-Term Outcome Study"  
Funding: NIH \$502,680

**John M. Flack, M.D., M.P.H.**

- Purpose: To compare several different approaches to the management of TMJ disorders.  
Period: 1992-97  
Role: Co-Principal Investigator, Epidemiologist
34. Title: "Arterial Disease Multiple Intervention Trial (The ADMIT Study)"  
Funding: NIH/NHLBI N01 HC25111 \$485,192  
Purpose: To evaluate treatment and prevention strategies for atherosclerosis, cardiovascular disease clinical centers  
Period: 1992-95  
Role: Assistant Project Director (Dr. Hunninghake, Principal Investigator)
35. Title: "Treatment of Low HDL Cholesterol (TOLC) Study"  
Funding: Innovite - Pharmaceuticals \$38,000  
Purpose: To determine the relative efficacy of Enduracin, a modified-release niacin preparation, versus Ciptalline (unmodified) niacin for raising HDL cholesterol levels in nonsmoking men and women with low HDL (<40 mg/dl)  
Period: 1991  
Role: Principal Investigator (Investigator initiated)
36. Title: "Ambulatory Blood Pressure Study in USA Blacks and Liberian Immigrants"  
Funding: BRSG, University of Minnesota \$6,792  
Purpose: To make preliminary observations regarding ambulatory blood pressure patterns in United States Blacks and Liberian Immigrants to obtain preliminary estimates of repeatability ambulatory blood pressure measurements in these unique populations.  
Period: 1991-92  
Role: Principal Investigator
37. Title: "Feasibility of Reduction of Dietary Sodium in Black Participants"  
Funding: BRSG \$11,075  
Purpose: To establish the methodology and demonstrate feasibility of this sodium reduction for an NIH proposal on the evaluation of the effect of dietary sodium intervention on blood pressure in Blacks and Whites.  
Period: 1990-91  
Role: Co-Principal Investigator
38. Title: "Lipid and Thiazide Study (LATS)"  
Funding: Reuben Miller Cardiovascular Fund \$6,000  
Purpose: To support my ongoing research on the effects of thiazide diuretics on cholesterol distribution across LDL cholesterol subclasses.  
Period: 1989-90  
Role: Principal Investigator
39. Title: "Multicenter Isradipine/Diuretic Atherosclerosis Study (MIDAS)"  
Funding: Sandoz Pharmaceuticals \$759,348  
Purpose: To monitor the rate of progression of medial intimal thickness in hypertensive men and women with extracranial carotid artery plaque who were randomized a thiazide diuretic or isradipine, a dihydropyridine calcium antagonist.  
Period: 1988-92  
Role: Co-Principal Investigator (R. Grimm, Principal Investigator)
40. Title: "The Effect of Thiazide Diuretics on LDL Cholesterol Subclasses"



**John M. Flack, M.D., M.P.H.**

- |          |   |          |
|----------|---|----------|
| Funding: | University of Minnesota School of Public Health Biomedical Research Grant; #BRSG 0696-5725-95                       | \$11,989 |
| Purpose: | To assess the influence of thiazide diuretics on the distribution of cholesterol across LDL cholesterol subclasses. |          |
| Period:  | 1989-91   |          |
| Role:    | Principal Investigator  |          |
- 
- |            |  |         |
|------------|--|---------|
| 41. Title: | "Northeast Oklahoma City Cholesterol and Cardiovascular Risk Factor Screening and Education Program" |         |
| Funding:   | University of Oklahoma Health Sciences Center Biomedical Research Support Grant                      | \$6,700 |
| Purpose:   | To conduct a church-based cholesterol education program.   |         |
| Period:    | 1987-88  |         |
| Role:      | Co-Principal Investigator (W. Wiist, Principal Investigator)   |         |
- 
- |            |   |          |
|------------|---|----------|
| 42. Title: | "Lovastatin Dose-Ranging Multicenter Study in Patients with Type II Hypercholesterolemia, Total Cholesterol 240-300 mg/dl With or Without Other Risk Factors and With and Without Evidence of Coronary Disease" |          |
| Funding:   | Merck Sharp and Dohme   | \$25,000 |
| Purpose:   | Obtain Lovastatin safety data   |          |
| Period:    | 1987-1988   |          |
| Role:      | Principal Investigator  |          |
- 
- |            |   |             |
|------------|---|-------------|
| 43. Title: | "Treatment of Mild Hypertension Study (TOMHS)"  |             |
| Funding:   | NHLBI/NIH R01 HL34767   | \$1,733,971 |
| Purpose:   | To determine optimal treatment of adults with mild diastolic hypertension (90-99 mmHg). |             |
| Period:    | 1985-1991   |             |
| Role:      | Co-Investigator   |             |

## **BIBLIOGRAPHY**

### Publications in Refereed Journals:

1. Grimm RH Jr, **Flack JM**. Management of hypertension. Potential trade-offs on coronary risk. *Am J Med*. 1989; 87(2A):62S-65S.
2. Grimm RH Jr, **Flack JM**, Byington R, Bond MG, Brugger S. For the MIDAS Research Group. A comparison of antihypertensive drug effects on the progression of extra cranial carotid atherosclerosis: The Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). *Drugs*. 1990; 40 Suppl 2: 38-43.
3. Wiist WH, **Flack JM**. A church-based cholesterol education program. *Public Health Rep*. 1990; 105(4):381-88.
4. McVeigh GE, Burns DE, Finkelstein SM, McDonald KM, Mock JE, Feske W, Carlyle PF, **Flack J**, Grimm RH Jr, Cohn JN. Reduced vascular compliance as a marker for essential hypertension. *Am J Hypertension*. 1991;4(3 Pt 1):245-51.
5. Elmer PJ, Grimm RH Jr, **Flack J**, Laing B. Dietary sodium reduction for hypertension prevention and treatment. *Hypertension*. 1991;17(1 Suppl):1182-9.

John M. Flack, M.D., M.P.H.

6. Mascioli S, Grimm R Jr, Launer C, Svendsen K, **Flack J**, Gonzalez, N, Elmer P, Neaton J. Sodium chloride raises blood pressure in normotensives subjects. The study of sodium and blood pressure. *Hypertension*. 1991;17(1 Suppl):I21-6.
7. The Treatment of Mild Hypertension. A randomized, placebo controlled trial of a nutritional-hygienic regimen along with various drug monotherapies. *Arch Intern Med*. 1991;151(7): 1413-1423.
8. **Flack JM**, Wiist WH. Epidemiology of hypertension and hypertensive target-organ damage in the United States. *J Assoc Acad Minority Phys*. 1991;2(4):143-150.
9. **Flack JM**, Ensrud KE, Launer CH, Mascioli SM, Svendsen KH, Elmer PJ, Grimm RH Jr. Racial and ethnic modifiers of the salt-blood pressure response. *Hypertension*. 1991;17(1 Suppl):I-115-121.
10. **Flack JM**, Wiist WH. Cardiovascular risk factor prevalence in African American adult screenees of a church-based cholesterol education program: The Northeast Oklahoma City Cholesterol Education Program (NEOCEP). *Ethn Dis*. 1991;1(1):78-90.
11. Belcher JD, Egan JO, Bridgman G, Baker R, **Flack JM**. A micro enzymatic method to measure cholesterol and triglyceride in lipoprotein subfractions separated by density gradient ultracentrifugation from 200 microliters of plasma or serum. *J Lipid Res*. 1991;32(2):359-370.
12. Folsom AR, Burke GL, Byers CL, Hutchinson RG, Heiss G, **Flack JM**, Jacobs DR Jr, Caan B. Implications of obesity for cardiovascular disease in blacks: the CARDIA and ARIC Studies. *Am J Clin Nutr*. 1991;53(6 Suppl):1604S-1611S. (Published erratum appears in *Am J Clin Nutr*. 1991;54(3):590).
13. **Flack JM**, Sowers JR. Epidemiologic and clinical aspects of insulin resistance and hyperinsulinemia. *Am J Med*. 1991;91(1A):11S-21S.
14. Oparil S, Berenson GB, Esler M, Falkner B, **Flack JM**, Grim C, Jesse MJ, Roccella EJ, Saunders E, Weinberger M. Epidemiology and classification of hypertension (workshop). *Hypertension*. 1991;18(Suppl 3):92-94.
15. Wiist WH, **Flack JM**. A Test of the John Henryism Hypothesis: Cholesterol and blood pressure. *J Behav Med*. 1992;15(1):15-29.
16. Borhani NO, Miller ST, Brugger SB, Schnaper HW, Craven TE, Bond MG, Khoury SA, **Flack J**. MIDAS: hypertension and atherosclerosis. A trial of the effects of antihypertensive drug treatment on atherosclerosis. MIDAS Research Group. *J Cardiovasc Pharmacol*. 1992;19 (Suppl 3):S16-S20.
17. Kimura Y, Engelman RM, Rousou J, **Flack J**, Iyengar J, Das DK. Moderation of myocardial ischemia reperfusion injury by calcium channel and calmodulin receptor inhibition. *Heart and vessels* 1992;7(4):189-95.
18. Melnick SL, Sprafka JM, Bostick RM, **Flack JM**, Burke GL. Antibiotic use in urban whites and blacks: The Minnesota Heart Survey. *Ann Pharmacother*. 1992;26(10):1292-1295.

John M. Flack, M.D., M.P.H.

19. **Flack JM**, Woolley A, Esunge P, Grimm RH Jr. A rational approach to hypertension treatment in the older patient. *Geriatrics*. 1992;47(11):24-8, 33-8.
20. Liebson PR, Grandits GA, Prineas RJ, Dianzumba S, **Flack JM**, Cutler JA, Grimm RH Jr, Stamler J. Echocardiographic correlates of left ventricular structure among 844 mild hypertensive men and women in the treatment of mild hypertension study (TOMHS). *Circulation*. 1993;87(2):476-486.
21. **Flack JM**, Neaton JD, Daniels B, Esunge P. Ethnicity and renal disease: Lessons from the Multiple Risk Factor Intervention Trial and the Treatment of Mild Hypertension Study. *Am J Kidney Dis*. 1993;21(4 Suppl 1):31-40.
22. Kaye SA, Folsom AR, Jacobs DR Jr, Hughes GH, **Flack JM**. Psychosocial correlates of body fat distribution in black and white young adults. *Int J Obes Relat Metab Disord*. 1993;17(5):271-7.
23. **Flack JM**, McVeigh GE, Grimm RH Jr. Hypertension therapy in the elderly. *Curr Opin Nephrol Hypertens*. 1993;2(3):386-394.
24. Bradley K, **Flack JM**, Belcher JD, Elmer PJ, Miller P, Grimm RH Jr. Chlorthalidone attenuates the reduction in total cholesterol and small, dense LDL cholesterol subclass associated with weight loss. *Am J Hypertens*. 1993;6(7 Pt 1):636-9.
25. Neaton JD, Grimm RH Jr, Prineas RJ, Stamler J, Grandits GA, Elmer PJ, Cutler JA, **Flack JM**, Schoenberger JA, McDonald R, Lewis CE, Liebson PR. Treatment of Mild Hypertension Study (TOMHS). Final results. Treatment of Mild Hypertension Research Group. *JAMA*. 1993;270(6):713-724.
26. Perloff D, Grim C, **Flack J**, Frohlich ED, Hill M, McDonald M, Morgenstern BZ. Human blood pressure determination by sphygmomanometry. *Circulation*. 1993;88(5 Pt 1):2460-70.
27. Folsom AR, Qamheih HT, **Flack JM**, Hilner JE, Liu K, Howard BV, Tracy RP. Plasma fibrinogen: levels and correlates in young adults. The Coronary Artery Risk Development in Young Adults (CARDIA) Study. *Am J Epidemiol*. 1993;138(12):1023-1036.
28. **Flack JM**, Ryder KW, Strickland D, Whang R. Metabolic correlates of theophylline therapy: a concentration-related phenomenon. *Ann Pharmacother*. 1994;28(2):175-9.
29. Kvasnicka J, **Flack JM**, Grimm RH Jr. Treatment of hypertension in the presence of coexisting medical conditions. *Drugs Aging*. 1994;4(4):304-312.
30. **Flack JM**. High blood pressure in older persons: a high-risk special population. *Can J Public Health*. 1994;85(Suppl 2):S9-11.
31. Howard BV, Le NA, Belcher JD, **Flack JM**, Jacobs DR Jr, Lewis CE, Marcovina SM, Perkins LL. Concentrations of Lp(a) in black and white young adults: relations to risk factors for cardiovascular disease. *Ann Epidemiol*. 1994;4(5):341-350.
32. Abraham PA, Mascioli SM, Launer CH, **Flack JM**, Liebson PR, Svendsen KH, Grandits GA, Opsahl JA, Schoenberger JA, Grimm RH Jr. Urinary albumin and N-acetyl-beta-D-glucosaminidase excretions in mild hypertension. *Am J Hypertens*. 1994;7(11):965-74.

John M. Flack, M.D., M.P.H.

33. Rinehart AL, Herzog CA, Collins AJ, **Flack JM**, Ma JZ, Opsahl JA. A comparison of coronary angioplasty and coronary artery bypass grafting outcomes in chronic dialysis patients. *Am J Kidney Dis*. 1995;25(2):281-90.
34. Gidding SS, Xie X, Liu K, Manolio T, **Flack JM**, Gardin JM. Cardiac function in smokers and nonsmokers: the CARDIA study. The Coronary Artery Risk Development in Young Adults Study. *J Am Coll Cardiol*. 1995;26(1):211-6.
35. **Flack JM**. The epidemiology of hypertension and related conditions in the African-American population. *J Natl Med Assoc*. 1995;87(8 Suppl):606-9.
36. **Flack JM**. Linking the medical and public health approaches for the prevention, management, and control of hypertension in the African-American population: what steps can we take today? *J Natl Med Assoc*. 1995;87(8 Suppl):657-8.
37. Braun BL, Wagenaar AC, **Flack JM**. Alcohol consumption and physical fitness among young adults. *Alcohol Clin Exp Res*. 1995;19(4):1048-54.
38. Maron BJ, Gardin JM, **Flack JM**, Gidding SS, Kurosaki TT, Bild DE. Prevalence of hypertrophic cardiomyopathy in the general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. *Circulation*. 1995;92(4):785-9.
39. Zhang S, Folsom AR, **Flack JM**, Liu K. Body fat distribution before pregnancy and gestational diabetes: findings from coronary artery risk development in young adults (CARDIA) study. *BMJ*. 1995;311(7013):1139-40.
40. Hoegerman GS, Lewis CE, **Flack J**, Raczynski JM, Caveny J, Gardin JM. Lack of association of recreational cocaine and alcohol use with left ventricular mass in young adults. The Coronary Artery Risk Development in Young Adults (CARDIA) Study. *J Am Coll Cardiol*. 1995;25(4):895-900.
41. **Flack JM**, Amaro H, Jenkins W, Kunitz S, Levy J, Mixon M, Yu E. Epidemiology of minority health. *Health Psychol*. 1995;14(7):592-600.
42. **Flack JM**, Neaton JD, Grimm RH Jr, Cutler JA, Shih J, Ensrud K, MacMahon S. Blood pressure and mortality among men with prior myocardial infarction. *Circulation*. 1995;92(9):2437-45.
43. Gardin JM, Wagenknecht LE, Anton-Culver H, **Flack JM**, Gidding S, Kurosaki T, Wong ND, Manolio TA. Relationship of cardiovascular risk factors to echocardiographic left ventricular mass in healthy young black and white adult men and women. The CARDIA study. Coronary Artery Risk Development in Young Adults. *Circulation* 1995;92(3):380-7
44. McVeigh GE, **Flack J**, Grimm R. Goals of antihypertensive therapy. *Drugs*. 1995;49(2):161-75.
45. Liu K, Ruth KJ, **Flack JM**, Jones-Webb R, Burke GL, Savage PJ, Hulley SB. Blood pressure in young blacks and whites: relevance of obesity and lifestyle factors in determining differences. The CARDIA Study. *Circulation*. 1996;93(1):60-6.
46. **Flack JM**, Novikov SV, Ferrario CM. Benefits of adherence to anti-hypertensive drug therapy. *Eur Heart J*. 1996;17 Suppl A:16-20.

John M. Flack, M.D., M.P.H.

47. Grimm RH Jr, **Flack JM**, Schoenberger JA, Gonzalez N, Liebson PR. Alpha-blockade and thiazide treatment of hypertension. A double-blind randomized trial comparing doxazosin and hydrochlorothiazide. *Am J Hypertens*. 1996;9(5):445-54.
48. Jones-Webb R, Jacobs DR Jr, **Flack JM**, Liu K. Relationships between depressive symptoms, anxiety, alcohol consumption, and blood pressure: results from the CARDIA Study. *Alcohol Clin Exp Res*. 1996;20(3):420-7.
49. Grimm RH Jr, **Flack JM**, Grandits GA, Elmer PJ, Neaton JD, Cutler JA, Lewis C, McDonald R, Schoenberger J, Stamler J. Long-term effects on plasma lipids of diet and drugs to treat hypertension. Treatment of Mild Hypertension Study (TOMHS) Research Group. *JAMA*. 1996;275(20):1549-56.
50. Lewis CE, Grandits A, **Flack J**, McDonald R, Elmer PJ. Efficacy and tolerance of antihypertensive treatment in men and women with stage I diastolic hypertension. Results of the Treatment of Mild Hypertension Study. *Arch Intern Med*. 1996;156(4):377-85.
51. Maron BJ, Gardin JM, **Flack JM**, Gidding SS, Bild DE. HCM in the general population. *Circulation*. 1996;94(3):588-9.
52. Folsom AR, Jacobs DR Jr, Wagenknecht LE, Winkhart SP, Yunis C, Hilner JE, Savage PJ, Smith DE, **Flack JM**. Increase in fasting insulin and glucose over seven years with increasing weight and inactivity of young adults. The CARDIA Study. *Am J Epidemiol*. 1996;144(3):235-246.
53. **Flack JM**, Cushman W. Evidence for the efficacy of low-dose diuretic monotherapy. *Am J Med*. 1996;101(3A):53S-60S.
54. Weir MR, **Flack JM**, Applegate WB. Tolerability, safety, and quality of life and hypertensive therapy: the case for low dose diuretics. *Am J Med*. 1996;101(3A):83S-92S.
55. Ferrario CM, **Flack JM**. Pathological consequences of increased angiotensin II activity. *Cardiovas Drugs Ther*. 1996;10(5):511-8.
56. National High Blood Pressure Education Program. 1995 update of the working group reports on chronic renal failure and renovascular hypertension. *Arch Intern Med*. 1996;156 (9):1928-1947.
57. Markovitz JH, Raczynski JM, Lewis CE, **Flack J**, Chesney M, Chettur V, Hardin JM, Johnson E. Lack of independent relationships between left ventricular mass and cardiovascular reactivity to physical and psychological stress in the Coronary Artery Risk Development in Young Adults (CARDIA) Study. *Am J Hypertens*. 1996;9(9):915-23.
58. Gidding SS, Liu K, Bild DE, **Flack J**, Gardin J, Ruth KJ, Oberman A. Prevalence and identification of abnormal lipoprotein levels in a biracial population aged 23 to 35 years (the CARDIA Study). The Coronary Artery Risk Development in Young Adults Study. *Am J Cardiol*. 1996;78(3):304-8.
59. **Flack JM**, Yunis C. Therapeutic implications of the epidemiology and timing of myocardial infarction and other cardiovascular diseases. *J Hum Hypertens*. 1997;11(1):23-8.



John M. Flack, M.D., M.P.H.

60. Grimm RH Jr, Grandits GA, Prineas RJ, McDonald RH, Lewis CE, **Flack JM**, Yunis C, Svendsen KH, Liebson PR, Elmer PJ, Stamler J, for the TOMHS Research Group. Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS). *Hypertension*. 1997;29(1 part 1):8-14.
61. Hall WD, Ferrario CM, Moore MA, Hall JE, **Flack JM**, Cooper W, Simmons JD, Egan BM, Lackland DT, Perry M, Jr., Roccella EJ. Hypertension-related morbidity and mortality in the southeastern United States. *Am J Med Sci*. 1997;313(4):195-209.
62. **Flack JM**. Living with hypertension. Introduction to dealing with elevated blood pressure. *N C Med J*. 1997;58(3):193-6.
63. Deitch JS, Hansen KJ, Craven TE, **Flack JM**, Appel RG, Dean RH. Renal artery repair in African-Americans. *J Vasc Surg*. 1997;26(3):465-72; discussion 473.
64. Weir MR, Hall PS, Behrens MT, **Flack JM**. Salt and blood pressure responses to calcium antagonism in hypertensive patients. *Hypertension*. 1997;30(3 Pt 1):422-7.
65. Ganguli MC, Grimm RH Jr, Svendsen KH, **Flack JM**, Grandits GA, Elmer PJ. Higher education and income are related to better Na:K ratio in blacks: baseline results of the Treatment of Mild Hypertension Study (TOMHS) data. *Am J Hypertens*. 1997;10(9 Pt 1):979-84.
66. Larochelle P, **Flack JM**, Marbury TC, Sareli P, Krieger EM, Reeves RA. Effects and tolerability of irbesartan versus enalapril in patients with severe hypertension. Irbesartan Multicenter Investigators. *Am J Cardiol*. 1997;80(12):1613-5.
67. Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). *Arch Intern Med*. 1997;157:2413-2446.
68. **Flack JM**, Hamaty M, Staffileno BA. Renin-angiotensin-aldosterone-kinin system influences on diabetic vascular disease and cardiomyopathy. *Miner Electrolyte Metab*. 1998;24(6):412-22.
69. Ferrario CM, Martel N, Yunis C, **Flack JM**, Chappell MC, Brosnihan KB, Dean RH, Fernandez A, Novikov SV, Pinillas C, Luque M. Characterization of angiotensin-(1-7) in the urine of normal and essential hypertensive subjects. *Am J Hypertens*. 1998;11(2):137-146.
70. **Flack JM**, Staffileno BA. Therapeutic strategies for hypertension treatment in patients with selected cardiovascular disease. *Drugs Today (Barc)*. 1998;34(9):813-822.
71. Hall WD, Reed JW, **Flack JM**, Yunis C, Preisser J. Comparison of the efficacy of dihydropyridine calcium channel blockers in African American patients with hypertension. ISHIB Investigators Group. International Society of Hypertension in Blacks. *Arch Intern Med* 1998;158(18):2029-34.
72. Ganguli MC, Grimm RH, Svendsen KH, **Flack JM**, Grandits GA, Elmer PJ, Urinary sodium and potassium profile of blacks and whites in relation to education in two different geographic urban areas. TOMHS Research Group. Treatment of Mild Hypertension Study. *Am J Hypertens*. 1999;12(1 Pt 1):69-72.

John M. Flack, M.D., M.P.H.

73. **Flack JM**, Hamaty M. Difficult-to-treat hypertensive population: focus on African-Americans and people with type 2 diabetes. *J Hypertens Suppl.* 1999;17(1):S19-S24.
74. **Flack JM**, Kvasnicka J, Gardin J, Gidding S, Manolio T, Jacobs DR Jr. Anthropometric and physiologic correlates in mitral valve prolapse in a biethnic cohort of young adults: the CARDIA Study. *Am Heart J.* 1999;138 (3 Pt 1):486-92.
75. **Flack JM**, Optimal blood pressure on antihypertensive medication. *Curr Hypertens Rep.* 1999;1(5):381-6.
76. **Flack JM**, Gardin JM, Yunis C, Liu K. Static and pulsatile blood pressure correlates of left ventricular structure and function in black and white young adults: the CARDIA study. *Am Heart J.* 1999;138(5 Pt 1):856-64.
77. Raskin P, Guthrie R, **Flack J**, Reeves R, Saini R. The long-term antihypertensive activity and tolerability of irbesartan with hydrochlorothiazide. *J Hum Hypertens.* 1999;13(10):683-7.
78. **Flack JM**, Mensah GA, Ferrario CM. Using angiotensin converting enzyme inhibitors in African-American hypertensives: a new approach to treating hypertension and preventing target-organ damage. *Curr Med Res Opin.* 2000;16(2):66-79.
79. **Flack JM**, Bledsoe K. Combination antihypertensive drug therapy: a therapeutic option long overdue. *Am Fam Physician.* 2000;61(10):2974, 2977.
80. **Flack JM**, Yunis C, Preisser J, et al. The rapidity of drug dose escalation influences blood pressure response and adverse effects burden in patients with hypertension: the Quinapril Titration Interval Management Evaluation (ATIME) Study. *Arch Intern Med.* 2000;160(12):1842-7.
81. **Flack JM**. Minimizing the progression of kidney disease. Introduction. *Am J Kidney Dis.* 2000;36(3 Suppl 1):S1-3.
82. Peters, RM, **Flack, JM**. Salt-sensitivity and hypertension in African Americans: implications for cardiovascular nurses. *Prog Cardiovasc Nurs.* 2000;15(4):138-144.
83. Clark LT, Ferdinand KC, **Flack JM**, Gavin JR 3rd, Hall WD, Kumanyika SK, Reed JW, Saunders E, Valantine HA, Watson K, Wenger NK, Wright JT. Coronary heart disease in African-Americans. *Heart Dis.* 2001;3(2):97-108.
84. **Flack JM**, Saunders E, Gradman A, et al. Antihypertensive efficacy and safety of losartan alone and in combination with hydrochlorothiazide in adult African Americans with mild to moderate hypertension. *Clin Ther.* 2001;23(8):1193-1208.
85. **Flack JM**, Grimm RH. Jr, Staffileno BA, Elmer P, Yunis C, Hedquist L, Dudley, A. New salt-sensitivity metrics: variability-adjusted blood pressure change and the urinary sodium-to-creatinine ratio. *Ethn Dis.* 2002;12(1):10-9.
86. Kostis JB, Cobbe S, Johnston C, Ford I, Murphy M, Weber MA, Black HR, Plouin PF, Levy D, Mancina G, Laroche P, Kolloch RE, Alderman M, Ruilope LM, Dahlof B, **Flack JM**, Wolf R. Design of the Omapatrilat in Persons with Enhanced Risk of Atherosclerotic events (OPERA) trial. *Am J Hypertens.* 2002;15(2 Pt 1):193-8.



John M. Flack, M.D., M.P.H.

87. **Flack JM**, Peters R, Mehra VC, Nasser SA. Hypertension in special populations. *Cardiol Clin*. 2002;20(2):303-319.
88. **Flack JM**. Effect of ramipril versus amlodipine on renal outcomes in hypertensive nephrosclerosis. *Curr Hypertens Rep*. 2002;4(3):183-4.
89. Crook ED, Washington DO, **Flack JM**. Screening and prevention of chronic kidney disease. *J Natl Med Assoc*. 2002;94(8):55S-62S.
90. **Flack, JM**. The effect of doxazosin on sexual function in patients with benign prostatic hyperplasia, hypertension, or both. *Int J Clin Pract*. 2002;56(7):527-530.
91. Crook ED, **Flack JM**, Salem M, Salahudeen AK, Hall J. Primary renal disease as a cardiovascular risk factor. *Am J Med Sci*. 2002;324(3):138-145.
92. Brown WW, Davis J, **Flack JM**, Gannon MR. NKF's KEEP leads to [longitudinal study]. *Nephrol News Issues*. 2002;16(12) 84-86.
93. **Flack JM**, Casciano R, Casciano J, Doyle J, Arikian S., Tang S, Arocho P. Cardiovascular disease costs associated with uncontrolled hypertension. *Manag Care Interface*. 2002; 15(11):28-36.
94. **Flack JM**, Ferdinand KC, Nasser SA. Epidemiology of hypertension and cardiovascular disease in African Americans. *J Clin Hypertens*. 2002; 5 (1 Suppl 1):5-11.
95. Peters RM, **Flack, JM**. Diagnosis and treatment of hypertension in children and adolescents. *J Am Acad Nurse Pract*. 2003;15(2):56-63.
96. **Flack JM**, Peters R, Mehra VC, Nasser SA. Hypertension in special populations. *Curr Probl Cardiol*. 2003;28(2):194-223.
97. Douglas JG, Bakris GL, Epstein M, Ferdinand KC, Ferrario C, **Flack JM**, Jamerson KA, et al for the ISHIB Working Group. Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society of Hypertension in Blacks. *Arch Intern Med*. 2003;163(5):525-41.
98. **Flack JM**, Oparil S, Pratt JH, Roniker B, Garthwaite S, Kleiman JH, Yang Y, Krause SL, Workman D, Saunders E. Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. *J Am Coll Cardiol*. 2003;41(7):1148-55.
99. **Flack JM**, Nasser SA; The Antihypertensive and Lipid-Lowering Treatment to prevent Heart Attack Trial (ALLHAT). Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker. *Curr Hypertens Rep*. 2003;5(3):189-91.
100. Crook ED, Clark BL, Bradford ST, Golden K, Calvin R, Taylor HA Jr, **Flack JM**. From 1960s Evans County Georgia to present-day Jackson, Mississippi: an exploration of the evolution of cardiovascular disease in African Americans. *Am J Med Sci*. 2003; 325(6):307-14.
101. Crook ED, Thallapureddy A, Migdal S, **Flack JM**, Greene EL, Salahudeen A, Tucker JK, Taylor HA Jr. Lipid abnormalities and renal disease: is dyslipidemia a predictor of progression of renal disease? *Am J Med Sci*. 2003;325(6):340-8.

John M. Flack, M.D., M.P.H.

102. **Flack JM**, Peters R, Shafi T, Alrefai H, Nasser SA, Crook E. Prevention of hypertension and its complications: theoretical basis and guidelines for treatment. *J Am Soc of Nephrol*. 2003;14(7 suppl 2):S92-8.
103. Ohmit SE, **Flack JM**, Peters RM, Brown WW, Grimm R. Longitudinal study of the National Kidney Foundation's (NKF) Kidney Early Evaluation Program (KEEP). *J Am Soc Nephrol*. 2003;14(7 suppl 2):S117-21.
104. Brown WW, Peters RM, Ohmit SE, Keane WF, Collins A, Chen SC, King K, Klag MJ, Molony DA, **Flack JM**. Early detection of kidney disease in community settings: The kidney early evaluation program (KEEP). *Am J Kidney Dis*. 2003;42(1):22-35.
105. Hall WD, Clark LT, Wenger NK, Wright TW Jr, Kumanyika SK, Watson K, Horton EW, **Flack JM**, Ferdinand KC, Garin JR 3ed, Reed JW, Saunders E. The Metabolic Syndrome in African Americans: a review. *Ethn Dis*. 2003;13(4):414-28.
106. Hall WD, Clark LT, Wenger NK, Wright TW Jr, Kumanyika SK, Watson K, Horton EW, **Flack JM**, Ferdinand KC, Reed JW, Saunders E, O'Neal W Jr. For the patient. What is the Metabolic Syndrome and why is it important? *Ethn Dis*. 2003;13(4):546.
107. King TE, Wesson DE, Dickinson TA, DuBose TD, **Flack JM**, Hellmann DB, et al. The case for diversity in academic internal medicine. *Am J Med*. 2004;116(4):284-289.
108. Peters RM, **Flack, JM**. Hypertensive disorders of pregnancy. *J Obstet Gynecol Neonatal Nurs*. 2004;33(2):209-20.
109. Mokwe E., Ohmit SE, Nasser SA, Shafi T, Saunders E, Crook ED, Dudley A, **Flack JM**. Determinants of blood pressure response to quinapril in black and white hypertensive patients: the Quinapril Titration Intervention Management Evaluation trial. *Hypertension*. 2004;43(6):1202-7.
110. **Flack JM**. Calcium antagonist strategies for coronary artery disease. *Curr Hypertens Rep*. 2004;6(3):161-3.
111. Benjamin EJ, Jessup M, **Flack JM**, et al. Discovering the full spectrum of cardiovascular disease disparities: the Minority Health Summit 2003: report of the Outcomes Writing Group. *Circulation*. 2005;111(10):e124-33.
112. El-Akchar T, Ohmit S, McCullough P, Crook E, Brown W, Grimm R, Bakris G, Keane W, **Flack JM**. Higher prevalence of anemia with diabetes mellitus in men in moderate kidney insufficiency: The Kidney Early Evaluation Program. *Kidney Int*. 2005;67(4):1483-8.
113. **Flack JM**, Sica D. Therapeutic considerations in the African-American patient with hypertension: considerations with calcium channel blocker therapy. *J Clin Hypertens*. 2005;7(4 Suppl 1):9-14.
114. Kaufman JS, **Flack JM**. Angiotensin-converting enzyme inhibitors in black patients. *Ann Intern Med*. 2005;142(7):589; author reply 589-90.
115. **Flack JM**. Clinical trials report. The CAMELOT Study. *Curr Hypertens Rep*. 2005;7(3):165-7.

John M. Flack, M.D., M.P.H.

116. McFarlane SI, Castro J, Kaur J, Shin JJ, Kelling D Jr, Faraq A, Simon N, El-Atat F, Sacerdote A, Basta E, **Flack J**, Bakris G, Sower JR. Control of blood pressure and other cardiovascular risk factors at different practice settings: outcomes of care provided to diabetic women compared to men. *J Clin Hypertens*. 2005;7(2):73-80.
117. Weir MR, Ferdinand KC, Saunders E, **Flack JM**, Jamerson KA, Daley W, Zelenkofske S. A noninferiority comparison of valsartan/hydrochlorothiazide combination versus amlodipine in black hypertensives. *Hypertension*. 2005;46(3):508-13.
118. Clark R, Benkert RA, **Flack JM**. Violence exposure and optimism predict task-induced changes in blood pressure and pulse rate in a normotensive sample of inner-city black youth. *Psychosom Med*. 2006;68(1):73-9.
119. Wesson DE, King TE Jr., Todd RF, Torres EA, Hellmann DB, **Flack JM**, Dubose TD Jr., Schuster VL. Achieving diversity in academic internal medicine: recommendations for leaders. *Am J Med*. 2006;119(1):76-81.
120. Hall WD, Watkins LO, Wright JT Jr, Wenger NK, Kumanyika SK, Gavin JR 3<sup>rd</sup>, Ferdinand KC, Watson K, Clark LT, **Flack JM**, Reed JW, Horton EW, Saunders E; African-American Lipid and Cardiovascular Council. The metabolic syndrome: recognition and management. *Dis Manag*. 2006;9(1):16-33.
121. Artinian NT, Washington OG, **Flack JM**, Hockman, EM, Jen KL. Depression, stress, and blood pressure in urban African-American women. *Prog Cardiovasc Nurs*. 2006;21(2):68-75.
122. Messerli FH, Bakris GL, Ferrera D, Houston MC, Petrella FJ, **Flack JM**, Sun W, Lee E, Neutel JM; AVALON Investigators. Efficacy and safety of co-administered amlodipine and atorvastatin in patients with hypertension and dyslipidemia: results of the AVALON trial. *J Clin Hypertens*. 2006;8(8):571-81.
123. Clark R, Benkert RA, **Flack JM**. Large arterial elasticity varies as a function of gender and racism-related vigilance in black youth. *J Adolesc Health*. 2006;39(4):562-9.
124. Peters RM, Aroian KJ, **Flack JM**. African American culture and hypertension prevention. *West J Nurs Res*. 2006;28(7):831-54; discussion 855-63.
125. Jen KL, Brogan K, Washington OG, **Flack JM**, Artinian NT. Poor nutrient intake and high obese rate in an urban African-American population with hypertension. *J Am Coll Nutr*. 2007;26(1):57-65.
126. Williams RA, **Flack JM**, Gavin JR 3<sup>rd</sup>, Schneider WR, Hennekens CH. Guidelines for management of high-risk African-Americans with multiple cardiovascular risk factors: recommendation of an expert consensus panel. *Ethn Dis*. 2007;17(2):214-20.
127. Williams RA, **Flack JM**, Gavin JR 3<sup>rd</sup>, Schneider WR, Hennekens CH. Managing cardiovascular risk factors in high-risk African-Americans. *Ethn Dis*. 2007;17(2):414-5.
128. Artinian NT, Warnecke RB, Kelly KM, Weiner J, Lurie N, **Flack JM**, et al. Advancing the science of health disparities research. *Ethn Dis*. 2007;17(3):427-33.

John M. Flack, M.D., M.P.H.

129. Basile J, Black HR, **Flack JM**, Izzo JL Jr. The role of therapeutic inertia and the use of fixed-dose combination therapy in the management of hypertension. *J Clin Hypertens*. 2007;9(8):636-45.
130. Artinian NT, **Flack JM**, Nordstrom CK, Hockman E, Washington OGM, Jen K-L, Fathy M. Effects of nurse-managed tele-monitoring on blood pressure at 12-months follow-up among urban African Americans. *Nurs Res*. 2007;56(5):312-22.
131. **Flack JM**. Maximizing antihypertensive effects of angiotensin II receptor blockers with a thiazide diuretic combination therapy: focus on irbesartan/hydrochlorothiazide. *Int J Clin Pract*. 2007 Oct 10.
132. **Flack JM**, Duncan K, Ohmit SE, Quah R, Liu X, Ramappa P, Norris S, Hedquist L, Dudley A, Nasser SA. Influence of albuminuria and glomerular filtration rate on blood pressure response to antihypertensive drug therapy. *Vasc Health Risk Manag*. 2007;3(6):1029-37.
133. Warnecke RB, Oh A, Breen N, Gehlert S, Paskett E, Tucker KL, Lurie N, Rebbeck T, Goodwin J, **Flack JM**, Srinivasan S, Kerner J, Heurtin-Roberts S, Abeles R, Tyson FL, Patmios G, Hiatt RA. Approaching Health Disparities from a Population Perspective: The NIH Centers for Population Health and Health Disparities. *American Journal of Public Health*. 2008; 98(9):1608-1615.
134. Payne KA, Caro JJ, Daley WL, Khan ZM, Ishak KJ, Stark K, Purkayastha D, **Flack J**, Velazquez E, Nesbitt S, Morisky D, Califf R, for the BPSZ-BLISS Study Steering Committee. The design of an observational study of hypertension management, adherence and pressure control in Blood Pressure Success Zone Program participants. *Int J Clin Pract*. 2008; 62(9): 1313-1321.
135. Nasser SA, Lai Z, O'Connor S, Liu X, **Flack JM**. Does earlier attainment of blood pressure goal translate into fewer cardiovascular events? *Curr Hypertens Rep*. 2008 Oct;10(5):398-404.
136. **Flack JM**, Victor R, Watson K, Ferdinand KC, Saunders E, Tarasenko L, Jamieson MJ, Shi H, Bruschi P. Improved attainment of blood pressure and cholesterol goals using single-pill amlodipine/atorvastatin in African Americans: the CAPABLE trial. Mayo Clinic proceedings. Mayo Clinic 2008;83(1):35-45.
137. **Flack JM**, Hilkert R. Single-pill combination of amlodipine and valsartan in the management of hypertension. *Expert Opin Pharmacother*. 2009 Aug;10(12):1979-94.
138. Ferdinand KC, **Flack JM**, Saunders E, Victor R, Watson K, Kursun A, Jamieson MJ, Shi H. Amlodipine/Atorvastatin single-pill therapy for blood pressure and lipid goals in African Americans: influence of the metabolic syndrome and type 2 diabetes mellitus. *J Clin Hypertens (Greenwich)*. 2009 Oct;11(10):585-93.
139. **Flack JM**, Calhoun DA, Satlin L, Barbier M, Hilkert R, Brunel P. Efficacy and safety of initial combination therapy with amlodipine/valsartan compared with amlodipine monotherapy in black patients with stage 2 hypertension: the EX-STAND study. *Journal of Human Hypertension* 2009;23(7):479-89

John M. Flack, M.D., M.P.H.

140. **Flack JM.** Basic Principles of effective hypertension therapeutics. *Ethnicity & Disease* 2009;19(4 Suppl 5):55-1-2.
141. Ferrario CM, **Flack JM**, Strobeck JE, Smits G, Peters C. Individualizing hypertension treatment with impedance cardiography: a meta-analysis of published trials. *Ther Adv Cardiovasc Dis.* 2010 Feb;4(1):5-16.
142. Townsend RR, Wimmer NJ, Chirinos JA, Parsa A, Weir M, Perumal K, Lash JP, Chen J, Steigerwalt SP, **Flack J**, Go AS, Rafey M, Rahman M, Sheridan A, Gadegbeku CA, Robinson NA, Joffe M. Aortic PWV in chronic kidney disease: a CRIC ancillary study. *Am J Hypertens.* 2010 Mar;23(3):282-9.
143. Bakris GL, Sarafidis PA, Weir MR, Dahlof B, Pitt B, Jamerson K, Velazquez EJ, Staikos-Byrne L, Kelly RY, Shi V, Chiang YT, Weber MA; ACCOMPLISH Trial investigators. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. *Lancet.* 2010 Apr 3;375(9721):1173-81.
144. Valina-Toth AL, Lai Z, Yoo W, Abou-Samra A, Gadegbeku CA, **Flack JM.** Relationship of vitamin D and parathyroid hormone with obesity and body composition in African Americans. *Clin Endocrinol (Oxf).* 2010 May;72(5):595-603.
145. Weir MR, Punzi HA, **Flack JM**, Stoakes KA, Chavanu, KJ, Li W, Dubiel R; A randomized, double-blind, forced-titration study to compare Olmesartan Medoxomil versus Losartan Potassium in patients with Stage I and 2 hypertension. *Postgraduate Medicine* 2011;123(1) : 80-87
146. Mitchell JE, Ferdinand KC, Watson KE, Wenger NK, Watkins LO, **Flack JM**, Gavin JR, Reed JW, Saunders E, Wright JT. Treatment of heart failure in African Americans—a call to action. *Journal of the National Medical Association* 2011;103(2):86-98.
147. Sica DA, **Flack JM.** Treatment considerations with aldosterone receptor antagonists. *Journal of Clinical Hypertension* 2011;13(1):65-9
148. Ference BA, Yoo W, **Flack JM**, Clark M. A common KIF6 polymorphism increases vulnerability to low-density lipoprotein cholesterol: two meta-analyses and a meta-regression analysis. *PLoS One.* 2011;6(12):e28834.
149. Ference BA, Yoo W, Alesh I, Mahajan N, Mirowska K, Mewada A, Afonso L, Kahn J, Williams K, **Flack JM.** Effect of Long-term Exposure to Lower Low-Density Lipoprotein Cholesterol Beginning Early in Life on the Risk of Coronary Heart Disease: a Mendelian Randomization Analysis. *J Am Coll Cardiol* 2012; 60(25): 2631-9.
150. **Flack JM**, Graff A, Li W, Chavanu K. “Efficacy and safety of Olmesartan Medoxomil Versus Losartan Potassium in patients by Stage 1 or 2 Hypertension”. *Postgrad Med* 2012;124(3):59-70.
151. Bakhtar O, Ference B, Hedquist L, Levy P, **Flack, JM.** “The relationship of resistant hypertension and treatment outcomes with total arterial compliance in a predominantly African American hypertensive cohort.” *J Clin Hypertens* 2012; 14(9):618-622.



John M. Flack, M.D., M.P.H.

152. Valina-Toth AL, Lai Z, Zhang S, **Flack JM**. "Vitamin D and parathyroid hormone relationships with urinary nitric oxide metabolites and plasma isoprostanes in African Americans." *Cardiorenal Med* 2012; 2(3):234-242.
153. Kandzari DE, Bhatt DL, Sobotka PA, O'Neill WW, Esler M, **Flack JM**, Katzen BT, Leon M, Massaro JM, Negoita M, Oparil S, Rocha-Singh K, Straley C, Townsend RR, Bakris G. "Catheter-Based Renal Denervation for Resistant Hypertension: Rationale and Design of the SYMPLICITY HTN-3 Trial." *Clin. Cardiol.* 2012 Sep;35(9):528-35.doi: 10.1002/clc.22008. Epub 2012 May 9.
154. Levy, PD, **Flack, JM**. Should African-Americans with elevated blood pressure be routinely screened for hypertensive heart disease? *Expert Rev Cardiovasc Ther* 2012;10(10):1201-4.
155. **Flack JM**, Okwuosa T, Sudhakar R, Ference B, Levy P, "Should African Americans have a lower blood pressure goal than other ethnic groups to prevent organ damage." *Curr Cardiol Rep* 2012 Dec 14(6):660-6. Doi: 10.1007/s11886-012-031406.
156. Levy P, Ye H, Compton S, Zalenski R, Byrnes T, **Flack JM**, Welch R. Subclinical Hypertensive Heart Disease in black patients with elevated blood pressure in an inner-city emergency department. *Ann Emerg Med* 2012;60(4):467-474.
157. Ferguson JC, Matthews GJ, Townsend RR, Raj DS, Kanetsky PA, Budoff M, Fischer MJ, Rosas SE, Karthety R, Rahman M, Master SR, Qasim A, Li M, Mehta NN, Shen H, Mitchell BD, O'Connell JR, Shuldiner AR, Ho WK, Young R, Rasheed A, Danesh J, He J, Kusek JW, Ojo AO, **Flack J**, Go AS, Gadegbeku CA, Wright JT Jr., Saleheen D, Feldman HI, Rader DJ, Foulkes AS, Reilly MP. CRIC Study Principal Investigators. Candidate Gene Association Study of Coronary Artery Calcification in Chronic Kidney Disease: Findings from the CRIC Study (Chronic Renal Insufficiency Cohort). *J Am Coll Cardiol* 2013; 62(9); 789-98.
158. **Flack JM**, Ference B, Levy, P, "Should African Americans with hypertension be treated differently than non-African Americans?" *Current Hypertension Rep* 2014; 16 (1): 409.
159. Ference BA, Julius S, Mahajan N, Levy PD, Williams KA Sr., **Flack, JM**. Clinical Effect of Natural Random Allocation to Lower Systolic Blood Pressure Beginning Before the Development of Hypertension. *Hypertension* 2014;63(6):1182-8.
160. Bhatt DL, Kandzari DE, O'Neill WW, D'Agostino R, **Flack JM**, Katzen BT, Leon MB, Liu M, Mauri L, Negoita M, Cohen SA, Oparil S, Rocha-Singh K, Townsend RR, Bakris GL, For the **SYMPLICITY** HTN-3 Investigators. A Controlled Trial of Renal Denervation for Resistant Hypertension. *N Engl J Med* 2014;370(15):1393-401.
161. Brody AM, **Flack JM**, Ference BA, Levy PD. Utility of Framingham Risk Score in Urban Emergency Department Patients with Asymptomatic Hypertension. *Crit Pathw Cardiol* 2014;13(3):114-116.
162. Bakris GL, Townsend RR, Liu M, Cohen SA, D'Agostino R, **Flack JM**, Kandzari DE, Katzen BT, Leon MB, Mauri L, Negoita M, O'Neill WW, Oparil S, Rocha-Singh K, Bhat DL. SYMPLICITY HTN-3 Investigators. Impact of renal denervation on 24-hour

John M. Flack, M.D., M.P.H.

ambulatory blood pressure: results from SYMPLICITY HTN-3. *J Am Coll Cardiol* 2014;64(11):1071-1078.

163. Vemulapalli S, Ard J, Bakris GL, Bhatt DL, Brown AS, Cushman WC, Ferdinand KC, **Flack, JM**, Fleg JL, Katzen BT, Kostis JB, Oparil S, Patel CB, Pepine CJ, Pina IL, Rocha-Singh KJ, Townsend RR, Peterson ED, Califf RM, Patel MR. Proceedings from Duke Resistant Hypertension Think Tank. *Am Heart J* 2014;167(6):775-88.
164. Burla MJ, Brody AM, Ference BA, **Flack JM**, Mahn JJ, Marinica AL, Carroll JA, Nasser SA, Zhang S, Levy PD. Blood pressure control and perceived health status in African Americans with subclinical hypertensive heart disease. *J Am Soc Hypertens* 2014;8(5):321-9.
165. Brody AM, Murphy E, **Flack JM**, Levy PD. Primary care in the Emergency Department – An untapped resource for public health research and innovation. *West Indian Med J* 2014;63(3):238-241.
166. Purakal JD, Williams-Johnson J, Williams EW, Pemba S, Kambona J, Welch R, **Flack J**, Levy P. Differences and similarities in explanatory models of hypertension in the United States of American, Tanzania and Jamaica. *West Indian Med J* 2014;63(3):242-250.
167. Mahn JJ, Dubey E, Brody A, Welch R, Zalenski R, **Flack JM**, Ference B, Levy PD. Test characteristics of electrocardiography for detection of left ventricular hypertrophy in asymptomatic emergency department patients with hypertension. *Acad Emerg Med* 2014;21(9):996-1002.
168. Brody A, Rahman T, Reed B, Millis S, Ference B, **Flack JM**, Levy P. Safety and efficacy of antihypertensive prescription at emergency department discharge. *Acad Emerg Med* 2015; 22(5):632-5.
169. Kandzari DE, Bhatt DL, Brar S, Devireddy CM, Esler M, Fahy M, **Flack JM**, Katzen BT, Lea J, Lee DP, Leon MB, Ma a, Massaro J, Mauri L, Oparil S, O'Neill WW, Patel MR, Rocha-Singh K, Sobotka PA, Svetkey L, Townsend RR, Bakris GL. Predictors of blood pressure response in the SYMPLICITY HTN-3 Trial. *Eur Heart J* 2015; Jan 21;36(4):219-27.
170. Thomas G, Xie D, Chen HY, Anderson A, Appel L, Bodana S, Brecklin C, Drawz P, **Flack JM**, Miller E III, Steigerwalt S, Townsend R, Weir M, Wright, Jr J, Rahman M; CRIC Study Investigators. Prevalence and prognostic significance of apparent treatment resistant hypertension in chronic kidney disease: A report from the CRIC Study. *Hypertens* 2016; Feb;67(2):387-96.
171. Lash J, Ricardo AC, Roy J, Deo R, Fischer M, **Flack JM**; et al. Race/Ethnicity and cardiovascular outcomes and death in adults with chronic kidney disease: Findings from the CRIC (Chronic Renal Insufficiency Cohort) and Hispanic CRIC studies. (manuscript submitted) 2015
172. Levy PD, Mahn JJ, Miller J, Shelby A, Brody A, Davidson R, Burla MJ, Marinica A, Carroll J, Purakal J, **Flack JM**, Welch RD. Blood pressure treatment and outcomes in hypertensive patients without acute target organ damage: A retrospective cohort. *Am J Emerg Med* 2015; 33(9): 1219-24.



John M. Flack, M.D., M.P.H.

173. Denker M, Boyle S, Anderson AH, Appel LJ, Chen J, Fink JC, **Flack J**, Go AS, Horwitz E, Hsu CY, Kusek JW, Lash JP, Navaneethan S, Ojo AO, Rahman M, Steigerwalt SP, Townsend RR, Feldman HI; Chronic Renal Insufficiency Cohort Study (CRIC): Overview and summary of selected findings. *Clin J Am Soc Nephrol* 2015; 10(11):2073-83.
174. Lipari M, Moser LR, Petrovitch EA, Farber M, **Flack JM**. As-needed intravenous antihypertensive therapy and blood pressure control. *J Hosp Med*. 2015 Nov 12. doi: 10.1002/jhm.2510. [Epub ahead of print] Review. PMID: 26560085.
175. **Flack JM**, Bhatt DL, Kandzari DE, Brown D, Brar S, Choi JW, D'Agostino R, East C, Katzen BT, Lee L, Leon MB, Mauri L, O'Neill WW, Oparil S, Rocha-Singh K, Townsend RR, Bakris G; SYMPLICITY HTN-3 Investigators. An analysis of the blood pressure and safety outcomes to renal denervation in African Americans and Non-African Americans in the SYMPLICITY HTN-3 trial. *J Am Soc Hypertens*. 2015 Oct;9(10):769-79.
176. Bakris GL, Townsend RR, **Flack JM**, Brar S, Cohen SA, D'Agostino R, Kandzari DE, Katzen BT, Leon MB, Mauri L, Negoita M, O'Neill WW, Oparil S, Rocha-Singh K, Bhatt DL; SYMPLICITY HTN-3 Investigators. 12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the SYMPLICITY HTN-3 trial. *J Am Coll Cardiol*. 2015 Apr 7;65(13):1314-21.
177. Ference BA, Majeed F, Penumetcha R, **Flack JM**, Brook RD. Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2 x 2 factorial Mendelian randomization study. *J Am Coll Cardiol*. 2015 Apr 21;65(15):1552-61.
178. Navaneethan SD, Roy J, Tao K, Brecklin CS, Chen J, Deo R, **Flack JM**, Ojo AO, Plappert TJ, Raj DS, Saydain G, Sondheimer JH, Sood R, Steigerwalt SP, Townsend RR, Dweik RA, Rahman M; Chronic Renal Insufficiency Cohort Investigators. Prevalence, Predictors, and Outcomes of Pulmonary Hypertension in CKD. *J Am Soc Nephrol*. 2016 Mar;27(3):877-86.
179. Kario K, Bhatt D, Kandzar D, Brar S, **Flack J**, Gilbert C, Oparil S, Robbins M, Townsend R, Barkris G. Impact of renal artery denervation on patients with obstructive sleep apnea and resistant hypertension: Insights from the SYMPLICITY HTN-3 Trial. *Circ J* 2016; 80(6):1404-1412.
180. Lash JP, Ricardo AC, Roy J, Deo R, Fischer M, **Flack JM**, He J, Keane M, Lora C, Ojo A, Rahman M, Steigerwalt S, Tao K, Wolf M, Wright, Jr JT, Go A, on behalf of the Chronic Renal Insufficiency Cohort (CRIC) Study Investigators. Race/ethnicity and cardiovascular outcomes in adults with chronic kidney disease: Findings from the CRIC (Chronic Renal Insufficiency Cohort) and Hispanic CRIC studies. *Am J Kidney Dis* 2016.
181. Gutierrez OM, Parsa A, Isakova T; Scialla JJ, Chen J, **Flack JM**, Nessel LC, Gupta J., Bellovich KA, Steigerwalt S, Sondheimer JH, Wright JT Jr, Feldman HI, Kusek JW, Lash JP, Wolf M. Genetic African ancestry and markers of mineral metabolism in CKD. *Clin J Am Soc Nephrol* 2016; Apr; 11(4):653-62.
182. Sampson UK, Kaplan RM, Cooper RS, Diez Roux AV, Marks JS, Engelgau MM, Peprah E, Mishoe H, Boulware LE, Felix KL, Califf RM, **Flack JM**, Cooper LA, Gracia JN,

John M. Flack, M.D., M.P.H.

Henderson JA, Davidson KW, Krishnan JA, Lewis TT, Sanchez E, Luban NL, Vaccarino V, Wong WF, Wright JT Jr, Meyers D, Ogedegbe OG, Presley-Cantrell L, Chambers DA, Belis D, Bennett GC, Boyington JE, Creazzo TL, de Jesus JM, Krishnamurti C, Lowden MR, Punturieri A, Shero ST, Young NS, Zou S, Mensah GA. Reducing health inequities in the U.S.: recommendations from the NHLBI's health inequities think tank meeting. *J Am Coll Cardiol* 2016; Aug; 68(5):517-24.

183. **Flack JM**, Nolasco C, Levy P. The case for low blood pressure targets. Invited State of the Art Commentary. *Am J Hypertens*, 2017; Jan; 30 (1): 3-7.
184. **Flack JM**. Method of blood pressure measurement, interpretation of SPRINT, and the Atlantic divide. *Curr Hypertens Report* 2017; 19(3):19.
185. Levy PD, Willock RJ, Burla M, Porody A, Mahn J, Marinica A, Namer SA, **Flack JM**. Total anti-hypertensive therapeutic intensity score and its relationship to blood pressure reduction. *J Am Soc Hypertens* 2016; 10(12):906-916.
186. Twiner MJ, Marinica AL, Kuper K, Goodman A, Mahn JJ, Burla MJ, Brody AM, Carroll JA, Willock JR, **Flack JM**, Namer SA, Leoy PD. Screening and treatment for subclinical hypertensive heart disease in emergency department patients with uncontrolled blood pressure: A cost-effectiveness analysis. *Acad Emerg Med* 2017; 24(2):168-176.
187. Egan B, **Flack J**, Patel M, Lombera S. Insights on Beta blockers for the treatment of hypertension: a survey of health care practitioners. *J Clin Hypertens* 2018 Oct;20(10):1464-1472.
188. Buhnerkempe MG, Botchway A, Nolasco Morales CE, Prakash V, Hedquist L, **Flack JM**. Predicting the risk of apparent treatment-resistant hypertension: a longitudinal, cohort study in an urban hypertension referral clinic. *J Am Soc Hypertens*. 2018 Sept 20. pii: S1933-1711(18)30281-x. DOI: 10.1016/j.jash.2018.09.006 [Epub ahead of print].
189. Carey RM, Calhoun DA, Bakris GL, Brook RD, Daugherty SL, Dennison-Himmelfarb CR, Egan BM, **Flack, JM**, et al. Resistant Hypertension: Detection, Evaluation, and Management: A scientific statement from the American Heart Association. *Hypertension* 2018 Nov;72(5):e53-e90. DOI: 10.1161/HYP.0000000000000084.
190. Buhnerkempe MG, Botchway A, Prakash V, Al-Akchar M, Nolasco Morales CE, Calhoun DA, **Flack JM**. Prevalence of refractory hypertension in the United States from 1999 – 2014. *J Hypertens* 2019; 37(9): 1797 – 1804
191. **Flack JM** and Adekola B. Blood pressure and the New ACC/AHA hypertension guidelines. *Trends Cardiovasc Med* 2019. May 15 (online ahead of print)
192. **Flack JM** and Calhoun D. The ACC/AHA and ESC/ESH Hypertension Guidelines: contrasting versions of idiosyncratic excellence. *Am J Hypertens* 2019; 32(8): 705 – 708.
193. Botchway A, Buhnerkempe MG, Prakash V, Al-Akchar M, Adekola O, **Flack JM**. Serious adverse events cluster in participants experiencing the primary composite cardiovascular endpoint: A post-hoc analysis of the SPRINT Trial. *Am J Hypertens* 2020. May 21; 33(6): 528-533. PMID: 31930338 DOI:10.1093/ajh/hpaa010

John M. Flack, M.D., M.P.H.

194. Mehta R, Cho ME, Cai X, Lee J, He J, **Flack JM**, Shafi T, Saraf SL, Valentin D, Feldman HI, Isakova T, Woff M. Iron Status, FGF23 and Cardiovascular and Renal Outcomes in Chronic Kidney Disease. *Kidney Int* 2021 Dec; 100(6):1292-1302. DOI: 10.1016/j.kint.2021.07.013
195. Romero CA, Mathew S, Wasinski B, Reed B, Brody A, Dawood R, Twiner MJ, McNaughton CD, Fridman R, **Flack JM**, Carretero OA, Levy PD. Angiotensin-converting enzyme inhibitors increase anti-fibrotic biomarkers in African Americans with left ventricular hypertrophy. *J Clin Hypertens* 2021 May; 23(5): 1008-1016. PMID: 33932079 DOI: 10.1111/jch.14206

Peer-Reviewed Book Chapters:

1. **Flack JM**, Grimm RH Jr. Diuretics, Kaplan NM, Brenner BM, Laragh JH, (eds). In Perspectives in hypertension Vol. III. New therapeutic strategies in hypertension. Raven Press Ltd. 1989, pp 17-32.
2. **Flack JM**, Yunis C. Ethnicity, SES, and hypertension. Izzo JL, Black HR (eds) In American Heart Association Hypertension primer. American Heart Association, Dallas, TX 1993, pp153-155.
3. **Flack JM**, Staffileno BA. Hypertension in blacks. Richard Johnson, MD (ed) In Comprehensive clinical nephrology, Mosby International. London, UK, 1998.
4. **Flack JM**, Weir MW, and Calcium antagonists as antihypertensive in African-American patients. Murray Epstein, MD FACP, (ed). In Calcium antagonists in clinical medicine, 2<sup>nd</sup> Edition. Huskey and Belfur Inc., pp. 291-305. Philadelphia, PA 1998.
5. **Flack JM**, Staffileno BA. Hypertension in Blacks, in Oparil and Webber (eds.), In Hypertension: A companion to Brenner and Rector's the kidney, W.B. Saunders, (62): pp 558-563. Philadelphia, PA 2000
6. **Flack JM**. Therapy of hypertension in primer on kidney diseases. Arthur Greenberg, (ed). Alfred K. Cheung et al (assoc ed). In Primer on kidney diseases, 2<sup>nd</sup> Edition. Academic Press, pp. 486-497. San Diego, CA 2001
7. **Flack JM**, Mann NK, Ramappa P., Rangi JK, Hypertension and other risk factors for stroke, Braithwaite RL and Taylor SE (eds) in Health/issues in the black community, 2<sup>nd</sup> edition, Jossey-Bass publishers, pp 189-208. San Francisco, CA 2001.
8. **Flack JM**. Drugs for Hypertension. Reed JW, Hudson HM (eds), in High blood pressure: the black man and woman's guide to living with hypertension, Hilton Publishing, Chapter 5 pp 63-82. Roscoe, IL 2002.
9. **Flack JM**, Nasser SA. Ethnicity and Socioeconomic Status in Hypertension, Izzo JL and Black HR (eds). In American Heart Association Hypertension primer. 3<sup>rd</sup> Edition, Chapter B88, pp 261-264. 2003.

John M. Flack, M.D., M.P.H.

10. **Flack JM**, Patel N, Mehra Vishal, Nasser SA. Hypertension treatment, Chaturvedi S, Levine SR (eds), in Transient ischemic attacks, Blackwell Futura Publishing, Chapter 14 pp 309-323. Malden, Massachusetts 2004
11. Shafi T., Nnolim B, **Flack JM**, Treatment of Hypertension in African Americans, Bakris G (eds). In The Kidney and Hypertension. Martin Dunitz Taylor and Francis Group 2004, pp 165-174.
12. Crook ED, Dews P, **Flack JM**. Hypertension, Current Challenges and Newer Perspectives in Pharmacotherapy. Kohli K, Gupta M. Tejwani S, (eds) in Contemporary Perspectives on Clinical Pharmacotherapeutics. Elsevier 2006, pp 293-305.
13. **Flack JM**, Shafi T, Chandra S, Ramos J, Nasser SA, Crook ED. Hypertension in African Americans, Black and Elliot (eds), in Hypertension, A Companion to Braunwald's Heart Disease. Elsevier pp 468-481, 2007.
14. **Flack JM**, Nasser SA, O'Connor SM. Should selection of antihypertensive therapy be focused on other markers for cardiovascular risk besides blood pressure? George Bakris, MD (ed). Therapeutic Strategies in Hypertension, Chapter 10, pp 115-124. Clinical Publishing Co., Oxford, UK 2006
15. **Flack JM**, Nasser SA, Britton M, Valina-Toth AB, Ahooja V, O'Connor SM. Hypertension in Racial and Ethnic minorities. Lip and Hall (eds). Comprehensive Hypertension. Philadelphia, Mosby (Elsevier), pp. 707-718, 2007.
16. **Flack, JM**, Nasser SA, O'Connor SM. Hypertension in African Americans. Feehally J, Floege J, and Johnson RJ (eds.) Comprehensive Clinical Nephrology, 3<sup>rd</sup> Edition. Chapter 39, pp 467-473, 2007
17. **Flack JM**, Nasser SA, O'Connor SM. Ethnicity and Socioeconomic Status in Hypertension. Henry R. Black, MD (ed). Hypertension Primer, 4<sup>th</sup> Edition. Chapter B84, Lippincott Williams & Wilkins, Philadelphia, PA, pp 276-278, 2008.
18. **Flack JM**, Nasser SA, O'Connor SM, Ethnicity and Socioeconomic Status in Hypertension. Joseph L. Izzo Jr, Domenic A. Sica, Henry R. Black (eds). Hypertension Primer, 4<sup>th</sup> Edition. Chapter B84, pp 276-278. Lippincott Williams & Wilkins, Philadelphia, PA, 2008.

Non-Peer Reviewed Book Chapters:

1. **Flack JM**. Atherosclerosis. Kaufman CE, and Clark B, Eds. Pathophysiology syllabus 1987-1988 University of Oklahoma, Oklahoma City 147-164, 1987.

Non-Peer Reviewed Articles:

1. **Flack JM**. Assessing functional outcomes in hypertension. Group practice J 41(3):82-85, 1992.
2. Grimm RH Jr, **Flack JM**. The management of hypertension: Potential trade-offs on coronary risk. Am J Med 87(2A):625-655, 1989.

John M. Flack, M.D., M.P.H.

3. **Flack JM**, Grimm RH Jr. Treating hypertension and lipids: A rational approach. *Med Mgt Dynamics* 6:3-8, 1988.
4. **Flack JM**. Living with hypertension. Introduction to dealing with elevated blood pressure. *NC Med J* 58(3):193-196, 1997.

Editorials/Letter to Editor:

1. **Flack JM**. Sisson L. Obesity is a major crisis for African-Americans. *Obesity and Health* 5(1):5-6, 1991.
2. **Flack JM**. Lifestyle modification and blood pressure: Lessons from TOMHS. *Obesity and Health* 6(6):106-107, 1992.
3. **Flack JM**. Calcium antagonists: friend, foe, or do we know? Consortium of Southeastern Hypertension Centers newsletter, 1996.
4. **Flack JM**. Bledsoe K. Combination antihypertensive drug treatment: A therapeutic option long overdue. *American Family Physician* 61(10):2974-2977, 2000.
5. **Flack JM**, Minimizing the progression of kidney disease: *AM J of Kidney Disease* 36 (3) Suppl 1:S1-S3, 2000.
6. Ofili E, **Flack JM**, Gibbons G. Race and responsiveness to drugs for heart failure. *N Engl J Med* 6;345(10):767; discussion 767-8, Sept 2001.
7. **Flack JM**, Crook ED, Klag M. Racial and ethnic disparities in kidney disease. *Adv Ren Ther*, 11(1) editorial 1-2, Jan 2004.
8. **Flack JM**. Editorial commentary on fixed combination isorbide dinitrate/hydralazine for nitric-oxide-enhancing therapy in heart failure. *Expert Opinion on Pharmacotherapy* 8(3): 275-277, Feb 2007.
9. **Flack JM**. Noninvasive hemodynamic measurements: an important advance in individualizing drug therapies for hypertensive patients. *Hypertens*. 2006 April; 47(4):646-7.
10. **Flack JM**. Epidemiology and unmet needs in hypertension. *JMCP Supplement*. 2007 Oct; 13(8): S-b (S1-8).
11. **Flack, JM**. Editorial commentary on fixed combination isosorbide dinitrate/hydralazine for nitric-oxide-enhancing therapy in heart failure. *Expert Opinion on Pharmacotherapy* 2007;8(3):275-7
12. **Flack JM**, Domenic A. Sica and Shawna Nesbitt. Chlorthalidone versus hydrochlorothiazide as the preferred diuretic: is there a verdict yet? *Hypertens* 2011; 57;665-666.
13. **Flack JM**, Nasser SA, Levy PD. Initial treatment of hypertension with aliskiren and amlodipine combination gives 6.5 mm H greater reduction in systolic blood pressure than does either monotherapy. *Evid Based Med* 2011;16(5):148-149.

John M. Flack, M.D., M.P.H.

14. PD. Levy, **Flack JM**. Should African-Americans with elevated blood pressure be routinely screened for hypertensive heart disease? *Expert Reviews Cardiovasc. Ther.* 10(10), 1201-1204 (2012).
15. **Flack JM**. Is evening dosing of antihypertensive therapy ready for prime time? *J Clin Hypertens* 2014;16(8):557-558.
16. Schiffrin EL, Calhoun DA, **Flack JM**, Ito S, Webb RC. A message from the new editorial team at the American Journal of Hypertension. *Am J Hypertens.* 2016 Jan;29(1):1. doi: 10.1093/ajh/hpv173. PMID: 26658829
17. Schiffrin EL, Calhoun DA, **Flack JM**. SPRINT proves that lower is better for nondiabetic high-risk patients, but at a price. *Am J Hypertens.* 2016 Jan;29(1):2-4. doi: 10.1093/ajh/hpv190. Epub 2015 Nov 23. PMID: 26597221
18. **Flack, JM**, Moser LR, Lipari M, Petrovich E, Farber M. The Authors Reply, "as-needed intravenous antihypertensive therapy and blood pressure control". *J Hosp Med.* 2016 Jul;11(7):526.
19. **Flack, JM**. A novel approach for estimating cost-effectiveness of pharmacological treatment in drug naïve adults with hypertension. *Am J Hypertens.* 2016; 29(10):1138-9.
20. Schiffrin, EL, Calhoun DA, **Flack JM**. Do we need a new definition of hypertension after SPRINT? *Am J Hypertens.* 2016; 29(10):1127-9.
21. Schiffrin, EL, Calhoun DA, **Flack JM**, Ito S, Webb RC. Update from the Editors to our readers. *Am J Hypertens.* 2017; 30(1):1-2.
22. **Flack, JM**, Calhoun, DA, Schiffrin EL. The New ACC/AHA Hypertension Guidelines for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. *Am J Hypertens* 2018; Jan 12;31(2): 133-135.
23. Calhoun DA, Schiffrin EL, **Flack JM**. Resistant Hypertension: An Update. *Am J Hypertens.* 2018 Nov 8. doi: 10.1093/ajh/hpy156 [epub ahead of print]
24. **Flack JM**. Better Implementation of what is known will reverse falling hypertension control rates: we know how to reverse falling hypertension control rates. *Hypertension* 2021 Sep; 78(3):588-590. doi: 10.1116/HYPERTENSION.AHA.121.17512.
25. **Flack JM** and Buhnerkempe M. Race and antihypertensive drug therapy: edging toward a new paradigm. *Hypertension* (editorial) in press.

Published Abstracts:

1. Gardin JM, Wagenknecht LE, Anton-Culver H, **Flack JM**, Gidding S, Wong ND, Manolio TA. Relationship of Race, sex, systolic blood pressure levels, and body mass to left ventricular mass in healthy young adults. The CARDIA Study. *Circulation* 84(4):133, 1991.
2. **Flack JM**, Gardin JM, Gidding S, Manolio TA, Sedlacek C, Nelson E, Jacobs DR. Mitral valve prolapse in a biracial cohort of young adults. The CARDIA Study. *Circulation* 84(4):130, 1991.



John M. Flack, M.D., M.P.H.

3. **Flack JM**, Liu K, Savage P. Baseline insulin predicts 2 year blood pressure changes in young adults. The CARDIA Study. *Circulation* 83(2):724, 1991.
4. Gidding S, Liu K, Gardin J, **Flack JM**, Hulley S. Ability of NCEP guidelines to identify young adults with high LDL cholesterol: The CARDIA Study. *Circulation* 83(2):731, 1991.
5. Gidding S, Liu K, Bild D, Wagenknecht L, **Flack JM**, Hulley S. Use of life style factors to identify young adults with low HDL cholesterol: The CARDIA Study. *Circulation* 83(2):732, 1991.
6. **Flack JM**, Adams-Campbell L, Gardin J, Yunis C, Lewis B, Levin R. Psychosocial correlates of left ventricular mass (LVM) in young adults: The CARDIA Study. *Am J Hypertens* 6(5 Part 2):22A, 1993.
7. Mercuri M, Bond M, Nichols F, Carr A, **Flack JM**, Byington R, Raines J. For the MIDAS Group. *J Cardiovasc Diag Proc* 11(4):241-256,1993.
8. **Flack JM**, Yunis C, Preisser J, Staffileno BA, Menssah G, Saunders E. The accupril titration interval management evaluation (ATIME) trial. *Am J Hypertens* 11(4); Part 2; 103 A, 1998.
9. **Flack JM**, Grimm RH, Staffileno BA, Yunis C, Elmer P. A Novel Z-Score method for determining salt-sensitivity: The sodium and blood pressure study (SNAP). *Hypertens* 32(3): 606, 1998.
10. Staffileno BA, Braun LT, **Flack JM**. The accumulative effects of physical activity in hypertensive post-menopause women. *Med Sci Sports Exerc* 30(5): Suppl; 582, 1998.
11. Staffileno BA, **Flack JM**, Brauen LT. Hemodynamic response from the accumulation of short bouts of moderate-intensity physical activity in hypertensive, postmenopausal women. *Am J Hypertension* 11(4): Part 2: 209A, 1998.
12. **Flack JM**, Grimm RH, Staffileno BA, Elmer P, Yunis C, Peters R. The influence of body mass index on salt-sensitivity in African American women: the sodium and blood pressure study [SNAP]. *Ethn & Dis* 8 (2), 1998.
13. Holmes CB, Staffileno BA, Hamaty M, Dudley A, Yunis C, Grimm RH, **Flack JM**. The interactive effect of body size and renin-angiotensin axis on blood pressure response to oral salt loading in normotensive African Americans. *Am J Hypertension* 12(4): Part 2: 17A – 18A, 1999.
14. Grimm RH, Bracha Y, **Flack JM**, Grandits G, Prineas R. Reasons for going off study medication in the Treatment of Mild Hypertension Study. (American Society of Hypertension [ASH], Annual Scientific Meeting, 2000.
15. Duncan K, Ramappa P, Thornburg R, Singh K, Okoye C, Mann N, Hedquist L, Dudley A, **Flack JM**. The influence of urinary albumin excretion and estimated glomerular filtration rate on blood pressure response in drug-treated hypertensive patients in an academic hypertension clinic. *Am J Hypertension* 14(4): Part 2: P-493, 2001.
16. Thornburg R, Ramappa P, Singh K, Okoye, Dudley A, Hedquist L, Mann N, **Flack JM**. Factors correlated to blood pressure response in hypertensive patients with Type 2 diabetes mellitus. *Am J Hypertension* 14(4): Part 2: P-578, 2001.



John M. Flack, M.D., M.P.H.

17. **Flack JM**, Garza D, Shi, Amlodipine Study Group. A multicenter single-blind trial evaluating the efficacy of amlodipine in patients with severe hypertension (JNC Stage 3). *Am J Hypertension* (14)4: Part 2: P-242, 2001.
18. Kostis JB, Cobbe S, Johnston C, Ford I, Murphy M, Webber MA, Black HR, Plouin PF, Levy D, Mancia G, Larochelle P, Kolloch RE, Alderman M, Ruilope LM, Dahlof B, **Flack JM**, Wolf R. OPERA Study Group. Omapatrilat in persons with enhanced risk of atherosclerotic events. *Am J Hypertension* (14)2: Part 1:P193-8, 2002.
19. **Flack JM**, Bakris G. LEAAD (Lotrel and Enalapril in AA Diabetics) Comparison of the antihypertensive efficacy and safety of fixed-dose combination therapy with amlodipine/benazepril vs emalapril monotherapy in African Americans with type 2 Diabetes. *Ethn & Dis* Vol (12) 2002.
20. El-Achkar T, Ohmit SE, Grimm R, Bakris G, **Flack JM**. Higher prevalence of anemia with diabetes mellitus in moderate kidney insufficiency. *Diab supp* (51)2: A224, 2002.
21. Hall WD, Clark LT, Wenger NK, Wright JT Jr, Kumanyika SK, Watson K, Horton EW, **Flack JM**, Ferdinand KC, Gavin Jr 3<sup>rd</sup>, Reed JW, Saunders E, O'Neal W Jr. African-American Lipid and Cardiovascular Council. The metabolic syndrome in African Americans: A review. *Ethn & Dis* Vol 13(4): 414-28, 2003.
22. Artinian, NT, **Flack JM**, Vander Wal JS, Jen KLC, Washington OGM. Depression, stress, and BP control in urban African American women. *Am J Hyper* 17(5,part3) 169A.
23. Messerli FH, Bakris GL, Ferrera D, Houston MC, Petrella RJ, **Flack JM**, Sun W, Lee E, Neutel JM. Efficacy and safety of coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia: results of the AVALON trial. *J Clin Hypertens* (Greenwich). 2006 Aug;8(8):571-81;quiz 582-3.
24. Williams RA, **Flack JM**, Gavin JR 3<sup>rd</sup>, Schneider WR, Hennekens CH. Guidelines for management of high-risk African Americans with multiple cardiovascular risk factors: recommendations of an expert consensus panel. *Ethn Dis*. 2007 Spring;17(2):214-20.
25. Artinian NT, **Flack JM**, Nordstrom CK, Hockman EM, Washington OG, Jen KL, Fathy M. Effects of nurse-managed telemonitoring on blood pressure at 12-month follow-up among urban African Americans. *Nurs Res*. 2007 Sep-Oct;56(5):312-22.
26. **Flack JM**. Maximising antihypertensive effects of angiotensin II receptor blockers with thiazide diuretic combination therapy: focus on irbesartan/hydrochlorothiazide. *Int J Clin Pract*. 2007 December; 61(12): 2093–2102.

#### Presentations and Abstracts:

1. **Flack JM** and Roswell R. "Vitamin D levels in familial hypocalciuric hypercalcemia." Presented at the American College of Physicians, Oklahoma Society of Internal Medicine State Conference, 1981.
2. **Flack JM**. "A case report of conversion of quinidine resistant atrial fibrillation to normal sinus rhythm with oral flecainide: A promising alternative to the standard therapeutic approaches."

**John M. Flack, M.D., M.P.H.**

- Presented at the Regional Meeting of the American College of Physicians, Oklahoma Society of Internal Medicine, October 1986.
3. Ryder KW, Oei TO, **Flack JM**, McDonald CJ, Whang R. "Serum electrolyte abnormalities in patients receiving theophylline." Presented at the Indiana University Medical Center, Indianapolis, IN and University of Oklahoma Health Sciences Center, Oklahoma City, OK.
  4. Cater NB, **Flack JM**. "Follow-up study of hypercholesterolemic persons identified during mass screening at two shopping centers." Presented at the 29th National Student Research Forum, Galveston, TX, April 6, 1988.
  5. **Flack JM**, Wiist W. "Clustering of hypercholesterolemia and hypertension in a large urban Black population." Presented at the First National Cholesterol Conference, Arlington, VA, November 1988.
  6. Cater N, **Flack JM**. "Observational study of house staff/attending physician recognition of hypercholesterolemia in a large teaching hospital." Presented at the First National Cholesterol Conference, Arlington, VA, November 1988.
  7. Wiist W, **Flack JM**. "A cholesterol education program in a black church." Presented at the First National Cholesterol Conference, Arlington, VA, November 1988.
  8. **Flack JM**, Wiist W. "Report of baseline CHD risk factor prevalence for Northeast Oklahoma City cholesterol education program screenees." Presented at the 116th Annual Meeting of the American Public Health Association, Arlington, VA, November 1988.
  9. **Flack JM**, Wiist W. "Relationships between blood pressure, body mass index, and income in black men and women." Presented at the National Conference on High Blood Pressure Control, Lake Buena Vista, FL, May 8, 1989.
  10. **Flack JM**, Burke G, Sprafka JM, Grimm RH, Hahn L. "Relationship between blood pressure, lipids and income in black Minnesota heart survey participants." Presented at the Second International Conference on Preventive Cardiology and the 29th Annual Meeting of the American Heart Association Council on Epidemiology. June 18-22, 1989.
  11. Mascioli SM, Launer CA, Svendsen KH, Grimm RH, Neaton JD, Elmer PJ, Gonzalez NM, **Flack JM**, Witte L, Bell M, Cox J, Clearman D. "Sodium chloride raises blood pressure in normotensives--The study of sodium and blood pressure." Presented at the 62nd Scientific Sessions of the American Heart Association, New Orleans, LA, November 13-16, 1989.
  12. **Flack JM**. "Racial and ethnic modifiers of the sodium-blood pressure response." Presented at the National Heart, Lung, and Blood Institute Salt and Blood Pressure Workshop, Bethesda, MD, Nov. 1-2, 1989.
  13. **Flack JM**. For the MIDAS Research Group. "The Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS)." Presented at the Fifth International Interdisciplinary Conference on Hypertension in Blacks, Long Beach, CA, May 3-7, 1990.
  14. **Flack JM**, Wiist W. "The influence of gender and diabetes status on blood pressure, cholesterol and joint blood pressure elevations in adult urban blacks." Presented at the Fifth International Interdisciplinary Conference on Hypertension in blacks, Long Beach, CA, May 3-7, 1990.

**John M. Flack, M.D., M.P.H.**

15. Wiist WH, **Flack JM**. "Dietary intake in African American church attendees." Presented at the Annual Convention of the American Public Health Association, Atlanta, Georgia, November 10-14, 1991.
16. Sowers JR, Byington R, Furberg CD, Mercuri M, Borhani NQ, Applegsie WB, Carr A, Brugger S, **Flack JM**, Schnaper H. "Risk factors associated with atherosclerosis carotid artery thickening in Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS)", 1991.
17. Gidding S, Xie X, Manolio T, **Flack JM**, Perkins L, Gardin J. "Relation between smoking and resting cardiac function: The CARDIA Study." Presented at the American Heart Conference in Orlando, Florida, May 21-23, 1992.
18. **Flack JM**, Grimm RH, Lewis CB, Grandits G, Elmer P, Prineas R, Schoenberger J. "Comparison of response to low dose antihypertensive medication between black and white participants in the treatment of mild hypertension study (TOMHS)." Presented at the Seventh International Interdisciplinary Conference on Hypertension in Blacks, Atlanta, Georgia, May 26-31, 1992.
19. Elmer PJ, **Flack JM**, Grimm RH, Gonzalez N, Cox J, Herbrandson M, Hillman D, Laing B. "Feasibility of diet sodium reduction in middle-aged Blacks." Presented at the Seventh International Interdisciplinary Conference on Hypertension in Blacks, Atlanta, Georgia, May 26-31, 1992.
20. Gidding SG, Gardin J, Xie X, **Flack JM**, Manolio T, Sedlacek C. "The prevalence of echocardiographically diagnosed cardiac disease in an asymptomatic population: The CARDIA Study" Presented at the American Heart Conference, New Orleans, Louisiana, November 16-19, 1992.
21. **Flack JM**, Liu K, Nelson E, Bild D, Hardin M, Hulley S. "Relationship of insulin level to 5-year risk of hypertension in a bi-ethnic cohort of young adults: The CARDIA Study" Presented at the American Heart Conference, Santa Fe, New Mexico, March 17-20, 1993.
22. **Flack JM**, Yunis C, Keenan J, Sprafka JM, Grimm R, Levin R, Sisson L. "Treatment of low high density lipoprotein (HDL) cholesterol (TOLC) Study" Presented at the 34th Annual Conference on Cardiovascular Disease Epidemiology and Prevention American Heart Association, Tampa FL, March 16-19, 1994.
23. Prisant LM, Khoury S, **Flack JM**, Carr AA, Sowers JR, Neuwirth R. "Biochemical changes of MIDAS patients according to treatment and race." Presented at the Ninth Interdisciplinary Conference on Hypertension in Blacks, June 22-26, 1994.
24. Prisant LM, Nichols F, **Flack JM**, Carr AA, Mercuri M, Neuwirth R, Bond G. "Risk factors correlated of carotid intima-media thickness (IMT) of MIDAS patients." Presented at the Ninth Interdisciplinary Conference on Hypertension in Blacks, June 22-26, 1994.
25. Prisant LM, **Flack JM**, Carr AA, Neuwirth R. "Antihypertensive effects in black and white MIDAS patients" Presented at the Ninth Interdisciplinary Conference on Hypertension in Blacks, June 22-26, 1994.
26. Prisant LM, Nichols F, **Flack JM**, Carr AA, Neuwirth R, Mercuri M, Bond G. "Change in carotid intima-media thickness (IMT) of MIDAS patients." Presented at the Ninth Interdisciplinary Conference on Hypertension in Blacks, June 22-26, 1994.

**John M. Flack, M.D., M.P.H.**

27. Cohen JD, Edwards A, Cooper R, **Flack JM**, D'Agostino R, Grimm RH, Grundy SM, Kannel WB, Higgins M, Kronmal RA, Hill M, Lee ET. "Workshop on assessing risk for coronary heart disease." Presented for the National Heart, Lung, and Blood Institute, National Institutes of Health, January 19-20, 1999.
28. Weinberger M, Denke M, **Flack JM**, Hunt S, Sacks F, Kotchen T, McCarron D, Svetkey L. Workshop on Sodium and Blood Pressure. "Response to dietary sodium and other nutrients." Presented at the Bethesda Marriott Hotel for the National Heart, Lung, and Blood Institute, National Institutes of Health, January 28-29, 1999.
29. Patel NR, Alrefai HA, Ohmit S, Nasser S, **Flack JM**. Benefits of revascularization in African Americans with critical renal artery stenosis. Presented at International Society of Hypertension in Blacks and Minorities (ISHIB) at Miami, FL; June 8-12, 2002.
30. Alrefai HA, Rangi J, Ohmit S, Nasser S, Dudley A, **Flack JM**. Total cholesterol and statins affect blood pressure response to antihypertensive drugs in hypertensive patients. Presented at The Endocrine Society's 84<sup>th</sup> Annual Meeting in San Francisco, CA; June 19-22, 2002.
31. Nnolim B, Ohmit SE, Nasser S, Hedquist LA, **Flack JM**. The Glomerular Filtration Rate (GFR) Estimator in Clinical Practice. Presented at the American College of Physicians American Society of Internal Medicine (ACP-ASIM) Michigan Chapter at Ypsilanti, MI; May 17, 2002.
32. Koul D, Dudley AI, Shafi T, Nasser S, Crook E, Spears R, **Flack JM**. Outcomes after renal angioplasty and stent placement in hypertensive African Americans with critical renal artery stenosis. Presented at the American Society of Hypertension 19<sup>th</sup> Annual Scientific Meeting, 2004.
33. Gebreselassie SF, Lai Z, Ohmit S, Tsilimingras D, Nasser S, Dews P, Britton M, **Flack JM**. Factors influencing blood pressure level and diurnal blood pressure variation in patients with complex hypertension. Presented at the American Heart Association 7<sup>th</sup> Scientific Meeting on Quality of Care and Health Outcomes on Cardiovascular Disease and Stroke: May 8-9, 2006.
34. Blank H, Lai Z, Anderson D, Guo X, Ohmit S, Nasser S, Dews P, **Flack JM**. Hypertension control and use of renin-angiotensin systems therapies in persons with diabetes and hypertension. Presented at the American Society of Hypertension Inc. 21<sup>st</sup> Annual Scientific Meeting and Exposition in New York, NY: May 16-20, 2006.
35. Das P, Lai Z, Ohmit S, Nasser S, Dews P, **Flack JM**. The influence of Albuminuria on longitudinal blood pressure (BP) response to antihypertensive drug therapy. Presented at the American Society of Hypertension, Inc. 21<sup>st</sup> Annual Scientific Meeting and Exposition in New York, NY; May 16-20, 2006.
36. Tinevimbo J, Lai Z, Nasser S, Dews P, Britton M, **Flack JM**. Effect of longitudinal blood pressure change and hypertension control in predominantly African American patients with hypertension and type 2 diabetes. Presented at the American Society of Hypertension, Inc. 21<sup>st</sup> Annual Scientific Meeting and Exposition in New, NY; May 16-20, 2006.
37. Levine D, Anderson D, Ohmit S, Corsino L, Guo X, Lai Z, Nasser S, Britton M, Dews P, **Flack J**. Comprehensive training and support intervention for diabetes (CTSI-D). Presented at the

**John M. Flack, M.D., M.P.H.**

- International Society of Hypertension in Blacks 21<sup>st</sup> Annual International Interdisciplinary Conference on Hypertension and Related Cardiovascular Risk Factors in Ethnic Populations in Atlanta, GA:June 23-26, 2006.
38. Penugonda N, Lai Z, Tsilimingras D, Britton M, Nasser SA, Dews P, **Flack JM**. A multi-component hypertension quality of care score predicts longitudinal blood pressure responses and hypertension control in a hypertensive cohort. Presented at the American Heart Association Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke in Washington DC;May 9-11, 2007.
  39. Potu S, Britton M, Tsilimingras D, Yoo Wonsuk, Quah R, Lai Z, Liu X, Nasser SA, Goel A, Dews P, **Flack JM**. The effect of Cox-2 selective NSAIDs on longitudinal blood pressure change according to the level of kidney function. Presented at the American Society of Hypertension 22<sup>nd</sup> Annual Scientific Meeting and Exposition in New York, NY;May 17-21, 2007.

**INVITED PRESENTATIONS (Selected Presentations):**

1. African-American International Collaborative Research Scientists Symposium. International Society on Hypertension in Blacks. Zimbabwe, Africa, February 24-28, 1992.
2. Case Western Reserve University, University Hospitals Janice Douglas-David Satcher Address, "Strategies in managing the African American hypertensive with multiple cardiovascular risk factors" Cleveland, Ohio, November 4, 1992.
3. "Salt and high blood pressure: unanswered questions and unquestioned answers." American Heart Association Twentieth Science Writers Forum. January 17-20, 1993.
4. "Is hypertension really different in blacks and the role of genetics in hypertension?" Preventive Cardiology Symposium, Morehouse School of Medicine. March 6, 1993.
5. "The evidence that treatment of hypertension works." Plenary Session VI Eight International Interdisciplinary Conference on Hypertension in Blacks. Yaounde, Cameroon, Africa, April 8, 1993.
6. "Salt and blood pressure: unanswered questions and unquestioned answers." The First Annual Department of Medicine House Staff Research Conference, University of Oklahoma Department of Internal Medicine, April 16, 1993.
7. "Role of Sodium," Plenary Session X, Symposium: Primary Prevention of Hypertension. American Heart Association Annual Scientific Session, Atlanta, Georgia, November 10, 1993.
8. Role of Angiotensin II in Cardiovascular Pathology. "Angiotensin II antagonists in salt-sensitive hypertension." Satellite Symposium 67th Scientific Sessions American Heart Association, Dallas, Texas, November 13, 1994.
9. Outcomes Management: Conception through Implementation. "Outcomes management: lessons from TOMHS." Miami Beach, Florida, December 7, 1994.



**John M. Flack, M.D., M.P.H.**

10. Visiting Professorship in Preventive Medicine "Hypertension and the evolving interface of public health, clinical management and managed care." Houston, Texas, March 7-9, 1995.
11. State of the Art Lecture "Systemic hypertension." American College of Cardiology. New Orleans, Louisiana, March 21, 1995.
12. Lectures at AHEC regional hospitals. "Evaluation of renal artery hypertension" North Wilkesboro, North Carolina, April 4, 1995.
13. Oklahoma Heart Research & Education Foundation. "Current trends in therapy, how aggressively should we be treating our patients?" Tulsa, Oklahoma, May 5, 1995.
14. Region III-National Medical Association Annual Conference "Treatment of hypertension: the state of the art." Mobile, Alabama, May 20-21, 1995.
15. American Heart Association Annual Conference. "Epidemiology of heart disease and hypertension in African Americans." Orlando, Florida, November 8, 1997.
16. "Managing cardiovascular risk in African-Americans." Presented at the First Conference on Cardiovascular Health: Coming together for the 21<sup>st</sup> century. San Francisco, California, February 19, 1998.
17. "Microalbuminuria in minority populations." Presented at National Kidney Foundation (NKF) Consensus Conference on Proteinuria, Nashville, Tennessee, March 25-26, 1998.
18. "Hypertension in blacks." Presented at the World Cardiology Congress, Rio de Janeiro, Brazil, April 30, 1998.
19. "Salt and cardiovascular disease: implications for African Americans." Third Congress on Treatment of Cardiovascular Disease in African Americans, Presented at the American Heart Association, Dallas, Texas, November 10, 1998.
20. "Difficult to treat patient populations and the identification of individual treatment needs." New Therapeutic Goals in Hypertension. Presented at the American Heart Association, Dallas, Texas, November 7, 1998.
21. Keynote speaker, DMC Heart Academy's First Annual Scholarship Banquet, McGregor Memorial Hall, Detroit, Michigan, November 14, 1998.
22. "Impact of smoking on the CVD-Renal system." Wayne State University Smoking and Interdisciplinary Research Breakfast and Conference, Karmanos Cancer Institute, Detroit, Michigan, November 19, 1998.
23. "Can the treatment of hypertension prevent sudden death in athletes?" Presented at the John B. Johnson Memorial Lecture and Dinner Gala, Las Vegas, Nevada, August 9, 1999.
24. Regional Differences in Cardiovascular Disease. "Does ethnicity play a role?" Presented at the American Heart Association 72<sup>nd</sup> Scientific Session, Atlanta, Georgia, November 8, 1999.
25. Hypertension management in special populations and conditions. "African Americans." Presented at the American Heart Association 72<sup>nd</sup> Scientific Session, Atlanta, Georgia, November 8, 1999.

**John M. Flack, M.D., M.P.H.**

26. 16<sup>th</sup> Annual International Society on Hypertension in Blacks (ISHIB). "Aldosterone: "a cardiovascular risk hormone and its importance in hypertension." Las Vegas, Nevada, July 10-15, 2000.
27. 4<sup>th</sup> Annual Scientific meeting (HFSA). "Racial differences in response to heart failure therapy". Boca Raton, Florida, Sept 10-13, 2000.
28. National Kidney Disease Education Program. "Screening and kidney early evaluation and prevention program" (KEEP). Natcher Conference Center, NIH Campus, Bethesda, Maryland, March 16, 2001.
29. 2<sup>nd</sup> International meeting of the International Federation of Kidney Foundation (IFKF). "Association between proteinuria, renal disease and morbidity and mortality. South Los Angeles, California, October 18-20, 2001
30. Hahemann University Hospital-MCP Hahnemann University School of Medicine, Department of Medicine. "Isolated systolic hypertension (Hypertension in the elderly). Philadelphia, Pennsylvania, December 12, 2001.
31. Annual International Society on Hypertension in Blacks (ISHIB). "Reversing the cardiovascular disease epidemic among ethnic minority populations: Translating strategies into success. Miami, Florida, June 8-12, 2002.
32. First International Summit on Kidney Disease Prevention Scientific Meeting of the National Kidney Foundation Singapore. "Primary prevention of renal disease and related chronic disease theoretical basis/clinical evidence. Singapore, July 23-27, 2002.
33. American Society of Nephrology, Treatment of hypertension in special populations: "Hypertension and African Americans: are they a special population"? Philadelphia, Pennsylvania, October 30-November 4, 2002.
34. Michigan Department of Health "Cardiovascular drug therapy, which drug for which patient." Detroit, Michigan, July 14 2003.
35. General Motors (GM) Corporation – 2003 GMAAN All People Meeting, panel discussion on "Hypertension" to GM employees. Warren, Michigan, October 27, 2003.
36. Annual Honor's Convocation Langston University, Keynote address "A legacy of leadership" to students who have demonstrated leadership and academically excelled. Langston, Oklahoma, April 8, 2004.
37. Henry Clark Stroke Foundation "Hypertension". Cobo Hall Arena, Detroit, Michigan, May 8, 2004.
38. 19<sup>th</sup> Annual International Society on Hypertension in Blacks (ISHIB). "Disparities in cardiovascular disease: bridging the great divide", Detroit, Michigan, June 13-16, 2004.
39. 6<sup>th</sup> Annual International Fatherhood Conference, "The silent killer of men". Detroit, Michigan, June 17, 2004.
40. The Michigan Consortium for Minority Health and Academic Development, Keynote Address "Racial and ethnic Disparities: The looking glass into broader societal and health system problems", Detroit, Michigan, September 29, 2004.



**John M. Flack, M.D., M.P.H.**

41. Wayne State University School of Medicine, Michigan Department of Community Health. "Health Disparities" Lansing, Michigan, January 18, 2005
42. Henry Ford Hospital Cardiology Grand Rounds. "Benefits of Aldosterone Blockers for Hypertensive Patients". Detroit, Michigan, January 26, 2005.
43. Wayne State University Lecture. "Center for Urban and African American health and disparities related research". Detroit, Michigan, February 7, 2005
44. Wayne State University Department of Medicine Faculty. "Center for Urban and African American (CUAAH) Grant Initiative". Detroit, Michigan, February 21, 2005.
45. Detroit Medical Society "Hypertension & Lipids", Detroit, Michigan, February 23, 2005.
46. 54<sup>th</sup> Annual Scientific Session, ACC. Co-Chair "Ethnic Disparity: optimizing therapy across patient populations" session, Orlando, Florida, March 6-9, 2005.
47. Wayne State University College of Nursing Research Day, "Center for Urban and African-American Health (CUAAH): A multidisciplinary approach to complex research questions", Detroit, Michigan, March 23, 2005.
48. Boehringer Ingelheim Speaker Series. "Treating the difficult hypertension patient", Southbend, Indiana, April 7, 2005
49. Boehringer Ingelheim Speaker Series. "Treatment of Hypertension", Fort Wayne Indiana, April 8, 2005.
50. Joint ASH/ISHIB Special Symposium. "Hypertension and Dyslipidemia: Dual therapy in cardiovascular disease risk reduction" San Francisco, California May 14, 2005
51. Henry Ford Wyandotte Grand Rounds. "Hypertension", Wyandotte, Michigan, May 26, 2005.
52. Novartis Speaker Meeting. "Strategies for managing hypertension", Kalamazoo, Michigan, May 26, 2005.
53. ISHIB 2005 Scientific Program, "Hypertension diagnosis, risk stratification and basic therapeutic principles" and "Hypertension in African Americans: A state of the art lecture" San Juan, Puerto Rico, July 13, 2005
54. Henry Ford Wyandotte Hospital – Cardiology Fall Symposium, "Hypertension", Wyandotte, Michigan, September 7, 2005
55. Maya Angelou Research Center, 2005 National Conference on CVD Disparities: Translating Research into Practice, "Unraveling the tangled web of race, genes, disease, and therapeutics" Winston-Salem, North Carolina, September 9, 2005
56. Case Western Reserve University – Health Disparities: from Genetics to Health Policy Symposium, "Health Disparities and Hypertension" Cleveland, Ohio, September 2006.
57. MLK Distinguished Visiting Professor Grand Rounds Duke University Medical Center, "The genesis of cardiovascular-renal diseases in African-Americans: New insights into unanswered questions and unquestioned answers," Durham, North Carolina, January 19, 2007

**John M. Flack, M.D., M.P.H.**

58. General Motors Corporation Black History Month Guest Speaker, "African-American Health Initiatives" February 23, 2007
59. Wayne State University Ambulatory Grand Rounds. "managing hypertension in ambulatory settings: The basics, common problems, and cardinal rules" March 6, 2007
60. GRAAH I Medical Grand Rounds, "Meeting the challenge of treating hypertension in diabetes mellitus: Challenges and opportunities for better blood pressure control" Grand Rapids, Michigan, May 30, 2007
61. International Society of Hypertension in Blacks 2007 Annual Meeting. "Clinical Trials in Endothelial Disease State Progression" Orlando, Florida, June 22, 2007
62. CRAIN Medical Grand Rounds Cleveland Clinic, "Ruminations Regarding the excess cardiovascular-renal disease burden in U.S. Blacks: Clues from interlinked deranged physiological pathways" Cleveland, Ohio, July 26, 2007
63. SUNY Downstate Medicine Grand Rounds, "Hypertension in African-Americans" Brooklyn, New York, April 10, 2008
64. UNC Medicine Grand Rounds, "Dietary cation intake and vitamin d deficiency as plausible mediators of excess cardiovascular diseases in Blacks" Chapel Hill, North Carolina, April 17, 2008
65. International Society of Hypertension in Blacks 23<sup>rd</sup> Annual Interdisciplinary Conference, "Commonly encountered problems in hypertension therapeutics" New Orleans, Louisiana, July 20, 2008
66. Association of Black Cardiologists, Dr. Walter M Booker, Sr. Memorial Symposium, The Inaugural Elijah B. Saunders Memorial Lecture; "Treatment of Resistant Hypertension: Current status and new innovations" Orlando, Florida, November 7, 2015

## **BOOKS REVIEWED**

1. Black Man in a White Coat, by Damon Tweedy, MD; Chicago Tribune, Oct. 1, 2015

# **EXHIBIT B**



*In re: Valsartan, Losartan, and Irbesartan Products Liability Litigation*  
Case No. 19-2875

**JOHN M. FLACK, M.D., MPH**  
**AMENDED LIST OF MATERIALS CONSIDERED**  
**JANUARY 12, 2022**

REVIEW MATERIALS PROVIDED	BATES NOS.
<b>MDL PLEADINGS AND GENERAL DOCUMENTS</b>	
2019.06.17 Am. Master Personal Injury Complaint	N/A
2019.06.17 Am. Master Medical Monitoring Complaint	N/A
2020.03.13 Am. Master Economic Monitoring Complaint	N/A
2019.06.26 Confidentiality and Protective Order	N/A
2021.02.11 0870 - Letter from Lori G. Cohen to Judge Vanaskie – overview	N/A
2021.02.11 0871 - Letter from Adam Slater to J. Vanaskie - overview	N/A
2020.12.18 0679 - Amended Complaint - Economic Class - Losartan	N/A
2020.12.18 0681 - Amended Complaint - Medical Monitoring Class Action Complaint - Master Losartan	N/A
2020.12.18 0682 - Amended Complaint - Personal Injury Complaint - Master Losartan	N/A
2021.01.15 0751 - 1st Amended Consolidated Losartan Class Action Complaint	N/A
2021.11.10 1748 - Memorandum ISO Plaintiffs' Class Certification of Consumer Economic Loss Claims with Exhibits	N/A
2021.11.10 1750 - Memorandum ISO the Medical Monitoring Plaintiffs' Motion for Class Certification with Exhibits	N/A
<b>WRITTEN DISCOVERY</b>	
2020.12.31 - Plaintiffs' Disclosure of Cancer Types	N/A
<b>DEPOSITION TRANSCRIPTS (WITH EXHIBITS)</b>	
<b>Raphael Nudelman – 04.08.2021 - Transcript</b>	N/A
<b>79</b> - Notice of Deposition	N/A
<b>80</b> - Response to Plaintiffs' Document Requests	N/A
<b>81</b> - Resumé Raphael Nudelman, Ph.D., ERT	TEVA-MDL2875-DEPS-000019-24
<b>82</b> - LinkedIn Raphael Nudelman, Ph.D., ERT	TEVA-MDL2875-DEPS-000025-26
<b>83</b> - No Exhibit	No Exhibit
<b>84</b> - No Exhibit	No Exhibit
<b>85</b> - Audit Report On ZHP (Chuannan Site) 9/2/11	TEVA-MDL2875-00051288
<b>86</b> - No Exhibit	No Exhibit
<b>87</b> - Auditing of API Manufacturers 3/27/12	TEVA-MDL2875-00102747
<b>88</b> - E-mail, 7/4/12 Subject, Genotoxicity Evaluation for Valsartan (Azide Route)	TEVA-MDL2875-00539802



<b>89</b> - Computational Toxicology Report for Valsartan Reagents and Intermediates 7/19/12	TEVA-MDL2875-00259857
<b>90</b> - E-mail Thread 8/1/12 Subject, Acetaldehyde Toxicity	TEVA-MDL2875-00514864-66
<b>91</b> - No Exhibit	No Exhibit
<b>92</b> - No Exhibit	No Exhibit
<b>93</b> - E-mail Thread 3/30/14 Subject, Amlodipine Besilate	TEVA-MDL2875-00158436-39
<b>94</b> - Caspofungin 50-70 mg Powder for Concentrate For Solution for Infusion 3.2.P.2	TEVA-MDL2875-00917440-19
<b>95</b> - Computational Mutagenicity Report For Potential Impurity In Valsartan 10/14/15	TEVA-MDL2875-00259986-87
<b>96</b> - E-mail Thread 6/15/16 Subject, Toxicology of Hydrolyzed Calpronium Chloride	TEVA-MDL2875-00158463-69
<b>97</b> - No Exhibit	No Exhibit
<b>98</b> - E-mail Thread 12/19/17 Subject, Valsartan Proposal for API Specifications Revision US	TEVA-MDL2875-00082321-24
<b>99</b> - Computational Mutagenicity and Control Recommendations For Potential Impurities In Valsartan	TEVA-MDL2875-00158698-05
<b>100</b> - Quality Risk Management for Cross Contamination Control	TEVA-MDL2875-00260122
<b>101</b> - E-mail Thread 6/28/18 Urgent and Important Genotoxic Impurity Notification	TEVA-MDL2875-00056559-61
<b>102</b> - Request for Safety Assessment of NDMA for Valsartan Dose 1x Daily for 320mg, 160mg, 80mg (June 28, 2018)	TEVA-MDL2875-00425812-14
<b>103</b> - Toxicological Assessment for NDMA In Valsartan Drug Substance 6/29/18	TEVA-MDL2875-00158529
<b>104</b> - No Exhibit	No Exhibit
<b>105</b> - E-mail Thread 7/3/18 Subject, Urgent Valsartan Safety Assessment Request	TEVA-MDL2875-00158519-22
<b>106</b> - E-mail Thread 7/4/18 Subject Valsartan Urgent	TEVA-MDL2875-00056924-29
<b>107</b> - E-mail Thread 7/4/18 Subject, Valsartan Urgent	TEVA-MDL2875-00514896-02
<b>108</b> - E-mail Thread 7/4/18 Subject, Valsartan Urgent	TEVA-MDL2875-00020609-18
<b>109</b> - E-mail Thread 7/5/18 Subject, Valsartan Urgent	TEVA-MDL2875-00158540-41
<b>110</b> - E-mail Thread 7/5/18 Subject, Valsartan Urgent	TEVA-MDL2875-00495085
<b>111</b> - E-mail Thread 7/5/18 Subject, Valsartan HHA draft V3 for Review	TEVA-MDL2875-00057083-85
<b>112</b> - No Exhibit	No Exhibit
<b>113</b> - No Exhibit	No Exhibit
<b>114</b> - Draft HHA Valsartan Tablets 40, 80, 160, 320 Multiple Lots	TEVA-MDL2875-00057086-94
<b>115</b> - No Exhibit	No Exhibit
<b>116</b> - E-mail Thread 7/12/18 Subject, Valsartan	TEVA-MDL2875-00158544



<b>117</b> - E-mail Thread 7/13/18 Subject, Valsartan Request from Hong Kong	TEVA-MDL2875-00540426-30
<b>118</b> - E-mail Thread 7/13/18 Subject, EDQM Valsartan Provisional Limit Potential Impact on HHAs	TEVA-MDL2875-00021077-78
<b>119</b> - Certification of Substances Department 8/10/18 Request for Information Relating to EU Referral Article 31 of Directive 2001/83/EC	N/A
<b>120</b> - No Exhibit	No Exhibit
<b>121</b> - E-mail Thread 9/6/18 Subject, Draft Valsartan Letter	TEVA-MDL2875-00552854-59
<b>121A</b> - NDMA Acceptable Limit (Handwritten Document From Plaintiff's Counsel Watt)	N/A
<b>122</b> - E-mail Thread 10/22/18 Subject, NDMA & NDEA Limits	TEVA-MDL2875-00514942-43
<b>123</b> - No Exhibit	No Exhibit
<b>124</b> - E-mail Thread 12/27/18 Subject, Update 26 <sup>th</sup> December 2018 RV Update	TEVA-MDL2875-00540783-88
<b>125</b> - No Exhibit	No Exhibit
<b>126</b> - E-mail Thread 3/26/19 Subject, Snodin & Elder Commentary	TEVA-MDL2875-00492386
<b>127</b> - E-mail Thread 6/27/19 Subject, Request to be An Honorable Keynote Speaker	TEVA-MDL2875-00540844-46
<b>128</b> - E-mail Thread 8/11/19 Subject, Editor's Spotlight Switzerland	TEVA-MDL2875-00158591-93
<b>129</b> - Questionnaire for Excipient Nitrosamines Risk Evaluation	TEVA-MDL2875-00158603-09
<b>130</b> - E-mail Thread 10/23/19 Subject, Ranitidine NDMA Formation	TEVA-MDL2875-00562588-97
<b>131</b> - No Exhibit	No Exhibit
<b>132</b> - No Exhibit	No Exhibit
<b>133</b> - HHA Valsartan Tablets 40, 60,160, 320 mg Multiple Lots	TEVA-MDL2875-00274341-49
<b>134</b> - Toxicological Assessment for NDMA And NDEA in Parallel in Sartan-Drug Substances	TEVA-MDL2875-00773542
2021.08.05 – Transcript of David Madigan with exhibits	N/A
2021.08.13 – Transcript of Stephen Lagana with exhibits	N/A
2021.08.24 – Transcript of Mahyar Etminan with exhibits	N/A
2021.08.17 – Transcript of Stephen Hecht with exhibits	N/A
2021.09.09 – Transcript of Dipak Panigrahy	N/A
2021.09.10 – Rough Transcript of Dipak Panigrahy	N/A
2021.09.14 – Transcript of Lee-Jen Wei	N/A
2021.09.15 – Transcript of Lee-Jen Wei	N/A
2021.09.13 – Transcript of Daniel Catenacci	N/A





2021.09.14 – Rough Transcript of Daniel Catenacci	N/A
2021.09.16 – Rough Transcript of Michael Bottorff	N/A
<b>EXPERT REPORTS (WITH EXHIBITS)</b>	
<b>Plaintiffs' Expert Reports (with Exhibits)</b>	
2021.11.10 Dr. Rena Conti Report with Attachments	N/A
2021.11.10 Dr. Rena Conti CV	N/A
2021.11.10 Dr. Rena Conti Materials Relied Upon	N/A
2021.11.10 Lara R. Craft Report with Attachments	N/A
2021.11.10 Lara R. Craft CV	N/A
2021.11.10 Lara R. Craft Materials Relied Upon	N/A
2021.07.04 Dr. Mahyar Etimanan Report	N/A
2021.05.00 Dr. Mahyar Etimanan CV	N/A
2021.07.06 Dr. Stephen Hecht Report	N/A
2021.07.06 Dr. Stephen Hecht CV	N/A
2021.07.06 Dr. Stephen Hecht Documents Reviewed	N/A
2021.07.06 Dr. Stephen Hecht Literature References	N/A
2021.11.10 Dr. Edward Kaplan Report	N/A
2021.11.10 Dr. Edward Kaplan CV	N/A
2021.11.10 Dr. Edward Kaplan List of Materials Considered	N/A
2021.07.06 Dr. Stephen Lagana Report	N/A
2021.04.05 Dr. Stephen Lagana CV	N/A
2021.07.07 Dr. David Madigan Report	N/A
2021.06.01 Dr. David Madigan CV	N/A
2021.11.04 Dr. Ron Najafi Report	N/A
2021.11.04 Dr. Ron Najafi CV	N/A
2021.11.09 Dr. Kali Panagos Report	N/A
2021.11.09 Dr. Kali Panagos List of Materials Reviewed	N/A
2021.11.09 Dr. Kali Panagos CV	N/A
2021.07.06 Dr. Dipak Panigraphy Report	N/A
2021.07.00 Dr. Dipak Panigraphy CV	N/A
2021.11.07 John L. Quick Report	N/A
2021.11.07 John L. Quick Materials Relied Upon	N/A
2021.11.07 John L. Quick CV	N/A
2021.11.10 Dr. Zirui Song Report	N/A
2021.11.10 Dr. Zirui Song CV	N/A
2021.11.10 Dr. Zirui Song Materials Relied On	N/A
<b>Defendants' Expert Reports (with Exhibits)</b>	
2021.08.02 – Report of Janice Britt	N/A
2021.08.02 – Report of Jon Fryzek	N/A
2021.08.02 – Report of Lewis Chodosh	N/A
2021.08.02 – Report of Michael Bottorff	N/A
2021.08.02 – Report of Daniel Catenacci	N/A
2021.08.02 – Report of John Gibb	N/A
2021.08.02 – Report of George Johnson	N/A
2021.08.02 – Report of Lee-Jen Wei	N/A
<b>TEVA DOCUMENTS</b>	
2017.12 – 2017.03 Annual Product Review for Valsartan, 40 mg, 80 mg, 160 mg, and 320 mg Tablets	TEVA-MDL2875-00828411

2018.06.29 Teva Toxicological Assessment of NDMA impurity in valsartan by Dr. Nudelman	TEVA-MDL2875-00414029
2018.06.29 Teva Toxicological Assessment of NDMA impurity in valsartan by Dr. Nudelman	TEVA-MDL2875-00274358
2018.07.06 Teva Health Hazard Assessment re Valsartan	TEVA-MDL2875-00329227-34
2018.07.06 Teva Health Hazard Assessment re Valsartan	TEVA-MDL2875-00274341
2018.07.06 Teva Health Hazard Assessment re Valsartan/HCTZ	TEVA-MDL2875-00274351
2018. 07.10 Health Hazard Assessment, Amlodipine, Valsartan and Hydrochlorothiazide (HCTZ) Tablets, 5/160/12.5 mg, 5/160/25 mg, 10/160/12.5 mg, 10/160/25 mg, and 10/320/25 mg, Multiple Lots	TEVA-MDL2875-00680244
2018.07.10 Health Hazard Assessment, Amlodipine and Valsartan Tablets, 5/160 mg, 10/160 mg, 5/320 mg, and 0/320 mg, Multiple Lots	TEVA-MDL2875-00680243
2018.11.12 Tox Assessment for NDEA in Valsartan by Dr. Nudelman	TEVA-MDL2875-00953115
2018.11.14 Toxicological Assessment for N-Nitrosodiethylamine (NDEA) in Valsartan Drug Substance	N/A
2018.11.19 Teva Health Hazard Assessment re NDEA in Valsartan Containing Drugs	TEVA-MDL2875-00414019-26
2018.11.19 Teva Health Hazard Assessment re NDEA in Valsartan Containing Drugs	TEVA-MDL2875-00426004
2019.03.13 Tox Assessment for NDMA and NDEA in Sartan Drugs in Parallel	TEVA-MDL2875-00773542
2019.07.03 Teva Risk Assessment Report for Valsartan Huahai	TEVA-MDL2875-00693424
2019.07.03 Teva Risk Assessment Report for Valsartan Mylan	TEVA-MDL2875-00693422
2019.07.18 Teva Valsartan Analytical Drug Substance & Drug Product Testing Results	TEVA-MDL2875-00063060
ZHP root cause	TEVA-MDL2875-00783229
Mylan root cause	TEVA-MDL2875-00019995
2018.07.06 HEALTH HAZARD ASSESSMENT, VALSARTAN AND HYDROCHLOROTHIAZIDE (HCTZ) TABLETS, 80/12.5 MG, 160/12.5 MG, 160/25 MG, 320/12.5 MG AND 320/25 MG, MULTIPLE LOTS	TEVA-MDL2875-00841748
<b>FDA/REGULATORY GUIDANCES AND DOCUMENTS</b>	
<b>Publicly Available FDA Documents</b>	
2012.09.21 FDA approves first ANDA for generic valsartan (ANDA#078020)	N/A
2018.07.13 FDA Announces Voluntary Recall, FDA News Release	N/A
2018.07.17 Teva Issues Voluntary Recall	N/A
2018.07.18 Recalled US Valsartan Labels	N/A
2018.08.30 FDA Statement on Ongoing Investigation into Valsartan Impurities	N/A
2018.10.02 Laboratory analysis of valsartan products	N/A
2018.10.11 FDA – Combined Direct Injection NDMA and NDEA Impurity Assay by GC/MS	N/A
2018.10.16 FDA - Combined Direct Injection NDMA and NDEA Impurity Assay by GC/MS	N/A
2018.11.27 Teva Announces Voluntary Recall of All Amlodipine	N/A
2019.04.04 FDA Statement – Update on Recall	N/A
2019.04.15 Laboratory analysis of valsartan products	N/A

2019.06.13 Valisure Citizens Petition	N/A
2020.10.02 FDA Overview of Guidance for Industry	N/A
2020.12.04 Laboratory analysis of valsartan products - FDA	N/A
<b>LITERATURE</b>	
ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 2018;71:e13-e115. DOI:10.1161/HYP.0000000000000065.	N/A
Adamson, RH, Chemical carcino-genesis in non-human primates. In:Longenbach R, Nesnow S, Rice JM, eds. Organand Species Specificity in Chemical Carcinogene-sis, New York and London: Plenum Publishing Corp. 129–156 (1983)	N/A
AHA, AMA launch high blood pressure initiative. www.heart.org. https://www.heart.org/en/news/2018/05/01/aha-ama-launch-high-blood-pressure-initiative. Accessed July 6, 2021.	N/A
Al-Kindi, S., et al, Abrupt Increase in Reporting of Neoplasms Associated with Valsartan After Medication Recall,” Circ. Cardiovascular Qual. Outcomes (2019)	N/A
Anderson, LM, et al., Characterization of ethanol's enhancement of tumorigenesis by N-nitrosodimethylamine in mice, Carcinogenesis 13:2107-2111 (1992)	N/A
Angsubhakorn S, et al., Enhancing effects of dimethylnitrosamine on aflatoxin B1 hepatocarcinogenesis in rats, International Journal of Cancer 28:621-626 (1981)	N/A
Arai, M, et al., Long-term experiment of maximal non-carcinogenic dose of dimethylnitrosamine for carcinogenesis in rats, Japanese Journal of Cancer Research 70:549-558 (1979)	N/A
ARB Trialists Collaboration. Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals. J Hypertens. 2011;29(4):623-635. doi:10.1097/HJH.0b013e328344a7de	N/A
Baker S, Priest P, Jackson R. Using thresholds based on risk of cardiovascular disease to target treatment for hypertension: modelling events averted and number treated [published correction appears in BMJ 2000 May 27;320(7247):1436]. BMJ. 2000;320(7236):680-685. doi:10.1136/bmj.320.7236.680	N/A
Bangalore S, Kumar S, Kjeldsen SE, et al. Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials. Lancet Oncol. 2011;12(1):65-82. doi:10.1016/S1470-2045(10)70260-6	N/A
Battistoni, A., et al, Recent Warnings About Antihypertensive Drugs and Cancer Risk: Where Do They Come From? Radcliffe Cardiology (2020)	N/A
Behrens G, Leitzmann MF. The association between physical activity and renal cancer: systematic review and meta-analysis. Br J Cancer. 2013;108(4):798-811. doi:10.1038/bjc.2013.37	N/A

Berger, MR, et al., Combination experiments with very low doses of three genotoxic N-nitrosamines with similar organotropic carcinogenicity in rats, <i>Carcinogenesis</i> 8:1635-1643 (1987)	N/A
Blood Pressure Lowering Treatment Trialists' Collaboration. Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data. <i>Lancet</i> 2014;384 (9943):591-598.	N/A
Boeing, H, et al., Dietary carcinogens and the risk for glioma and meningioma in Germany (1993)	N/A
Brauch L, Glazer RD, Aknay N, Vanhaecke J, et al. Morbidity, mortality, physiologic and functional parameters in elderly and non-elderly patients in the Valsartan Heart Failure Trial (Val-HeFT). <i>Am Heart J</i> 2004; 148(6):951-957	
Brunner HR. Clinical efficacy and tolerability of olmesartan. <i>Clin Ther.</i> 2004;26 Suppl A:A28-A32. doi:10.1016/s0149-2918(04)90143-9	N/A
Bunin, GR, et al., Maternal diet and risk of astrocytic glioma in children: A report from the Children's Cancer Group (1994)	N/A
Bunin, GR, et al., Relation between maternal diet & subsequent primitive neuroectodermal brain tumors in young children (1993)	N/A
Cao L, Zhang S, Cheng-ming J, He W, et al. Antihypertensive drugs use and the risk of prostate cancer: a meta-analysis of 21 observational studies. <i>BMC Urology</i> 2018;18:17 DOI10.1186/s12894-018-0318-7	N/A
Center for Drug Evaluation and Research. ARB Recalls: Valsartan, Losartan and Irbesartan. U.S. Food and Drug Administration. <a href="https://www.fda.gov/drugs/drug-safety-and-availability/recalls-angiotensin-ii-receptor-blockers-arbs-including-valsartan-losartan-and-irbesartan">https://www.fda.gov/drugs/drug-safety-and-availability/recalls-angiotensin-ii-receptor-blockers-arbs-including-valsartan-losartan-and-irbesartan</a> . Accessed July 6, 2021.	N/A
Choi, NW, et al., Consumption of precursors of N-nitroso compounds and human gastric cancer (1987)	N/A
Chow WH, Gridely G, Ffraumeni JF Jr, Jarvholm B. Obesity, hypertension, and the risk of kidney cancer in men. <i>N Engl J Med</i> 2000;343:1305-1311. doi: 10.1056/NEJM2000110234531804	N/A
Christakoudi S, Kakourou A, Markozannes G, et al. Blood pressure and risk of cancer in the European Prospective Investigation into Cancer and Nutrition. <i>Int J Cancer.</i> 2020;146(10):2680-2693. doi:10.1002/ijc.32576	N/A
Chyou, P, et al., A Case-Cohort Study of diet and stomach cancer (1990)	N/A
Colt JS, Schwartz K, Graubard BI, et al. Hypertension and risk of renal cell carcinoma among white and black Americans. <i>Epidemiology.</i> 2011;22(6):797-804. doi:10.1097/EDE.0b013e3182300720	N/A
D'Elia L, Rossi G, Ippolito R, et al. Habitual salt intake and risk of gastric cancer: a meta-analysis of prospective studies. <i>Clin Nutr.</i> 2012;31(4):489-498. doi:10.1016/j.clnu.2012.01.003	N/A
De Stefani, E, et al., Dietary Nitrosodimethylamine and the Risk of Lung Cancer: A Case-Control Study from Uruguay (1996)	N/A
De Stefani, E, et al., Dietary Nitrosamines, Heterocyclic Amines, and Risk of Gastric Cancer: A Case-Control Study in Uruguay (1998)	N/A
De Stefani, E, et al., Meat consumption and risk of stomach cancer in Uruguay: A case-control study (2001)	N/A

De Stefani, E, et al., Meat consumption, cooking methods, mutagens, and risk of squamous cell carcinoma of the esophagus (2012)	N/A
Derington CG, King JB, Herrick JS, et al. Trends in Antihypertensive Medication Monotherapy and Combination Use Among US Adults, National Health and Nutrition Examination Survey 2005-2016. Hypertension. 2020;75(4):973-981. doi:10.1161/HYPERTENSIONAHA.119.14360	N/A
Egan BM, Sutherland SE, Rakotz M, et al. Improving hypertension control in primary care with the measure accurately, Act Rapidly, and Partner with Patients Protocol. Hypertension. 2018;72(6):1320-1327. doi:10.1161/HYPERTENSIONAHA.118.11558	N/A
European Medicines Agency, Update on review of recalled valsartan medicines: Preliminary assessment possible risk to patients, <i>available at</i> <a href="https://www.ema.europa.eu/en/news/update-review-recalled-valsartan-medicines-preliminary-assessment-possible-risk-patients">https://www.ema.europa.eu/en/news/update-review-recalled-valsartan-medicines-preliminary-assessment-possible-risk-patients</a> (Aug. 2, 2018).	N/A
FDA, Information About Nitrosamine Impurities in Medications, <a href="https://www.fda.gov/drugs/drug-safety-and-availability/information-about-nitrosamine-impurities-medications">https://www.fda.gov/drugs/drug-safety-and-availability/information-about-nitrosamine-impurities-medications</a> (last visited July 5, 2021).	N/A
FDA, Statement on the Agency's Ongoing Efforts to Resolve Safety Issue with ARB Medications, <a href="https://www.fda.gov/news-events/press-announcements/statement-agencys-ongoing-efforts-resolve-safety-issue-arb-medications">https://www.fda.gov/news-events/press-announcements/statement-agencys-ongoing-efforts-resolve-safety-issue-arb-medications</a> (Aug. 28, 2019).	N/A
Fischer MA, Choudhry NK, Brill G, et al. Trouble getting started: predictors of primary medication nonadherence. Am J Med. 2011;124(11):1081.e9-1081.e1.081E22. doi:10.1016/j.amjmed.2011.05.028	N/A
Flack JM, Yunis C, Preisser J, et al. The rapidity of drug dose escalation influences blood pressure response and adverse effects burden in patients with hypertension: the Quinapril Titration Interval Management Evaluation (ATIME) Study. ATIME Research Group, Arch Intern Med. 2000;160(12):1842-1847.	N/A
Fristachi, A., et al, Estimation of Total Daily Oral Intake of NDMA Attributable to Drinking Water, Journal of Water and Health (2007)	N/A
Giles, GG, et al., Dietary factors and the risk of glioma in adults: Results of a case-control study in Melbourne, Australia (1994)	N/A
Giordano G et al., Postmenopausal status, hypertension and obesity as risk factors for malignant transformation in endometrial polyps. Maturitas. 2007;56(2):190-197.	N/A
Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer. A consensus report. Diabetes Care 2010;33:1674-1685.	N/A
Gomm, W., et al., N-Nitrosodimethylamine-Contaminated Valsartan and the Risk of Cancer – A Longitudinal Cohort Study Based on German Health Insurance Data, English (2021)	N/A
Gomm, W., et al., N-Nitrosodimethylamine-Contaminated Valsartan and the Risk of Cancer – A Longitudinal Cohort Study Based on German Health Insurance Data, German (2021)	N/A
González CA, Riboli E, Badosa J, Batiste E, Cardona T, Pita S, Sanz JM, Torrent M, Agudo A. Nutritional factors and gastric cancer in	N/A



Spain. Am J Epidemiol. 1994 Mar 1;139(5):466-73. doi: 10.1093/oxfordjournals.aje.a117029. PMID: 8154470.	
Goodman MT, Hankin JH, Wilkens LR, Kolonel LN. High-fat foods and the risk of lung cancer. Epidemiology. 1992 Jul;3(4):288-99. doi: 10.1097/00001648-199207000-00004. PMID: 1637893.	N/A
Gricute, L, et al., Influence of ethyl alcohol on carcinogenesis with Nnitrosodimethylamine, Cancer Letters 13:345-352 (1981)	N/A
Habs, M, et al., Synergistic effects of N-nitroso compounds in experimental long-term carcinogenesis studies, Oncology 37:259-265 (1980)	N/A
Han H, Guo W, Shi W, et al. Hypertension and breast cancer risk: a systematic review and meta-analysis. Sci Rep. 2017;7:44877. Published 2017 Mar 20. doi:10.1038/srep44877	N/A
Hidayat K, Du X, Zou SY, et al. Blood pressure and kidney cancer risk: meta-analysis of prospective studies. J Hypertens. 2017;35(7):1333-1344. doi:10.1097/HJH.0000000000001286	N/A
Hidajat M, McElvenny DM, Ritchie P, <i>et al</i> Healthy worker effects explain differences in internal and external comparisons in a rubber industry cohort study <i>Occupational and Environmental Medicine</i> 2019;76:781.	N/A
Hidajat M, McElvenny DM, Ritchie P, et al. Lifetime cumulative exposure to rubber dust, fumes and N-nitrosamines and non-cancer mortality: a 49-year follow-up of UK rubber factory workers. <i>Occupational and Environmental Medicine</i> 2020;77:316-323.	N/A
How to accurately measure blood pressure at home, <a href="http://www.heart.org">www.heart.org</a> , available at <a href="https://www.heart.org/en/news/2020/05/22/how-to-accurately-measure-blood-pressure-at-home">https://www.heart.org/en/news/2020/05/22/how-to-accurately-measure-blood-pressure-at-home</a> (last accessed July 29, 2021).	N/A
Hughes D, Judge C, Murphy R, Loughlin E, Costello M, Whiteley W, Bosch J, O'Donnell MJ, Canavan M. Association of blood pressure lowering with incident dementia or cognitive impairment: a systematic review and meta-analysis. JAMA 2020;323(19):1934-1944.	N/A
Jackevicius, CA, et al., Population Impact of Generic Valsartan Recall. <i>Circulation</i> . 2020; 141:411-413	
Jakszyn, P, et al., Endogenous vs exogenous exposure to N-nitroso compounds & gastric cancer risk in the Euro prospective (2006)	N/A
Jakszyn, P, et al., Red meat, dietary nitrosamines, and heme iron and risk of bladder cancer in the European prospective Investigation into Cancer and Nutrition (EPIC) (2011)	N/A
Jakszyn, PG, et al., Nitrosamines and heme iron and risk of prostate cancer in the European prospective investigation into cancer and nutrition (2012)	N/A
Jakszyn, P., et al, Nitrosamine and related food intake and gastric and esophageal cancer risk: A systemic review of the epidemiological evidence, <i>World J. of Gastroenterology</i> (2006)	N/A
Johnson, G., et al, Permitted Daily Exposure of Noteworthy N-nitrosamines, PubMed (2021)	N/A
Kantor ED, O'Connell K, Du M, Mendelsohn RB, Liang PS, Braunstein LZ. 2021. Ranitidine Use and Cancer Risk: Results From	N/A



UK Biobank. Gastroenterology 160(5):1856-1859.e5. doi: 10.1053/j.gastro.2020.12.037.	
Kasmari AJ, Welch A, Liu G, et al. Independent of Cirrhosis, Hepatocellular Carcinoma Risk Is Increased with Diabetes and Metabolic Syndrome. Am J Med. 2017;130(6):746.e1-746.e7. doi:10.1016/j.amjmed.2016.12.029	N/A
Kim CS, Han K-D, Choi HS, Bae EH, et al. Association of hypertension and blood pressure with kidney cancer risk. A nationwide population-based cohort study. Hypertension 2020; 75:1439-1446. DOI.	N/A
Keimling M et al., "The association between physical activity and bladder cancer: systematic review and meta-analysis", Br. J. Cancer 2014;110(7):1862-1870.	N/A
Keszei, AP, et al. (2013) Dietary N-nitroso compounds, endogenous nitrosation & the risk of esophageal & gastric cancer subtypes in the Neth.	N/A
Keszei, AP, et al., Supplemental Material to Dietary N-nitroso compounds, endogenous nitrosation & the risk of esophageal & gastric cancer subtypes in the Neth. (2013)	N/A
Keszei, AP, et al., Supplemental Material 2 to Dietary N-nitroso compounds, endogenous nitrosation & the risk of esophageal & gastric cancer subtypes in the Neth. (2013)	N/A
Keszei, AP, et al., Supplemental Material 3 to Dietary N-nitroso compounds, endogenous nitrosation & the risk of esophageal & gastric cancer subtypes in the Neth. (2013)	N/A
Knekt, P, et al., Risk of colorectal and other gastro-intestinal cancers after exposure to nitrate, nitrite and N-nitroso compounds: A follow up study (1999)	N/A
Kroes, R, et al., Study on the carcinogenicity of lead arsenate and sodium arsenate and on the possible synergistic effect of diethylnitrosamine, Food and Cosmetics Toxicology 12:671-679 (1974)	N/A
Largent JA, McEligot AJ, Ziogas A, et al. Hypertension, diuretics and breast cancer risk. J Hum Hypertens. 2006;20(10):727-732. doi:10.1038/sj.jhh.1002075	N/A
Larsson, SC, et al., Processed meat consumption, dietary nitrosamines and stomach cancer risk in a cohort of Swedish women (2006)	N/A
LaVecchia, C, et al., Nitrosamine intake and gastric cancer risk (1995)	N/A
Lindgren AM, Nissinen AM, Tuomilehto JO, Pukkala E. Cancer pattern among hypertensive patients in North Karelia, Finland. J Hum Hypertens. 2005;19(5):373-379. doi:10.1038/sj.jhh.1001834	N/A
Lijinsky, W, et al., Carcinogenesis by combinations of N-nitroso compounds in rats, Food and Chemical Toxicology 21:601-605 (1983)	N/A
Lijinsky, W, et al., Carcinogenesis by nitrosodialkylamines and azoxyalkanes given by gavage to rats and hamsters, Cancer Research 47:3968-3972 (1987)	N/A
Lijinsky, W, et al., Carcinogenesis in rats by nitrosodimethylamine and other nitrosomethylalkylamines at low doses, Cancer Letters 22:83-88 (1984)	N/A

Loh, YH, et al., N-nitroso compounds and cancer incidence: the European prospective investigation into cancer and nutrition (2011)	N/A
McElvenny DM, Mueller W, Ritchie P, et al. British rubber and cable industry cohort: 49-year mortality follow-up. <i>Occup Environ Med</i> 2018;75:848–55.doi:10.1136/oemed-2017-104834.	N/A
McGwin, G., “The Association Between Ranitidine Use and Gastrointestinal Cancers,” <i>Cancers</i> (2020)	N/A
Michaud, DS, et al., Prospective study of meat intake and dietary nitrates, nitrites, and nitrosamines and risk of adult glioma (2009)	N/A
Miller, AB, et al., Epidemiological assessment of risk to humans from exposure to nitrosamines (1984)	N/A
Muntner P, Carey RM, Gidding S, Jones DW, Taler SJ, Wright Jr JT, Whelton PK. Potential US population impact of the 2017 ACC/AHA high blood pressure guideline. <i>Circulation</i> 2018;137(2):109-118.	N/A
Muntner P, Hardy ST, Fine LJ, Jaeger BC, Wozniak G, Levitan EB, Colantonio LD. Trends in blood pressure control among US adults with hypertension, 1999-2000 to 2017-2018. <i>JAMA</i> 2020;324(12):1190-1200. DOI:10.1001/jama.2020.14545.	N/A
Nixon, JE, et al., Effect of cyclopropenoid compounds on the carcinogenic activity of diethylnitrosamine and aflatoxin B in rats, <i>Journal of the National Cancer Institute</i> 53:453-458 (1974)	N/A
Palli, D, et al., Dietary patterns, nutrient intake and gastric cancer in a high-risk area of Italy (2001)	N/A
Pasternak B, Svanström H, Callréus T, et al. Use of angiotensin receptor blockers and the risk of cancer. <i>Circulation</i> . 2011;123(16):1729-1736. doi:10.1161/CIRCULATIONAHA.110.007336	N/A
Peto, et al, “Dose and Time Relationships for Tumor Induction in the Liver and Esophagus of 4,080 Inbred Rats by Chronic Ingestion of N-Nitrosodiethylamine or N-Nitrosodimethylamine,” <i>Cancer Research</i> (1991)	N/A
Peto, et al, “Effects on 4,080 Rats of Chronic Ingestion of N-Nitrosodiethylamine or N-Nitrosodimethylamine: A Detailed Dose-Response Study,” <i>Cancer Research</i> (1991)	N/A
Pobel, D, et al., Nitrosamine, nitrate and nitrite in relation to gastric cancer: A case-control study in Marseille, France (1995)	N/A
Pool JL, Glazer R, Chiang YT, Gatlin M. Dose-response efficacy of valsartan, a new angiotensin II receptor blocker. <i>J Hum Hypertens</i> . 1999;13(4):275-281. doi:10.1038/sj.jhh.1000788	N/A
Pottegard, A, et al., Use of N-nitrosodimethylamine (NDMA) contaminated valsartan products and risk of cancer (2018)	N/A
Pottegard, A, et al., Supplement to Use of N-nitrosodimethylamine (NDMA) contaminated valsartan products and risk of cancer (2018)	N/A
Raman NV, Prasad AV, Ratnakar Reddy K. Strategies for the identification, control and determination of genotoxic impurities in drug substances: a pharmaceutical industry perspective. <i>J Pharm Biomed Anal</i> . 2011 Jun 25;55(4):662-7. doi: 10.1016/j.jpba.2010.11.039. Epub 2010 Dec 3. PMID: 21193280.	N/A
Risch HA, Jain M, Choi NW, Fodor JG, Pfeiffer CJ, Howe GR, Harrison LW, Craib KJ, Miller AB. Dietary factors and the incidence	N/A

of cancer of the stomach. Am J Epidemiol. 1985 Dec;122(6):947-59. doi: 10.1093/oxfordjournals.aje.a114199. PMID: 2998182.	
Rogers MA, Vaughan TL, Davis S, Thomas DB. Consumption of nitrate, nitrite, and nitrosodimethylamine and the risk of upper aerodigestive tract cancer. Cancer Epidemiol Biomarkers Prev. 1995 Jan-Feb;4(1):29-36. PMID: 7894321.	N/A
Seretis A, Cividini S, Markozannes G, et al. Association between blood pressure and risk of cancer development: a systematic review and meta-analysis of observational studies. Sci Rep. 2019;9(1):8565. Published 2019 Jun 12. doi:10.1038/s41598-019-45014-4	N/A
Sipahi I, Debanne SM, Rowland DY, Simon DI, Fang JC. Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol. 2010;11(7):627-636. doi:10.1016/S1470-2045(10)70106-6	N/A
Song P, Wu L, Guan W. Dietary Nitrates, Nitrites, and Nitrosamines Intake and the Risk of Gastric Cancer: A Meta-Analysis. Nutrients. 2015 Dec 1;7(12):9872-95. doi: 10.3390/nu7125505. PMID: 26633477; PMCID: PMC4690057.	N/A
Sorahan T. Conflicting findings from a rubber industry cohort study: what is the explanation? Occupational and Environmental Medicine 2019;76:780.	N/A
Sorahan TM. Cancer incidence in UK electricity generation and transmission workers, 1973-2015. Occup Med (Lond). 2019 Aug 22;69(5):342-351. doi: 10.1093/occmed/kqz082. PMID: 31375830; PMCID: PMC6704976.	N/A
Spearman CW, Dusheiko GM, Hellard M, Sonderup M. Hepatitis C. Lancet 2019; 394:1451 – 1466.	N/A
Straif K, Weiland SK, Bungers M, Holthenrich D, Taeger D, Yi S, Keil U. Exposure to high concentrations of nitrosamines and cancer mortality among a cohort of rubber workers. Occup Environ Med. 2000 Mar;57(3):180-7. doi: 10.1136/oem.57.3.180. PMID: 10810100; PMCID: PMC1739921.	N/A
Takayama et al., Chemical carcinogenesis studies in nonhuman primates, Proc. Japan Academy 84:176-88 (2008)	N/A
Terao, K, et al., A synergistic effect of nitrosodimethylamine on sterigmatocystin carcinogenesis in rats, Food and Cosmetics Toxicology 16:591-596 (1978)	N/A
Terracini, B, et al. Hepatic pathology in rats on low dietary levels of dimethylnitrosamine, British Journal of Cancer 21:559-565 (1967)	N/A
Terracini, B, et al., The effects of long-term feeding of DDT to BALB/c mice, International Journal of Cancer 11:747-764 (1973)	N/A
van der Leeuw J, Ridker PM, van der Graaf Y, et al. Personalized cardiovascular disease prevention by applying individualized prediction of treatment effects. Eur Heart J. 2014;35(13):837-843. doi:10.1093/eurheartj/ehu004	N/A
Vrijens B, Vincze G, Kristanto P, et al. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ. 2008;336(7653):1114-1117. doi:10.1136/bmj.39553.670231.25	N/A

Whelton PK et al., 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, Hypertension 2018;71:e13-e115.	N/A
White HD, Aylward PEG, Huang Z, Dalby AJ, et al. Mortality and morbidity remain high despite captopril and/or valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT). Circulation 2005;112(22):3391-3399.	N/A
World Health Organization, Concise International Chemical Assessment Doc. 38, "N-Nitrosodimethylamine"	N/A
Xie Y, Xu P, Wang M, et al. Antihypertensive medications are associated with the risk of kidney and bladder cancer: a systematic review and meta-analysis. Aging (Albany NY). 2020;12(2):1545-1562. doi:10.18632/aging.102699	N/A
Yang, R., et al, "The Relationship Between Anti-Hypertensive Drugs and Cancer: Anxiety to be Resolved in Urgent," Frontiers in Pharmacology (2020)	N/A
Yoon, H., et al, "Risk of Cancer Following the Use of NNitrosodimethylamine (NDMA) Contaminated Ranitidine Products: A Nationwide Cohort Study in South Korea," J. of Clinical Med. (2021)	N/A
Zhao, Y., et al, "Angiotensin II Receptor Blockers and Cancer Risk," Medicine (2016)	N/A
Zheng, J, et al., Dietary N-nitroso compounds and risk of pancreatic cancer: Results from a large case-control study (2019)	N/A
Zheng, J, et al., Supplemental Table 1 to Dietary N-nitroso compounds and risk of pancreatic cancer: Results from a large case-control study (2019)	N/A
Zhu, Y, et al., Dietary N-nitroso compounds and risk of colorectal cancer (2014)	N/A
<b>POST-MARKETING PERIODIC SAFETY REPORTS</b>	
<b>ANDA 077530</b>	
<b>Valsartan Tablets 40 mg, 80 mg, 160 mg, 320 mg</b>	
Teva Pharmaceuticals, 01 April 2015 – 30 June 2015	N/A
Teva Pharmaceuticals, 04 January 2016 – 03 April 2016	N/A
Teva Pharmaceuticals, 04 April 2016 – 03 July 2016	N/A
Teva Pharmaceuticals, 04 July 2016 – 03 October 2016	N/A
Teva Pharmaceuticals, 04 October 2016 – 03 January 2017	N/A
Teva Pharmaceuticals, 01 January 2017 – 31 March 2017	N/A
Teva Pharmaceuticals, 01 April 2017 – 30 June 2017	N/A
Teva Pharmaceuticals, 01 July 2017 – 30 September 2017	N/A



Teva Pharmaceuticals, 01 October 2017 – 31 December 2017	N/A
Teva Pharmaceuticals, 01 January 2018 – 31 March 2018	N/A
Teva Pharmaceuticals, 01 April 2018 – 30 June 2018	N/A
Teva Pharmaceuticals, 01 July 2018 – 30 September 2018	N/A
Teva, 01 October 2017 – 31 December 2018	N/A
<b>ANDA 090642</b>	
<b>Valsartan Tablets 40 mg, 80 mg, 160 mg, 320 mg</b>	
Watson Laboratories, 05 January 2015 – 04 April 2015	N/A
Watson Laboratories, 05 April 2015 – 04 July 2015	N/A
Watson Laboratories, 05 July 2015 – 04 October 2015	N/A
Watson Laboratories, 05 October 2015 – 04 January 2016	N/A
Watson Laboratories, 05 January 2016 – 04 April 2016	N/A
Watson Laboratories, 05 April 2016 – 04 July 2016	N/A
Watson Laboratories, 05 July 2016 – 04 October 2016	N/A
Teva Pharmaceuticals, 05 October 2016 – 04 January 2017	N/A
Teva Pharmaceuticals, 05 January 2017 – 04 April 2017	N/A
Teva Pharmaceuticals, 05 April 2017 – 04 July 2017	N/A
Teva Pharmaceuticals, 05 July 2017 – 04 October 2017	N/A
Teva, 01 January 2018 – 31 December 2018	N/A
<b>ANDA 091235</b>	
<b>Amlodipine and Valsartan Tablets 5/160 mg, 10/160 mg, 5/320 mg, 10/320 mg</b>	
Teva Pharmaceuticals, 01 June 2015 – 31 August 2015	N/A
Teva Pharmaceuticals, 01 September 2015 – 30 November 2015	N/A
Teva Pharmaceuticals, 01 December 2015 – 29 February 2016	N/A
Teva Pharmaceuticals, 01 March 2016 – 31 May 2016	N/A
Teva Pharmaceuticals, 01 June 2016 – 31 August 2016	N/A
Teva Pharmaceuticals, 01 September 2016 – 30 November 2016	N/A
Teva Pharmaceuticals, 01 December 2016 – 28 February 2017	N/A
Teva Pharmaceuticals, 01 March 2017 – 31 May 2017	N/A
Teva Pharmaceuticals, 01 December 2017 – 28 February 2018	N/A
Teva, 01 March 2018 – 28 February 2019	N/A
<b>ANDA 091519</b>	
<b>Valsartan and Hydrochlorothiazide Tablets 80/12.5 mg, 160/12.5 mg, 160/25 mg, 320/12.5 mg, 320/25 mg</b>	
Watson Laboratories, 21 March 2013 – 20 June 2013	N/A



Watson Laboratories, 21 June 2013 – 20 September 2013	N/A
Watson Laboratories, 21 September 2013 – 20 December 2013	N/A
Watson Laboratories, 21 December 2013 – 20 March 2014	N/A
Watson Laboratories, 21 March 2014 – 20 June 2014	N/A
Watson Laboratories, 21 June 2014 – 20 September 2014	N/A
Watson Laboratories, 21 September 2014 – 20 December 2014	N/A
Watson Laboratories, 21 December 2014 – 20 March 2015	N/A
Watson Laboratories, 21 March 2015 – 20 June 2015	N/A
Watson Laboratories, 21 June 2015 – 20 September 2015	N/A
Watson Laboratories, 21 September 2015 – 20 December 2015	N/A
Watson Laboratories, 21 December 2015 – 20 March 2016	N/A
Teva Pharmaceuticals, 21 March 2016 – 20 March 2017	N/A
Teva Pharmaceuticals, 21 March 2017 – 20 March 2018	N/A
<b>ANDA 200435</b> <b>Amlodipine, Valsartan and Hydrochlorothiazide Tablets 5/16012.5 mg, 10/160/12.5 mg, 5/160/25 mg, 10/160/25 mg, 10/320/25 mg</b>	
Teva Pharmaceuticals, 01 December 2014 – 28 February 2015	N/A
Teva Pharmaceuticals, 01 March 2015 – 31 May 2015	N/A
Teva Pharmaceuticals, 01 June 2015 – 31 August 2015	N/A
Teva Pharmaceuticals, 01 September 2015 – 30 November 2015	N/A
Teva Pharmaceuticals, 01 December 2015 – 29 February 2016	N/A
Teva Pharmaceuticals, 01 September 2016 – 30 November 2016	N/A
Teva Pharmaceuticals, 01 September 2017 – 31 August 2018	N/A
<b>BELLWETHER PLAINTIFFS</b>	
<b>Bonmon, Yolanda</b>	
<b>Plaintiff Fact Sheet</b>	
Plaintiff Fact Sheet, 09/08/20	YBonmon-PFS-000001 – 93
Plaintiff Fact Sheet, 09/08/20	YBonmon-PFS-000094 – 186
Plaintiff Fact Sheet, 09/08/20	YBonmon-PFS-000187 – 279
Plaintiff Fact Sheet Declaration, 08/06/20	YBonmon-PFS-000280
Plaintiff Fact Sheet Declaration, 09/08/20	YBonmon-PFS-000281
Plaintiff Fact Sheet, 08/06/20	YBonmon-PFS-000282 – 371
Plaintiff Fact Sheet, 02/25/21	YBonmon-PFS-000465 – 558





Plaintiff Fact Sheet Declaration, 02/25/21	YBonmon-PFS-000559
Plaintiff Fact Sheet, 04/16/21	YBonmon-PFS-000560-653
Plaintiff Fact Sheet Declaration, 04/16/21	YBonmon-PFS-000654
Plaintiff Fact Sheet, 04/27/21	YBonmon-PFS-000655-748
<b>Medical Records</b>	
Plaintiff Produced Records	YBonmon-PPR-000319
Apothecare Pharmacy III	YBonmon-ApothPIII-000001 – 13
Authorizations, 01/27/21	YBonmon-Auth-000019 – 39
Authorizations, 05/17/21	YBonmon-Auth-000087 – 93
Authorizations, 05/27/21	YBonmon-Auth-000094 – 100
Bluegrass Women's Healthcare	YBonmon-BlueWHC-000001 – 55
Central Medical Associates PLLC	YBonmon-CMA-000001 – 89
Embry Charles, MD	YBonmon-CEmbry-000001 – 88
Hardin Memorial Hospital	YBonmon-HMH-000019 – 480
New Hope Foster Agency Foster Care	YBonmon-NHFAFC-HR-000001
<b>Deposition</b>	
<b>Bonmon, Yolanda – 2021.04.20 – Transcript</b>	N/A
<b>1 – 2021.04.16 Plaintiff Fact Sheet</b>	N/A
<b>2 – 2021.04.16 Signed Declaration of Plaintiff Fact Sheet</b>	N/A
<b>3 – Photograph of Valsartan Bottle</b>	YBonmon-PPR-000319
<b>4 - 2019.06.17 Amended Complaint - Master Personal Injury Complaint</b>	N/A
<b>5 – 2020.07.21 Bonmon Short Form Complaint</b>	N/A
<b>6 – Bonmon Medical Records from Charles K. Embry, MD</b>	YBonmon-CEmbry-000001 – 88
<b>7 – Bonmon Pharmacy Records from Apothecare Pharmacy</b>	YBonmon-ApothPIII-000001 – 13
<b>8 – Bonmon Medical Records from Bluegrass Women's Healthcare</b>	YBonmon-BlueWHC-000001 – 55
<b>9 – Bonmon Medical Records from Central Medical Associates</b>	YBonmon-CMA-000035 – 89
<b>10 – Bonmon Medical Record from UK Healthcare</b>	YBonmon-PPR-000030
<b>11 – Bonmon Medical Records from Central Medical Associates</b>	YBonmon-CMA-000035 – 89
<b>12 – Bonmon Medical Records from Central Medical Associates</b>	YBonmon-CMA-000001 – 34
<b>13 – Bonmon Medical Records from Hardin Memorial Hospital</b>	YBonmon-HMH-MD-000019 – 480
<b>14 – Bonmon Medical Records from Charles K. Embry, MD</b>	YBonmon-CEmbry-000001 – 88
<b>15 – 2021.04.16 Plaintiff Fact Sheet</b>	N/A
<b>16 – Bonmon executed authorization for New Hope Foster Agency</b>	N/A



17 – Bonmon records from New Hope Foster Homes, Inc.	YBonmon-NHFAFC-HR-000001
18 – Bonmon Executed Tax Authorization	N/A
<b>Weygandt, Robert</b>	
<b>Plaintiff Fact Sheet</b>	
2020.04.07 Plaintiff Fact Sheet	RWeygandt-PFS-000267-000355
<b>Medical Records</b>	
Plaintiff-Produced Medical Records	RWeygandt-PPR-000001-000796
Plaintiff-Produced Medical Records	RWeygandt-PPR-000797-001546
Plaintiff-Produced Medical Records	RWeygandt-PPR-001547-001817
Abrams Royal Pharmacy II Pharmacy	RWeygandt-ARPharmII-000001-000002
Advanced Imaging Center	RWeygandt-AImagingCe-000001-83
Aetna US Healthcare Legal Support Svcs	RWeygandt-AUSH-000001-000013
Baylor Regional Med Ctr at Plano Med Recs Dept	RWeygandt-BRMCP-MD-000001-000307
Baylor Regional Med Ctr at Plano Path Dept	RWeygandt-BRMCP-PD-000001-000001
Baylor Scott and White Health Rad Dept	RWeygandt-BSW-RD-000001-000002
Baylor Scott and White Health - NRS	RWeygandt-BSW-PD-000001-000001
Baylor Scott and White Health Med Recs Dept	RWeygandt-BSW-MD-000001-000002
Baylor Scott and White Health	RWeygandt-BSW-BD-000001-17
Baylor Surgicare at Plano Patient Accts	RWeygandt-BSPlano-BD-000001-000002
Baylor Surgicare at Plano - NR Radiology Cert	RWeygandt-BSPlano-RD-000001
Blue Cross Blue Shield of Texas Claims Dept	RWeygandt-BCBST-000001-000048
Carrell Clinic – Medical	RWeygandt-CarrellC-000001-000057
Clinical Path Labs Inc	RWeygandt-CPL-000001-000004
Colon and Rectal Assocs of Texas	RWeygandt-C&RAT-000001-000027
Death Certificate Proof of Authority	RWeygandt-DCPOA-000001-000004
DFW Smiles	RWeygandt-DFWS-000001-000018
Endocrine Assocs of Dallas	RWeygandt-EAD-000001-000342
Express Scripts Inc Recs	RWeygandt-ES-000001-000021
Fleshman James Jr MD	RWeygandt-JFleshamnJr-000001-000219
Heart Hosp Baylor Plano Med Recs Dept	RWeygandt-HHBP-MD-000001-000657
Hollabaugh, Eric, MD - Medical	RWeygandt-EHollabaugh-000001-000008
Lab Corp of America Med Recs Dept	RWeygandt-LabCorpA-MD-000001-000009
Legacy Heart Ctr Med Recs Dept	RWeygandt-LHC-MD-000001-000001
Med Ctr of Plano Med Recs Dept	RWeygandt-MCPlano-MD-000001-000122



Med Ctr of Plano Rad Dept	RWeygandt-MCPlano-RD-000001-000001
Med Ctr of Plano Path Dept	RWeygandt-MCPlano-PD-000001-000002
Med Clinic of North Texas PA	RWeygandt-MCNT-000001-000093
North Central Surgical Ctr	RWeygandt-NCSC-000001-000250
North Point Lab	RWeygandt-NPL-000001-000001
Plano Dermatology Assocs	RWeygant-PDA-000001-000003
Quest Diagnostics Irving	RWeygandt-QD-Irving-000001-000002
Safeway Inc Corporate Pharmacy Dept	RWeygandt-Safeway-000001-000017
Texas Health Presbyterian Hosp Dallas Patient Accts	RWeygandt-THPHD-BD-000001-000009
Texas Health Presbyterian Hosp Dallas Path Dept	RWeygandt-THPHD-PD-000001-000001
Texas Health Presbyterian Hosp Dallas Rad Dept	RWeygandt-THPHD-RD-000001-000001
Texas Oncology Pharmacy Sammons	RWeygandt-TOPS-000001-000002
Texas Oncology Plano Prestonwood Med Recs Dept	RWeygandt-TO-PP-MD-000001-000391
TMI Sports Medicine and Orthopedic Surgery - NR Cert	RWeygandt-TMISMOS-000001-000001
Verity Cancer Center	RWeygandt-VCC-000001-56
VerityPET CT	RWeygandt-VPET-CT-000001-000065
Verity PET CT Rad Dept	RWeygandt-VPET-CT-RD-000001-000087
Walgreen Company	RWeygandt-WC-000001-000006
<b>Deposition</b>	
<b>2021.04.13 Weygandt, Martha Transcript</b>	
<b>1</b> - Plaintiff's Fact Sheet	N/A
<b>2</b> - Declaration	N/A
<b>Composite 3</b> - Bankruptcy petition	N/A
<b>3</b> - Motion for Setting and Request for Expedited Hearing on Motion to Use Cash Collateral	N/A
<b>4</b> - Master Personal Injury Complaint	N/A
<b>5</b> - First Amended Short Form Complaint	N/A
<b>6</b> - Medical Records	N/A
<b>7</b> - Death certificate	RWeygandt-DCPOA-000001
<b>8</b> - Follow Up Examination	RWeygandt-PPR-000217-229
<b>9</b> - Patient Tax / Insurance	RWeygandt-Safeway-0003-17
<b>10</b> - Medical Records from Endocrine Associates of Dallas, P.A.	RWeygandt-EAD-000055-60
<b>11</b> - Medical Records from W B Carrell Memorial Clinic	RWeygandt-CarrellC-000003-6
<b>12</b> - Medical Records from Cardiology	RWeygandt-HHBP-MD-000431-433



13 - Medical Records from Endocrine Associates of Dallas, P.A.	RWeygandt-EAD-000074-78
14 - Medical Records Bates 1-16 with cover page	N/A
15 - Medical Records Bates 570-605	N/A
16 - Pharmacy Defendants' Exemplar Defendant Fact Sheet	N/A
<b>Ramirez, Richard</b>	
<b>Medical Records</b>	
Gerardo J. Franco, D.O., P.A.	RRamirez-GJFranco-000001-000003
Sylvester Comprehensive Cancer Center	RRamirez - SCCC-MD-000001-000616
University of Miami Hospital	RRamirez-UMHosp-MD-000001-000158
Jackson Health System	RRamirez-JHS-MD-000001-000549
<b>Deposition</b>	
2021.04.23 Ramirez, Richard Transcript	
<b>Briones, Joe</b>	
<b>Plaintiff Fact Sheet</b>	
2021.01.13 Plaintiff Fact Sheet	JBriones-PFS-000095-000187
<b>Medical Records</b>	
Plaintiff-Produced Medical Records	JBriones-PPR-000001-431
Aetna US Healthcare	JBriones-AUSH-000001-000118
Centers for Medicare and Medicaid Services	JBriones-CMMS-R6-000001-000505
Citizens Medical Center Patient Accounts	JBriones-CMCen-BD-000001-000017
Citizens Medical Center	JBriones-CMCen-MD-000001-407
Citizens Med Ctr Path Dept	JBriones-CMCen-PD-000001-0000002
Citizens Med Ctr Rad Dept	JBriones-CMCen-RD-000001-000003
Clinical Path Labs Inc Path Dept	JBriones-CPL-PD-000001-000001
Costco Wholesale	JBriones-CostcoW-000001-5
DeTar Hosp Navarro Path Dept	JBriones-DeTarH-N-PD-000001-000001
DeTar Hospital-Navarro	JBriones-DeTarH-N-MD-000001-436
DeTar Hosp Navarro Rad Dept	JBriones-DeTarH-N-RD-000001-000004
DeTar Hosp Navarro Med Recs Dept	JBriones-DeTarH-N-MD-000437-000492
Envision Pharmacies	JBriones-EnvisionP-000001-000002
Gastroenterology of Victoria	JBriones-GVictoria-000001-7
HEB Pharmacy Privacy Office	JBriones-HEBPharm-000001-000002
Humana Inc Attention Critical Inquiry Dept	JBriones-Humana-000001-000001
Leggett Richard H DO Med Recs Dept	JBriones-RHLeggett-000001-000001
Minocha Gulshan K MD	JBriones-GKMinocha-000001-000217
Mundy Construction Company HRs	JBriones-MCC-HR-000001-000378
Plaintiff Produced Records	JBriones-PPR-000001-000431
Regional Path Assocs Path Dept	JBriones-RPA-PD-000001-000002
Regional Path Assocs	JBriones-RPA-000001-000002
Sierra Hoffman Miguel MD	JBriones-MSierra-Hoffman-000001-000001



Univ of Texas MD Anderson Cancer Ctr Rad Dept	JBriones-UTMDACC-RD-000001-000039
Univ of Texas MD Anderson Cancer Ctr Path Dept	JBriones-UTMDACC-PD-000001-000002
Univ of Texas MD Anderson Cancer Ctr Patient Accts	JBriones-UTMDACC-BD-000001-000113
Univ of Texas MD Anderson Cancer Ctr Med Recs Dept	JBriones-UTMDACC-MD-000001-008520
Zachry Industrial Inc HRs	JBriones-ZI-HR-000001-000021
<b>Dawson, Nellie</b>	
<b>Plaintiff Fact Sheet</b>	
2020.05.14 Plaintiff Fact Sheet	NDawson-PFS-000092-000180
<b>Medical Records</b>	
Plaintiff-Produced Medical Records	NDawson-PPR-000001-000179
3HC Home Health Hospice Healthcare	NDawson-3HCHH-H-HC-000001-000114
Jordan And Assocs Gastroenterology PA	NDawson-J&AG-000001-000068
Riverdale Family Medicine PA	NDawson-RFM-000001-000332
UNC Health Care System Path Dept	NDawson-UNCHCS-PD-000001-000001
UNC HealthCare System Rad Dept	NDawson-UNCHCS-RD-000001-000001
<b>Dufrene, Lana</b>	
<b>Plaintiff Fact Sheet</b>	
Plaintiff Fact Sheet, 07/28/20	LDufrene-PFS-000001 – 90
Plaintiff Fact Sheet, 07/28/20	LDufrene-PFS-000091 – 180
Correspondence from B. Schwartz, 08/18/20	LDufrene-PFS-000181 – 184
Plaintiff Fact Sheet Declaration, 01/21/20	LDufrene-PFS-000185 – 186
<b>Medical Records</b>	
Plaintiff Produced Records	LDufrene-PPR-000001 – 178
Cardiovascular Institute of the South	LDufrene-CIS-000001 – 183
Lady of the Sea General Hospital	LDufrene-LSGH-000001 – 77
Leonard J. Chabet Medical Center	LDufrene-LJCMC-000001 – 2271
Ochsner Family Doctor Clinic	LDufrene-OFDC-000001 – 193
Racelands Pharmacy	LDufrene-RPE-000001 – 13
Walmart Pharmacy	LDufrene-WMS-000001 – 20
<b>Garcia, Robert</b>	
<b>Plaintiff Fact Sheet</b>	
2021.03.10 Plaintiff Fact Sheet	RGarcia-PFS-000188-00280
<b>Medical Records</b>	
Plaintiff-Produced Medical Records	RGarcia-PPR-000001-000434
Baylor St Lukes Med Ctr Health Information Mgmt	RGarcia-BStLMC-MD-000001-000831
Baylor St Lukes Med Ctr Patient Accts	RGarcia-BStLMC-BD-000001-000040
Baylor St Lukes Med Ctr Rad Dept	RGarcia-BStLMC-RD-000001-000003
Blue Cross Blue Shield of Texas Recs Dept	RGarcia-BCBSTexas-000001-000004
Ctrs for Medicare and Medicaid Svcs Region 6 Legal Dept Privacy Office	RGarcia-CMMS-R6-000001-000017



Cigna Healthcare Central HIPPA Unit Legal Dept	RGarcia-CHCHU-000001-000064
City of Houston HRs	RGarcia-CHouston-HR-000001-000246
CVS Pharmacy Inc Privacy Office	RGarcia-CVS-000001-000025
Digestive Disease Consultants PA	RGarcia-DDC-000001-000001
Express Scripts Inc Records	RGarcia-ES-000001-000012
Harris County Psychiatric Ctr	RGarcia-HCPC-000001-000001
Harris County Psychiatric Ctr Patient Accts	RGarcia-HCPCenter-000001-000001
HEB Pharmacy Privacy Office	RGarcia-HEBPharm-000001-000025
Kelsey Pharmacy Berthelsen Main Campus	RGarcia-KelseyP-BMC-000001-000003
Kelsey Seybold Clinic	RGarcia-KSC-000001-001500
Kelsey Seybold Clinic Rad Dept	RGarcia-KSC-RD-000001-000002
Selzman Harold MD	RGarcia-HSelzman-000001-000002
Texas Digestive Disease Consultants	RGarcia-TexasDDC-000001-000042
Walgreen Company	RGarcia-WC-000001-000079
Walker Frank S Jr MD	RGarcia-FSWalkerJr-000001-000001
Walmart Pharmacy	RGarcia-WMS-000001-000010
Wellspire Med Group	RGarcia-WMG-000001-000001
<b>Kennedy, Paulette</b>	
<b>Plaintiff Fact Sheet</b>	
2021.06.17 Plaintiff Fact Sheet	PKennedy-PFS-000377-000469
<b>Medical Records</b>	
Plaintiff-Produced Medical Records	PKennedy-PPR-000001-000590
Baylor Scott And White Med Ctr McKinney Med Recs Dept	PKennedy-BS&WMC-M-MD-000001-000438
Baylor Scott & White Medical Center-McKinney	PKennedy-BS&WMC-M-BD-000001-12
Ctrs for Medicare and Medicaid Svcs Region 6 Legal Dept Privacy Office	PKennedy-CCMS-R6-000001-001371
Dallas Nephrology Assocs	PKennedy-DallasNephA-000001-000125
Eye Assocs of Tallahassee	PKennedy-EAT-000001-000085
Kroger Pharmacy Corporate HQ Legal Dept	PKennedy-KrogerPharm-000001-000009
Lajara Rosemarie MD	PKennedy-RLajara-000001-000010
Med City Dallas Hosp Patient Accts	PKennedy-MCDH-BD-000001-000080
Med City Dallas Hosp Med Recs Dept	PKennedy-MCDH-MD-000001-000453
Med City Dallas Hosp Rad Dept	PKennedy-MCDH-RD-000001-000005
North Star Diagnostic Imaging	PKennedy-NStarDI-000001-000033
North Star Diagnostic Imaging Rad Dept	PKennedy-NStarDI-RD-000001-000001
Orthopaedic Surgery and Sports Medicine of Dallas	PKennedy-OSSMD-000001-000119
Snyder Hopkins Family Medicine Ctr	PKennedy-S-HFMC-000001-000001
Solis Mammography	PKennedy-SolisM-000001-000034
Southern Endocrinology And Diabetes Assocs	PKennedy-SEndo&DA-000001-000033
Texas Breast Specialists	PKennedy-TBS-000001-168





Texas Colon And Rectal Surgeons	PKennedy-TC&RSurgeons-000001-000128
Texas Eye Plastics	PKennedy-TEyeP-000001-000021
Texas Health Family Care	PKennedy-TexasHFC-000001-000001
Texas Health Family Care Clinic 040	PKennedy-THFCC040-000001-000001
Texas Oncology	PKennedy-TOncology-000001-000385
Texas Oncology Patient Accts	PKennedy-TO-BD-000001-000053
Texas Oncology PA Rad Dept	PKennedy-TOncology-RD-000001-000002
United Healthcare Insurance AARP Claims Customer Svc	PKennedy-UHI-000001-000019
Walgreen Company	PKennedy-WC-000001-000091
Walton, William J., MD - NRS	PKennedy-WJWalton-000001-2
Winter John W IV MD	PKennedy-JWinterIV-000001-000001
<b>Kinkela, Silvano</b>	
<b>Plaintiff Fact Sheet</b>	
2021.06.10 Plaintiff Fact Sheet	SKinkela-PFS-000547-000639
<b>Medical Records</b>	
Plaintiff-Produced Medical Records	SKinkela-PPR-000216-000430
Aaron Jay S MD	SKinkela-JSAaron-000001-000085
Ctrs for Medicare And Medicaid Svcs	SKinkela-CMMS-R3-000001-000779
Costco Wholesale HIPAA Compliance	SKinkela-CostcoW-000001-000002
Kmart Pharmacy	SKinkela-KmartP-000001-2
Lackawanna Valley Dermatology Assocs	SKinkela-LVDA-000001-000019
Optum Rx	SKinkela-OptumRx-000001-000138
Pocono Ambulatory Surgery Ctr Rad Dept	SKinkela-PASC-RD-000001-000006
Pocono Med Ctr Patient Accts	SKinkela-PMC-BD-000001-000031
Pulmonary And Critical Care Specialists Med Recs Dept	SKinkela-P&CCS-MD-000001-000056
Rx Express Pharmacy	SKinkela-RxExpress-000001-000001
Sentara Leigh Hosp Med Recs Dept	SKinkela-SentaraLH-MD-000040-000262
Sentara Princess Anne Hosp Path Dept	SKinkela-SPAH-PD-000001-000001
Sentara Surgery Specialists	SKinkela-SSS-000424-000749
Sentara Virginia Beach General Hosp Path Dept	SKinkela-SVBGH-PD-000001-000001
St Lukes Univ Hosp Bethlehem Campus Patient Accts	SKinkela-SLUH-BC-BD-000001-000001
Urology Assocs ofThe Poconos	SKinkela-UAP-000001-000062
Village Family Medicine of Lionville	SKinkela-VFML-000001-000001
Virginia Oncology Assocs	SKinkela-VOA-000001-000093
Walgreen Company	SKinkela-WC-000001-000024
<b>Lee, Robert</b>	
<b>Plaintiff Fact Sheet</b>	
Plaintiff Fact Sheet, 12/23/20	RLee-PFS-000001-000094
Plaintiff Fact Sheet, 11/09/20	RLee-PFS-000001-000162
Correspondence from D. Nigh, 01/26/21	RLee-PFS-000001-000166
PFS Attachment regarding medical expenses	RLee-PFS-000001-000167



Medical Records	
Plaintiff-Produced Medical Records	RLee-PPR-000001-000958
Blue Cross Blue Shield of South Carolina	RLee-BCBSSC-000001-000092
Ctrs for Medicare and Medicaid Svcs Region 4	RLee-CMMS-R4-000001-000126
Death Certificate Proof Of Authority	RLee-DCPOA-000001-000002
Family Healthcare Clinton	RLee-FH-C-000001-000404
Greenville Health System Patient Accts	RLee-GHS-BD-000001-000027
Greenville Health System Med Recs Dept	RLee-GHS-MD-000001-001985
Greenville Memorial Hosp Rad Dept	RLee-GMH-RD-000001-000017
Greenville Memorial Hospital -Billing	RLee-GMH-BD-000001-000005
Ingles Markets, Inc.	RLee-InglesM-000001-000029
Piedmont Neurology	RLee-PNeurology-000001-000001
Walmart Pharmacy	RLee-WMS-000001-000027
<b>Meeks, Ronald</b>	
Plaintiff Fact Sheet	
Plaintiff Fact Sheet, 01/15/20	RMeeks-PFS-000001-000068
Plaintiff Fact Sheet, 01/15/20	RMeeks-PFS-000069-000144
Plaintiff Fact Sheet, 01/15/20	RMeeks-PFS-000145-000212
Plaintiff Fact Sheet, 01/15/20	RMeeks-PFS-000213-000280
Correspondence from D. Nigh, 02/19/20	RMeeks-PFS-000218-000288
Medical Records	
Plaintiff-Produced Medical Records	RMeeks-PPR-000001-006576
Central Arkansas Veterans Healthcare System Med Recs Dept	RMeeks-CAVHS-MD-000001-000011
Central Arkansas Veterans Healthcare System Path Dept	RMeeks-CAVHS-PD-000001-000002
Death Certificate Proof Of Authority	RMeeks-DCPOA-000001-000005
East Jefferson Cardiovascular Specialists Inc Med Recs Dept	RMeeks-EJCS-MD-000001-000163
East Jefferson General Hosp Path Dept	RMeeks-EastJGH-PD-000001-000001
East Jefferson General Hosp Med Recs Dept	RMeeks-EJGH-000751-002405
East Jefferson General Hosp Patient Accts	RMeeks-EastJGH-BD-000001-000027
East Jefferson General Hosp Rad Dept	RMeeks-EastJGH-RD-000001-000001
East Jefferson Internal Medicine	RMeeks-EJIM-000001-000057
Med Plaza ENT Physicians	RMeeks-MPENTP-000001-000036
Nola Discount Pharmacy Pharmacy	RMeeks-NDP-000001-000027
Ochsner Med Ctr Release of Information	RMeeks-OchsnerMC-MD-000001-003194
Ochsner Med Ctr Patient Accts	RMeeks-OchsnerMC-BD-000001-000124
Ochsner Med Ctr Kenner Med Recs Dept	RMeeks-OMC-K-MD-000001-000797
Ochsner Med Ctr Kenner Patient Accts	RMeeks-OMC-K-BD-000001-000010
Ochsner Med Ctr Kenner Path Dept	RMeeks-OMC-K-PD-000001-000001
Ochsner Med Ctr Kenner Rad Dept	RMeeks-OMC-K-RD-000001-000001
Ochsner Medical Complex - NR Cert Ltr	RMeeks-OMComp-000001-000001
Smith Kenneth B MD	RMeeks-KBSmith-000001-000175



Southeast Louisiana Veterans HealthCare System Rad Dept	RMeeks-SLVHCS-RD-000001-000062
Southeast Louisiana Veterans Health Care System	RMeeks-SLVHCS-RD-000008-000009
Tulane Univ Hosp and Clinic Rad Dept	RMeeks-TUHC-RD-000001-000003
Tulane Univ Hosp and Clinic Med Recs Dept	RMeeks-TUHC-MD-000001-000001
Univ Med Ctr New Orleans Rad Dept	RMeeks-UMCNO-RD-000001-000002
Univ Med Ctr New Orleans Patient Accts	RMeeks-UMCNO-BD-000001-000009
Univ Med Ctr New Orleans Path Dept	RMeeks-UMCNO-PD-000001-000001
Univ Med Ctr New Orleans Med Recs Dept	RMeeks-UMCNO-MD-000001-000389
<b>Suits, James</b>	
<b>Plaintiff Fact Sheet</b>	
Plaintiff Fact Sheet, 02/03/21	JSuits-PFS-001131-1224
Correspondence from G. Coates, 09/05/20	JSuits-PFS-001125-001130
Plaintiff Fact Sheet Declaration, 11/30/20	JSuits-PFS-001124-001124
Plaintiff Fact Sheet, 08/18/20	JSuits-PFS-001031-001123
Plaintiff Fact Sheet, 01/19/21	JSuits-PFS-000937-001030
Plaintiff Fact Sheet, 12/10/20	JSuits-PFS-000749-000842
Plaintiff Fact Sheet, 09/18/20	JSuits-PFS-000656-000748
Plaintiff Fact Sheet, 08/14/20	JSuits-PFS-000563-000655
Plaintiff Fact Sheet, 11/30/20	JSuits-PFS-000468-000562
Plaintiff Fact Sheet, 01/14/21	JSuits-PFS-000374-000467
Plaintiff Fact Sheet, 12/10/20	JSuits-PFS-000280-000373
Plaintiff Fact Sheet, 09/18/20	JSuits-PFS-000187-000279
Plaintiff Fact Sheet, 09/18/20	JSuits-PFS-000094-000186
Plaintiff Fact Sheet, 08/14/20	JSuits-PFS-000001-000093
Plaintiff Fact Sheet, 01/14/21	JSuits-PFS-000843-000936
<b>Medical Records</b>	
Plaintiff-Produced Medical Records	JSuits-PPR-000001-001335
Aetna US Healthcare Legal Support Svcs	JSuits-AUSH-000001-000002
John Deere - NRS	JSuits-JohnDeere-HR-000001-000001
McCaysville Internal Medicine	JSuits-McCIM-000001-000251
Mutual of Omaha Insurance Company Claims Dept	JSuits-MOIC-000001-000003
Premier Surgical Assocs Cleveland	JSuits-PremierSAC-000001-000048
Tallent Drug Store	JSuits-TDS-000001-000036
Uhlik, Allen, MD	JSuits-AUhlik-000001-000383
<b>MISCELLANEOUS</b>	
All materials cited or referenced in my expert report and attachments	N/A
All materials cited in the reports of Drs. Mahyar Etminan, David Madigan, Stephen S. Hecht, Lagana, and Dipak Panigraphy and attachments	N/A
This list includes items Plaintiffs' experts relied upon. By so doing, Teva and this expert are not waiving any arguments or objections related to admissibility.	N/A